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Abstract 
 
Physical characterisation of pharmaceutical solids is an integral aspect of the drug 
development process and has attracted increased attention over the past decades. Each 
active pharmaceutical ingredient (API), may exist in different crystalline forms 
(polymorphs), incorporate water in their structure (pseudopolymorphs) or be converted, 
intentionally or not, to an amorphous state. As consequence of all this variety of forms, a 
full toolbox of characterisation techniques is nowadays available, combining high 
resolution thermoanalytical techniques with highly precise diffraction methods and 
advanced computational resources.  
The work presented in this thesis aimed to provide an in-depth understanding of the 
physicochemical properties of single drug molecules (olanzapine and paroxetine HCl) and 
final formulated systems in varying physical states including different crystalline entities 
and amorphous systems. In this work, a combination of thermal (standard differential 
scanning calorimetry (DSC), modulated temperature DSC (MTDSC), thermogravimetric 
analysis (TGA) and hot stage microscopy (HSM)), diffraction (X-ray powder diffraction 
(XRPD) combined, in some studies, with variable humidity (VH) or temperature (VT)) and 
spectroscopic techniques (attenuated total reflectance–Fourier transform infrared  
(ATR-FTIR)) were extensively used. Dynamic vapour sorption (DVS), Karl Fischer 
titration (KFT) and scanning electron microscopy (SEM) were as well of great importance. 
Dissolution performance and physical stability studies were also evaluated.  
At first, a thorough investigation into the solid state of paroxetine HCl was performed. 
Aspects such as the interaction with water and the interconversion between the two 
crystalline forms, Form I and II, were fully explored. This enabled to successfully 
clarifying the nature, location and bonding strength of the water molecules in the 
crystalline structure of paroxetine HCl Form II (Chapter 3). These findings allowed proper 
recognition of Form II as a non-stoichiometric hydrate with unusual behaviour, and 
challenges the previous designation as an anhydrous form with a hygroscopic nature. On 
the other hand, the specific conditions that led to the dehydration of Form I were fully 
investigated (Chapter 4). The dehydration of Form I was found to require both ultra-dry 
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environment and high temperatures. As a consequence of this process a new anhydrous 
form of paroxetine HCl has been identified. 
After this structural characterisation, studies were conducted on the conversion of 
paroxetine HCl to an amorphous state, either alone (Chapter 5) or molecularly dispersed in 
polyvinylpyrrolidone vinyl-acetate (PVPVA, Chapter 6). Chapter 5 provided a detailed 
thermal characterisation using thermodynamic and kinetic parameters of amorphous 
paroxetine HCl prepared via melt quenching method. The results obtained were then 
correlated with the stability of this form over storage. In Chapter 6, parameters such as the 
initial hydration state of the drug (paroxetine Forms I and II) and the methodology used 
(spray drying (SD) and hot melt extrusion (HME)) were found not only to influence the 
dissolution rate of the prepared systems but also its physical stability. Finally, the acquired 
knowledge in the preparation of solid dispersion systems was applied to a 
Biopharmaceutical Classification System (BCS) Class 2 drug (olanzapine, OLZ) using 
HME as the selected technology and considering the influence of different polymeric 
carriers (Chapter 7). This study showed an interesting interplay between the extrusion 
temperature, drug loading, drug physical state and polymer chemistry that can be further 
applied to other poorly soluble APIs. 
To conclude, the research carried out and detailed within this thesis aims to contribute to a 
better understanding of the complex solid state characterisation of pharmaceutical drugs 
and formulated systems prepared via solid dispersion methods. To the end, this work has 
identified several issues and possible areas for future research in the pharmaceutical field.  
 
Keywords: amorphous, anhydrous, hydrate, olanzapine, paroxetine HCl, polymorphism, 
pseudopolymorphism, solid dispersion, solid state, structural analysis, thermal analysis 
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Resumo 
 
A caracterização física de fármacos e excipientes é um aspecto integrante do processo de 
desenvolvimento de medicamentos e tem atraído crescente atenção ao longo das últimas 
décadas. Cada fármaco (active pharmaceutical ingredient (API)) ou mesmo excipiente, 
pode existir em diferentes formas cristalinas (polimorfos), incorporar água na sua estrutura 
(pseudopolimorfos) ou ser convertido, de forma intencional ou não, num estado amorfo. 
Em consequência desta variedade possível de formas, um conjunto de técnicas de 
caracterização encontra-se hoje em dia disponível, combinando técnicas termoanalíticas de 
alta resolução com métodos de difração de alta precisão e recursos computacionais 
avançados.  
O trabalho apresentado nesta tese teve como objetivo proporcionar uma compreensão 
profunda das propriedades físico-químicas de fármacos (olanzapina e cloridrato de 
paroxetina) e produtos finais em vários estados físicos, incluindo diferentes entidades 
cristalinas e sistemas amorfos. Neste trabalho, uma combinação de técnicas térmicas 
(calorimetria de varrimento diferencial (DSC), com ou sem modelação de temperatura 
(MTDSC)), análise termogravimétrica (TGA) e microscopia de platina aquecida (HSM)), 
difração (difração de raios X de pó (XRPD) combinada, em alguns estudos, com variação 
de humidade (VH) ou temperatura (VT)) e técnicas espectroscópicas (espectroscopia de 
infravermelho (ATR-FTIR)) foram amplamente utilizadas. Dynamic vapour sorption 
(DVS), Karl Fischer (KFT) e microscopia eletrónica de varrimento (SEM) foram também 
de grande importância. Finalmente, ensaios de dissolução e estudos de estabilidade física 
foram ainda conduzidos em casos específicos.  
Numa primeira fase, foi desenvolvido um estudo pormenorizado sobre o estado sólido do 
cloridrato de paroxetina. Aspectos tais como a interação com a água e a interconversão 
entre as duas formas cristalinas do cloridrato de paroxetina, Formas I e II, foram 
cuidadosamente exploradas. Este estudo permitiu clarificar a natureza, localização e força 
de ligação das moléculas de água na estrutura cristalina da Forma II do cloridrato de 
paroxetina (Capítulo 3). Estes resultados permitiram assim identificar a Forma II como um 
hidrato não estequiométrico com um comportamento peculiar e excluir a sua prévia 
designação enquanto forma anidra com uma natureza higroscópica. Por outro lado, as 
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condições específicas capazes de promover a desidratação da Forma I foram também 
estudadas (Capítulo 4). Verificou-se que a desidratação desta forma exige um ambiente 
extremamente seco e altas temperaturas. Em consequência deste processo uma nova forma 
anidra do cloridrato de paroxetina foi identificada.  
Após a caracterização estrutural das duas formas cristalinas do cloridrato de paroxetina, 
foram ainda realizados estudos sobre a conversão deste fármaco num estado amorfo, quer 
individualmente (Capítulo 5) ou disperso a nível molecular em polivinilpirrolidona  
vinil-acetato (PVPVA, Capítulo 6). O Capítulo 5 apresenta uma caracterização detalhada, 
com recurso a parâmetros termodinâmicos e cinéticos, da forma amorfa do cloridrato de 
paroxetina preparada por fusão e rápido arrefecimento. Os resultados obtidos foram em 
seguida correlacionados com a estabilidade física observada experimentalmente. Em 
continuação, o trabalho apresentado no Capítulo 6 concluiu que parâmetros, tais como o 
estado inicial de hidratação das duas formas da paroxetina e a metodologia usada para 
preparar as dispersões sólidas (spray drying (SD) e extrusão a quente (HME)), influenciam 
não só a velocidade de dissolução dos sistemas preparados, mas também a sua estabilidade 
e tendência para recristalização. Finalmente, o conhecimento adquirido na preparação de 
sistemas de dispersão sólida foi aplicado a um fármaco (olanzapina, OLZ) pertencente à 
Classe 2 do Sistema de Classificação Biofarmacêutico (BCS) usando HME como 
tecnologia selecionada e considerando a influência de diferentes polímeros (Capítulo 7). 
Este estudo revelou uma interessante relação entre a temperatura de extrusão, dosagem e 
estado físico do fármaco e ainda estrutura química do polímero. Os resultados obtidos 
neste estudo visam contribuir para um melhor entendimento das estratégias possíveis 
usadas no melhoramento da velocidade de dissolução de outros fármacos pouco solúveis. 
A título de conclusão, o estudo conduzido e apresentado detalhadamente nesta tese 
pretende contribuir para uma melhor compreensão da caracterização complexa do estado 
sólido de fármacos e sistemas farmacêuticos preparados através de métodos de dispersão 
sólida. Finalmente, este trabalho identificou vários problemas e possíveis áreas de 
investigação futura no domínio farmacêutico. 
 
Palavras-chave: amorfo, análise estrutural, análise térmica, anidro, cloridrato de 
paroxetina, dispersão sólida, estado sólido, hidrato, olanzapina, polimorfismo, 
pseudopolimorfismo
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Motivation and Contextual Objectives 
 
Solid state characterisation represents, nowadays, a well-established program in the 
pharmaceutical industry since an incomplete characterisation of a drug substance can 
jeopardize the development and commercialisation of a final product. 
In the present work, a range of analytical techniques were used to obtain a more accurate 
and thorough understanding of the solid state of two well-known drugs: paroxetine HCl 
and olanzapine. These drugs were selected due to their complex nature and not yet fully 
understood solid state properties. Moreover, the preparation of solid dispersion systems of 
these two drugs using different technologies was evaluated as a way to explore the 
parameters that can influence the dissolution behaviour and physical stability of such 
systems.  
 
Organisation of the Thesis and Main Objectives  
 
This thesis is divided into 8 chapters. The contents and objectives of each chapter are 
briefly summarised as follows, 
Chapter 1 provides a broad overview on the topics explored in the subsequent chapters. 
Chapter 2 presents the chemical structure and main physicochemical properties of all 
APIs and polymers used throughout this dissertation. A brief theoretical background to the 
techniques used to prepare solid dispersions and all the analytical methods is also 
presented. Moreover, a paragraph describing the instruments characteristics is added at the 
end of each technique. 
Chapter 3 provides a thorough investigation of paroxetine HCl Form II. Differentiation 
between surface water and hydrate formation was critically accessed as a function of 
relative humidity and temperature. 
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Chapter 4 explores the conditions that could lead to the dehydration of paroxetine HCl  
Form I. The possibility of any structural relationship between the dehydrated From II and 
Form I was investigated. 
Chapter 5 provides the calculation of several thermodynamic and kinetic parameters as 
possible predicting tools of the physical stability of amorphous paroxetine HCl. Correlation 
between those predictions and the experimental stability over storage was evaluated. 
Chapter 6 provides an evaluation of the theoretical predictions used to describe miscibility 
between drug and polymer and the effect of different preparation methods on the 
processing of the pseudopolymorphs of paroxetine HCl, dissolution rates and stability over 
storage. 
Chapter 7 presents an investigation on the effect of drug loading and physical state, 
extrusion temperature and physicochemical properties of the selected polymers on the 
dissolution enhancement and stability of solid dispersions of a poorly soluble drug 
(olanzapine) prepared via hot melt extrusion.  
Chapter 8 presents the main conclusions and future work. 
 
It is worth mentioning that the author of this thesis was not directly involved in the 
molecular modeling simulations (Chapter 3), Pawley refinement, unit cell parameters 
determinations and high performance liquid chromatography (HPLC) analysis (Chapter 4). 
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1 INTRODUCTION 
 
 
 
 
 
 
 
 
     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
. . . a major deficiency in our current knowledge and understanding concerns the relationship 
among the members of a polymorph cluster—what is their relative mutual stability,  
how do they transform, one into another, what are the thermodynamic factors  
governing their mutual stability, what are the kinetics of the transitions.  
Answers to the last of these questions are very important to users of, and sufferers from, 
polymorphism. 
 
Herbstein 
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1.1 General Introduction 
 
Interest in the solid state properties of pharmaceutical compounds has grown greatly in 
recent decades. Firstly, an insufficient understanding of solid state properties can lead to 
serious complications in the development of a final pharmaceutical product, including their 
physical and chemical stability. Secondly, a thorough characterisation of any new, or even 
existent, molecule can create new opportunities and uncover important properties that can 
enhance its bioavailability. This is extremely important from the patient perspective. In 
addition, from a commercial point of view, companies can see their patents extended with 
economic benefits.  
This section provides a background on the concepts and principles related to the solid state 
of pharmaceutical compounds. Additionally, some relevant topics on formulation 
strategies, new preparation techniques and principal obstacles frequently encountered 
during the manufacturing process are also explored.  
 
1.2 States of Matter 
 
Matter is broadly classified as being either a solid, liquid or a gas. At normal room 
temperature and pressure the majority of active pharmaceutical ingredients (APIs) and 
excipients exist as solids. In the solid state, molecules are held in close proximity to each 
other by intermolecular forces such as hydrogen bonding and van der Waals interactions. 
In the liquid state, there are still molecular interactions but the molecules are more mobile 
and lack long-range order. Finally, in the gas phase the molecules only interact weakly 
with each other and travel large distances without colliding.  
The solid phase can be classified into two major types of sub-phases based upon the order 
of molecular packing. The most common type of state is the crystalline state where the 
structural units, called unit cells, are regularly repeated in a three dimension (3D) lattice, 
presenting both short and long-ranges order. In this context, ‘short-range order’ refers to 
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the way (molecular coordination) that molecules arrange next to each other, while  
‘long-range order’ refers to the regularity or periodicity that hundreds and thousands of 
molecules aggregate, first through ‘neighbouring’ (short-range) and then propagate to an 
‘appreciable’ distance, to form a phase crystalline (Ossi, 2010). On the contrary, 
amorphous solids have a regularity of structure limited to the immediate neighbours of any 
particular molecule within the solid, which means that they only have short-range order 
and therefore greater mobility when compared to crystalline solids (Florence and Attwood, 
2006).  
Crystalline solids can also exist in multiple sub-phases, such as polymorphs, solvates,  
co-crystals and salts (Figure 1.1).  
 
  
 
 
 
 
  
 
 
 
                                                                                              
                                                                                                        
 
Figure 1.1: Schematic depiction of the various types of solids: amorphous (a) and crystalline (b-f). 
Crystalline solids can be further classified as polymorphs (b and c), solvates/hydrates (d), 
pharmaceutical co-crystals (e) and salts (f).  
 
Polymorphs are compounds with same chemical composition but different crystal 
arrangements. On the other hand, solvates and co-crystals are multicomponent crystals. A 
solvate is defined as a solid in which molecules of solvent are incorporated into the crystal 
(a) (b) (c) 
(d) (e) (f) 
Neutral API
Charged API  
Solvent Co-crystal former            
Counter ion 
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lattice (Hosokawa et al., 2004). The incorporated solvent is often termed the guest and the 
major component is termed the host (Herbstein, 2004). When the solvent is water, the 
solvate is called hydrate. The terminology of hydrates is related to the amount of molecular 
water compared to one molecule of host and is denoted by terms such as ‘hemihydrate’, 
‘monohydrate’, ‘dihydrate’, etc. ‘Anhydrate’ is actually a redundant term but is used to 
emphasise that water (or solvent) is not incorporated in the crystal structure. The suggested 
nomenclature of this particular group as pseudopolymorphs generated a polemic discussion 
and it was recently replaced by solvatomorphs (Seddon, 2004; Desiraju, 2004; Nangia, 
2005).  
Several APIs are commercialised in a hydrate phase (Lee et al., 2011), such as alendronate 
sodium trihydrate (Fosamax
®
), amoxicillin trihydrate (Amoxil
®
) and atorvastatin calcium 
trihydrate (Lipitor
®
). Solvates other than hydrates are usually not selected for development 
owing to risk of desolvation and toxicity concerns with organic solvents that are not  
Class III. Class III solvents are considered to be less toxic and with lower risk to Human 
health. This is the outcome of acute and short-term safety studies, although there are no 
long-term toxicity or carcinogenicity studies for many of the solvents belonging to this 
class. Nonetheless, there are some drug products marketed in the solvate form such as 
darunavir ethanolate (Prezista
®
), indinavir sulfate ethanolate (Crixivan
®
) and warfarin 
sodium isopropanol solvate (Coumadin
®
) (Lee et al., 2011).  
Co-crystals are multiple component crystals in which all components are solid under 
ambient conditions when in their pure form (Shan and Zaworotko, 2008).  
Co-crystallisation has gained more and more interest in pharmaceutical research, since the 
complexation of an API with another molecule can produce a solid form with different 
physical properties (Trask et al., 2006; McNamara et al., 2006). 
Salts represent a considerable enlargement of the portfolio of solid forms of 
pharmaceutical molecules. Salts are stable and highly soluble in water. A necessary 
prerequisite for the formation of salts is the presence of ionisable groups in the molecule. 
Salts may also form hydrates such as atorvastatin calcium trihydrate and paroxetine 
hydrochloride hemihydrate. 
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1.2.1 Structural Aspects of Crystalline Solids 
 
As mentioned above, crystals consist in a regular array of atoms and molecules organised 
in a basic structural motif repeated in a three-dimensional arrangement. Each motif in 
crystallography is called unit cell which has a geometry defined by the lengths of the three 
axes (a, b, c) and the angles between them (α, β, γ) (Gilmore, 2011). The convention is that  
α defines the angle between b and c, β defines the angle between a and c, and γ defines the 
angle between a and b. The regular and periodic arrangement of unit cells is called crystal 
lattice, which is organised in a way that each lattice point has an identical environment 
with respect to the basic motif and other lattice points (Brittain, 2009). There are seven 
fundamental types of primitive unit cells, as shown in Figure 1.2. 
 
 
 
Figure 1.2: The seven crystal systems, their unit cells and the constraints on the unit cell dimensions 
(Florence and Attwood, 2006). 
 
However, there are other arrangements of points which fulfil the requirements of a point 
lattice, namely, that each point has identical surroundings which leads to the existence of 
 
Chapter I 
 
47 
 
fourteen possible point lattices and no more. This work was carried out by the French 
crystallographer Bravais in 1848 and therefore they are called the 14 Bravais lattices  
(Cullity, 1956).  
 
1.2.2 Cambridge Structural Database 
 
The Cambridge Structural Database (CSD) is the world’s repository for the results 
obtained from the X-ray crystal structure analysis of small organic molecules and 
organometallic compounds. It contains the results of over half-a-million X-ray and neutron 
diffraction analyses. The CSD is compiled and distributed by the Cambridge 
Crystallographic Data Centre (CCDC), a fully independent institution based in Cambridge 
(England) since 1987. 
Each entry in the CSD contains 1D, 2D and 3D information. The 1D data contains 
bibliographical and chemical information (name and empirical formula). The 2D 
information is used to generate the structural formula and chemical connectivity, which 
obviously is the same for polymorphs. And finally, the 3D information contains all the 
results obtained from X-ray structure determination, namely cell constants, space group, 
atomic coordinates and atomic attributes needed to generate the three-dimensional 
molecular and crystal structures (Bernstein, 2002).  
This unique database of accurate 3D structures has become an essential resource to 
scientists around the world providing high quality information, software and services. 
 
1.3 Polymorphism 
 
Polymorphism, is a term originally derived from Greek (poly = many; morph = form) and 
according to McCrone’s definition (Haleblian and McCrone, 1969): “Polymorphism is the 
ability of any element or compound to crystallize as more than one distinct crystal 
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species”. This author also states that “every compound has different polymorphic forms 
and that, in general, the number of forms known for a given compound is proportional to 
the time and money spent in research on that compound”. Earlier in 1788, Klaproth found 
that calcium carbonate crystallises both as calcite and aragonite, giving the first insight on 
polymorphism. A few years later, Humphrey Davy in 1809 presented that diamond and 
graphite are both carbon, but they differ on the way carbon atoms are arranged in the solid 
state. This became the classical and most famous example of polymorphism. 
Different polymorphs exhibit different properties, favourable or not in a particular context, 
which became the subject of considerable practical, and hence financial, importance, 
especially in the pharmaceutical arena (Herbstein, 2004). Polymorphs of a drug substance 
can have different chemical and physical properties, including melting point, chemical 
reactivity, apparent solubility, dissolution rate, optical and mechanical properties, vapour 
pressure, and density. These properties can have a direct effect on the ability to process 
and/or manufacture the drug substance and the drug product, as well as, on drug product 
stability, dissolution, and bioavailability. Thus, polymorphism can affect the quality, 
safety, and efficacy of the drug product. 
From an industrial perspective, the drug development program is a highly interdisciplinary 
field connecting chemistry, technology, pharmacology and toxicology, at the last instance. 
At first it involves solid state knowledge covering crystal chemistry and materials 
properties with a goal to select the appropriate crystal form with the desired physical and 
chemical properties. The following step then embraces formulation development and 
process design. The general program of a drug product development is illustrated in  
Figure 1.3. 
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Figure 1.3: Relationship between the selection/optimisation of a drug candidate and  
the development stages (Chow et al., 2008).  
 
In the case of a new drug substance, it is crucial to perform a thorough polymorphic 
screening prior to the initiation of pivotal clinical studies and primary stability batches. The 
importance and difficulties related to polymorphism in the pharmaceutical industry can be 
exemplified by examining the history of a number of well-known drug products as shown 
in Figure 1.4. 
In most of the cases, the products are recalled owing to ambiguous product performance 
and quality as a result of unpredicted changes in the polymorphic form which resulted in 
problematic quality release and stability testing (i.e. dissolution) of the finished dosage 
form. As a consequence, companies have experienced market shortages due to 
manufacturing troubleshooting, batch rework, and delays in project or clinical trials 
timelines.  
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Figure 1.4: A timeline of events concerning solid state issues with polymorphism/pseudopolymorphism 
 of pharmaceutical drugs (adapted from (Lee et al., 2011)). 
 
1.3.1 Structural Aspects of Polymorphism 
 
1.3.1.1 Packing and Conformational Polymorphism 
 
Polymorphism in molecular crystals can be divided into two categories: packing and 
conformational polymorphism. In the former, molecules exhibit as rigid grouping of atoms 
that may be stacked in different motifs to occupy the points of different lattices. On the 
other hand, conformationally flexible molecules adopt more than one conformation in the 
solid state (Bernstein, 2002; Yu et al., 2000). The differentiation between packing 
polymorphism and conformational polymorphism is not always obvious. Several examples 
of drugs that exhibit conformational polymorphism can be scattered from literature such as 
the antidepressant venlafaxine hydrochloride (Kavitha et al., 2005), the antipsychotic 
olanzapine (Reutzel-Edens et al., 2003a) and the non-steroidal anti-inflammatory drug 
nimesulide (Sanphui et al., 2011). 
Conformers have very similar conformational energies which makes possible the existence 
of different molecular conformations in a single crystal structure. This energy is enough to 
provoke changes in molecular torsional parameters about single bonds, but it is generally 
1998 – Withdrawal of 
Norvir
® 
(ritonavir) due to 
the conversion to a more 
thermodynamic stable and 
less soluble polymorph. 
1999– Examination of the raw 
material of Velmox
® 
(mebendazole) confirmed a 
mixture of Forms A and B, found 
to be inactive/less effective than 
the intended Form C. 
2008 – Batch recall of 
Neupro
®
 (rotigotine) 
patches due to 
crystallisation of a new 
polymorph. 
2010 – Recall of 
Coumadin
®
 (warfarin 
sodium 2-propanol) as a 
result of variability in the 
content of 2-propanol. 
1988 – Clinical failure of 
Tegretol
®
 (carbamazepine) 
due to the conversion of the 
anhydrate form to the 
dihydrate. 
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not sufficient to significantly perturb bond lengths and bond angles. Differences in the 
torsion angles are usually the first focus to identify conformational polymorphism, though 
this is not a rigid and straight rule (Bernstein, 2002).  
 
1.3.1.2 Monotropism and Enantiotropism 
 
Thermodynamically, polymorphs can be classified as monotropics or enantiotropics, 
depending upon whether one can reversibly transform to another or not. In an enantiotropic 
system, there is a transition temperature (Ttrans) before melting (Tm), at which the stability 
order between two polymorphic forms is reversed. On the contrary, in a monotropic 
system, one form is more stable than the other at any temperature before melting 
(Vippagunta et al., 2001). Figure 1.5 shows phase diagrams representing each system. 
In an enantiotropic system, Form I has a lower free energy over the lower temperature 
range, while Form II is shown to have a lower free energy over a higher temperature range. 
At the Ttrans, the free energy curves cross and the forms are isoenergetic. For a monotropic 
system, one polymorph has the lowest free energy at any given temperature and therefore 
is the most thermodynamically stable form. The free energy curves do not cross, so no 
reversible transition can be observed below the melting point (Brittain, 2009). 
 
 
 
 
 
 
 
 
Figure 1.5: Free energy (G) as a function of temperature for enantiotropic (left) and monotropic (right) 
systems (adapted from (Craig and Reading, 2007)). 
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To understand if a polymorphic system is monotropic or enantiotropic is of considerable 
relevance from the stability perspective. Such knowledge can help to determine whether a 
compound will be stable at a certain temperature during manufacture and storage 
conditions. There are a series of rules that have been developed to help differentiating and 
characterising these two systems, as presented next. 
 
1.3.2 Thermodynamics of Polymorphic Systems 
 
In a polymorphic system, the relative stability of polymorphs depends on their free 
energies, with the most stable form having the lowest free energy under determined 
experimental conditions. In those circumstances, the other forms are thermodynamically 
unstable and therefore considered metastable with a rate of conversion to the most stable 
form that can vary from seconds to years. 
An example is the well reported case of ritonavir. Ritonavir is a protease inhibitor for 
Human Immunodeficiency Virus (HIV), discovered in late 1992 and introduced to the 
market in 1996 as a semisolid capsule formulation and as a liquid formulation. The final 
product, Norvir
®
, was withdrawn two years later because some lots of capsules failed the 
dissolution tests specification. It was found that a large portion of the drug substance was 
precipitating out of the final (semisolid) formulated product. Further investigation into this 
matter revealed that a new, previously unknown, thermodynamically more stable and much 
less soluble crystalline form had emerged (Chemburkar et al., 2000). 
The main approaches used to assess thermodynamic stability relationships of polymorphs 
are based on the Burger and Ramberger rules established in 1979 (Burger and Ramberger, 
1979a;b). Three particularly important rules proposed by these authors are the heat of 
transition, the heat of fusion, and the density rule, described below. 
Heat of Transition Rule 
This rule states that if, at some temperature, an endothermic transition between two crystal 
forms is observed, then there is a transition point below this temperature and the two 
polymorphs are enantiotropically related. On the contrary, if an exothermic transition is 
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observed at some temperature, there is no thermodynamic transition point below this 
temperature. As a result, this could be an indication of a monotropic system, but also of an 
enantiotropic system with the thermodynamic transition temperature happening at a higher 
temperature (Hilfiker, 2006). 
Heat of Fusion Rule 
The heat of fusion rule states that the polymorph with higher melting point has the lower 
heat of fusion thus the two polymorphs are enantiotropic, otherwise they are monotropic. 
Frequently, the rate of polymorphic transition is too slow to allow for an accurate 
measurement of the heat of transition, in which case the heat of fusion rule may be applied 
(Hilfiker, 2006).  
Density Rule 
True density is a physical property of both fundamental and practical importance to the 
study of pharmaceutical powders. The density rule states that for a system at absolute zero, 
the most stable polymorph will have the highest density, as a result of the closer packing of 
the molecules. This is the case of nabumetone, for example, with the stable Form I having 
a density of 1.26 g/cm
3
 while the metastable Form II possesses a density of 1.21 g/cm
3
  
(Price et al., 2002). However, if crystal packing is dominated by energetically more 
favourable directional or electrostatic interactions, such as hydrogen bonding, crystals with 
a closer packing may not always exhibit a lower lattice energy and free energy even at 0 K 
(Sun, 2007). An example of this situation, is the case of oxybuprocaine hydrochloride, a 
local anaesthetic drug, with the metastable Form III having a higher density (1.21 g/cm
3
) 
than the stable Form II (1.20 g/cm
3
) (Griesser et al., 2008). 
The thermodynamic stability between polymorphs represents one of the most important 
points of concern in the pharmaceutical industry. It is crucial to ensure that the final 
product contains the desired polymorph, which was previously selected due to its physical 
properties combined with a suitable stability. The well-known expression of disappearing 
polymorphs perfectly exposes the numerous cases of crystals being observed over a period 
of time but not thereafter. Over the past decades, the combination of new crystallisation 
techniques and more accurate and precise screening approaches have significantly reduced 
the tendency for this phenomenon to happen.  
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1.4 Hydrates in the Pharmaceutical Industry  
 
Hydrates are the most common type of solvates and the ones with highest importance from 
a pharmaceutical perspective. Hydrates can be formed as a result of processing  
(wet granulation, crystallisation, freeze drying or spray drying) or during storage, when 
exposed to an atmosphere containing water vapour.  
The incorporation of water molecules into the crystal lattice produces a new unit cell 
different from that of the anhydrate. As a result, the intermolecular interactions within the 
solid change, which contribute to alter the enthalpy and entropy of the solid. This fact will 
result in changes in the free energy which consequently affects the thermodynamic activity 
of hydrates (Khankari and Grant, 1995).  
Figure 1.6 below presents the effect on the physical properties of a drug as a consequence 
of hydration. 
In this dissertation, a considerable attention was paid to the study of hydrates, Chapters 3  
and 4. Although each of those chapters has its own introduction and related theoretical 
concepts, a general overview in the study of pharmaceutical hydrates is presented as 
below.  
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Water Molecules in the Crystal Lattice 
 
 
Interactions between the molecules within the solid 
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Figure 1.6: Effect of hydration on the physical properties of a pharmaceutical API  
(Khankari and Grant, 1995). 
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1.4.1 Classification of Hydrates 
 
As referred earlier, hydrates incorporate water molecules in their crystal lattice, which can 
happen in a stoichiometric or non-stoichiometric manner. 
Stoichiometric hydrates have a fixed, although not strictly integral, ratio of water to the 
compound (Hilfiker, 2006; Vippagunta et al., 2001). Generally, in this type of hydrates, 
water plays a structural role in the whole crystalline network and its dehydration frequently 
can lead to a disordered or amorphous state.  
Non-stoichiometric hydrates have their water content dependent on the surrounding water 
vapour pressure and temperature. The water acts as a space filler of structural voids or 
channels and it is usually present in uncommon, yet well-defined, solvent/compound ratios 
(Rodríguez-Spong et al., 2004). Though, it is common practice in the pharmaceutical 
literature to wrongly round odd numbered water ratios to integer values. For example, 
caffeine 0.8 hydrate (Griesser and Burger, 1995) is still quoted as monohydrate.  
Non-stoichiometric hydrates can lose their water without changing the main structural 
characteristics and therefore, in this case, are called isomorphic dehydrates (Pfeiffer et al., 
1970; Stephenson et al., 1998).  
Hydrates in general and, non-stoichiometric hydrates in particular, represent a challenge 
for development due to its instability. The characterisation of hydrates doubtlessly needs 
more effort and time when compared to the characterisation of polymorphs and can be a 
real challenge. In the next section, specific points are presented to be considered in the 
characterisation of hydrated systems. 
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1.4.2 Insights on the Characterisation of Hydrates 
 
Thermal Analysis 
 
Dynamic scanning calorimetry (DSC) in combination with thermogravimetric analysis 
(TGA) and hot stage microscopy (HSM) are the most common techniques used in the 
study of hydrates. The use of DSC alone may not be very elucidative as endothermic 
transitions due to dehydration can be easily seen as melting, or the other way around. 
Furthermore, the distinction between true hydrates and sorbed water is not always 
straightforward (Craig and Reading, 2007). Different scenarios can be observed when 
carrying on a study of a hydrate compound in DSC (Giron, 1995). The dehydration and 
melting of the anhydrous phase can be observed in separate and therefore two endotherms 
are observed. On the contrary, if these two phenomena cannot be isolated and dehydration 
happens at the melting temperature, an exotherm might be seen as the new anhydrous 
phase recrystallises from the melt. The picture can become even more complex when a 
change in the hydration level is observed (see Chapter 3). The pan configuration, closed or 
open, can also influence the outcome of a DSC experiment, as well as the heating rate, 
crystal size and sample mass.  
TGA measurements give information about the thermal stability of the hydrate form 
depending on the onset of the water loss. Less stable forms will show dehydration starting 
from low temperatures. More stable hydrated forms, usually the case of stoichiometric 
hydrates, show a water loss signal at well-defined temperatures. TGA has recently been 
used in combination with infrared spectroscopy to understand the thermal behaviour of 
other solvates and at the same time to confirm the nature of the vapour (Rastogi et al., 
1999). 
Moreover, TGA experiments performed under isothermal and/or non-isothermal conditions 
can be used to quantify the kinetic parameters of dehydration, such as activation energy 
(Ea) (Vyazovkin et al., 2011). Both methods have advantages/disadvantages and the hard 
decision is to know which one can give results with more accuracy. The biggest 
disadvantage of isothermal methods is the unavoidable non-isothermal heat-up time in the 
beginning of the experiment. As a result, if lower temperatures cannot allow the complete 
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dehydration in a reasonable time, higher temperatures can lead to a significant extent of 
conversion during that heating-up period. With regard to non-isothermal experiments, the 
biggest disadvantage is the difficulty in differentiating between the different kinetic models 
(Vyazovkin et al., 2011).  
HSM is also a very helpful technique in the characterisation of hydrates. A widely used 
procedure when studying hydrates under HSM is by dispersing the sample in silicone oil in 
order to aid the visualisation of the thermally induced release of any included solvent.  
As dehydration occurs it is supposed to observe the formation of bubbles in the oil (Zhu 
and Grant, 2001; Zhu, 2006). Thus, attention must be paid during the data interpretation 
since this observation could be potentially complicated by the release of entrapped air from 
the solids or by the simple presence of air bubbles in the dispersion medium (Brittain, 
2009).  
The use of HSM often provides unique insights not afforded by other techniques and the 
combination with the results obtained from DSC and TGA, constitute an optimal routine 
approach. 
 
Dynamic Vapour Sorption  
 
Dynamic vapour sorption (DVS) experiments give information on the equilibrium water 
content as a function of relative humidity (RH) at a constant temperature. In the case of 
stoichiometric hydrates the water content at equilibrium may experience stepwise jumps 
whereas for non-stoichiometric a continuous increase in the water content until complete 
saturation of the structure might be observed (Hilfiker, 2006). Commonly,  
non-stoichiometric hydrates show identical profiles during sorption and desorption and 
hysteresis is not observed. 
Attention should be paid to the kinetic stability observed during moisture sorption isotherm 
experiments. One would expect that at higher RH, a hydrated crystal form is more stable 
than the anhydrous form, however this cannot be readily transported when solubility 
experiments are performed. In fact, cases are reported of the opposite stability relationship, 
such as the example of LY334370 HCl used for the treatment of acute migraine, where the 
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anhydrous form is more stable in water than the dihydrate crystal (Reutzel-Edens et al., 
2003b). Mannitol is an example of a metastable hydrate that converts to the anhydrous 
form when exposed to moisture (Yu et al., 1999). 
Another important piece of information that can be derived when performing DVS 
experiments is related to the hygroscopic behaviour of the dehydrated phase. The 
definition of hygroscopicity combines thermodynamic driving forces and kinetic rates and 
can be broadly described by the amount and the rate of moisture uptake at a certain RH. 
Among all the classification systems that can be found in the literature, the one commonly 
followed was proposed by Callahan and it is based on data obtained from sorption isotherm 
experiments (Callahan et al., 1982), as presented in Table 1.1. 
 
Table 1.1: Hygroscopicity classification scheme according to Callahan. 
 
Class Classification Features 
I Non-hygroscopic 
Essentially there is no moisture uptake at RHs below 90%. 
Furthermore, the increase in moisture content after storage for 
one week above 90% RH is less than 20%. 
II Slightly hygroscopic 
There is no significant moisture uptake at RHs below 80%. The 
increase in moisture content after storage for one week above 
80% RH is less than 40%. 
III 
Moderately 
hygroscopic 
The moisture content does not increase more than 5% after 
storage at RHs below 60%. The increase in moisture content 
after storage for one week above 80% RH is less than 50%. 
IV Very hygroscopic 
The increase in the moisture content may increase at RHs as low 
as 40 to 50%. The increase in moisture content after storage for 
one week above 90% RH may exceed 30%. 
 
Adapted from (Callahan et al., 1982). 
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Crystallographic Studies 
 
X-ray crystallography is a powerful technique for characterising water-solid interactions in 
crystalline hydrates, providing information about their structural behaviour and stability.  
The dehydration of non-stoichiometric hydrates lead to the formation of isomorphic 
dehydrates that tend to retain the three-dimensional structures of the parent compound. 
Dehydration resulted in shifts in the X-ray peak positions, as a function of lattice 
expansion or contraction. This is the behaviour of paroxetine HCl Form II described in 
Chapter 3 of this thesis. The use of variable temperature (VT) and variable humidity (VH) 
X-ray powder diffraction (XRPD) is sometimes imperative to monitor dehydration in situ 
or to investigate potentially complex solid state transformations (Rastogi et al., 2001). 
Recently, significant developments in crystallographic computing systems have allowed to 
solve the structure of compounds by powder diffraction methods that have not been 
possible to be solved by single crystal methods (David et al., 1998; Stephenson, 2000). 
This represents a great achievement as many crystalline substances are complex or beyond 
the capability of single crystal techniques. 
 
Nuclear Magnetic Resonance 
 
In the past decade, nuclear magnetic resonance (NMR) relaxometry has been widely used 
to study water-solid interactions. Water absorption generally has a strong influence on 
molecular dynamics in solids and therefore 
1
H and 
13
C spin lattice relaxation is affected. 
Hydrogen bonding interactions between thiamine HCl and water were studied using NMR 
and the results showed a reduced molecular mobility for the hydrate phase in comparison 
with the isomorphic dehydrate (Te et al., 2003). In addition, the non-stoichiometric 
behaviour of LY297802 tartrate, a muscarinic agonist, was studied using solid state NMR 
in combination with X-ray crystallography (Reutzel, 1998).  
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1.4.3 Stability and Performance of Hydrates  
 
When dealing with hydrates, their physical and chemical stabilities are important 
parameters to consider. Hydrates might dehydrate or change their hydration level during 
processing or storage, especially if they are in a metastable thermodynamic state. It is 
therefore crucial to understand their dehydration behaviour from both kinetic and 
thermodynamic standpoints before including a hydrated API in a final drug product 
formulation. 
The physical stability of hydrates depends on the temperature and water vapour pressure in 
the surroundings of the solid. Dehydration can be described in a simplistic manner by the 
reaction below, 
                           
 
Please note the above reaction can be, from a thermodynamic point of view, reversible or 
irreversible.  
Dehydration of crystalline solids represents an important group of heterogeneous reactions. 
Galwey proposed a classification for solid state dehydrations entitled ‘Water Evolution 
Type’ (WET) based on a structural, observational and kinetic criteria (Galwey, 2000). This 
complex classification system was developed with the primary objective to reconcile the 
differences and inconsistencies related to the dehydration reactions. 
In this classification, the author divided dehydration reactions into six main groups as 
briefly described below:  
WET 1: Crystal structure is maintained. This class includes hydrates that lose their 
intracrystalline water without significant modification of the host (original) 
structure. 
WET 2: Diffusion across an adherent and coherent barrier layer of product. In this 
group, the rate of dehydration is controlled by the diffusion of the water across the 
crystalline barrier formed by the dehydrated layer. 
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WET 3: Interface advance, nucleation, growth and contracting envelope. In 
general, the nucleation step determines the subsequent geometric development and 
starts at the crystal imperfections.  
WET 4: Homogeneous dehydration reactions in crystals. The chemical change 
occurs with equal probability throughout the crystalline reactant. 
WET 5: Melting and the formation of poorly permeable outer layers. Melting can 
be complete or partial, leading to difficulties in interpretation and development of 
kinetic equations to describe the process. 
WET 6: Comprehensive melting. When the water is liberated during the complete 
melting of the solid. 
 
Parameters such as particle size, morphology and the existence of crystal defects can 
strongly affect the dehydration behaviour of hydrates. Generally, the smaller the particle 
size, the faster is the dehydration process. Also, the presence of crystal defects, usually as a 
result of high-energy particle size reduction processes, can enable dehydration to start at 
that imperfection points and thus accelerating the whole process. The impact on the crystal 
morphology is normally more subtle (Brittain, 2009). 
Apart from the physical stability, it is also important to consider the chemical stability of 
hydrates, namely pharmaceutical hydrates. An intriguing example of chemical stability is 
the case of cefixime trihydrate (Kitamura et al., 1990). When partially dehydrated, 
cefixime trihydrate was found to be unstable due to a highly disordered crystal structure 
caused by loss of its water of crystallisation, which enables a hydrolytic reaction. Although 
the anhydrous form is chemically stable it cannot be used because it readily picks up water 
and rehydrates on storage. Therefore a careful control of temperature and humidity 
conditions is needed upon storage in order to maintain the hydration state of this drug. 
In terms of bioavailability and performance, anhydrous forms are, in general, more soluble 
in aqueous media than the corresponding hydrate forms (Pudipeddi and Serajuddin, 2005).  
This could be explained by the lower release of free energy when the hydrated form 
interacts with water in comparison with the anhydrate form. Nevertheless, some examples 
can be scattered from the literature showing hydrates to be more soluble than the 
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anhydrous form. An example is the case of norfloxacin, a broad spectrum fluoroquinolone 
antibacterial agent, where its hydrates are more soluble than the anhydrate form (Roy et al., 
2008).  
These differences in the hydration level of an API will be translated into distinct aqueous 
solubility/dissolution rates and, as a consequence, bioavailability. An example is the study 
carried out with ampicillin administrated to humans as anhydrous and trihydrate forms 
(Poole et al., 1968). This study showed higher blood serum concentrations for the 
formulations containing anhydrous ampicillin when compared to the concentrations 
produced by the trihydrate. Another aspect to be carefully considered as well is the phase 
transitions occurring during storage or dissolution experiments, as observed with 
nitrofurantoin (Wafik Gouda et al., 1984) and theophylline (Herman et al., 1989), 
respectively. 
The determination of the aqueous solubility of metastable forms can in some cases be a 
challenge. This is the case of carbamazepine that can crystallise as an anhydrate and as a 
dihydrate form. The anhydrous form is reported to be practically insoluble in water, 
however this observation is difficult to be confirmed due to the transformation to the 
dihydrate, once it makes contact with water (Young and Suryanarayanan, 1991).  
Above all, solid state hydrates represent a great slice in the pharmaceutical industry and 
their erratic behaviour hitherto still provides significant manufacturing and processing 
challenges. Nowadays, and taking advantage of characterisation methods, such as, dynamic 
vapour sorption, thermoanalytical, spectroscopic and X-ray diffraction techniques can be 
implemented to evaluate the kinetics, solid state properties and the nature of both tightly 
bound and disordered hydration water. 
 
1.5 Polymorphism and Patents  
 
Finally, a brief overview on the patent systems and legal aspects related to polymorphism 
is presented. Since crystal modifications of a compound represent different crystal entities 
with potentially different physical properties, pharmaceutical companies have all the 
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interest to claim the new discovery to be potentially recognised in the awarding of a patent. 
This will confer the inventor exclusive rights regarding the preparation, sale and use of the 
patented subject matter, which can be used to restrain competition and set prices higher 
than those that would have existed if competitive products were available (Hilfiker, 2006). 
Several disputes in Court have been recorded over the past decades involving drugs with a 
strong position in the market. It is the case of ranitidine HCl, cefradoxil and paroxetine 
HCl. For the relevance to this study, the latter case will be presented in more detail. 
Paroxetine HCl is a selective inhibitor of serotonin and it was firstly prepared as a maleate 
salt by Ferrosan, a Danish company in the 1970s. In 1980, Beecham (now Glaxo 
SmithKline – GSK) started scaling up the preparation of the hydrochloride salt of 
paroxetine and a hemihydrate crystal (Form I) was found (Barnes et al., 1988). GSK was 
able to start marketing paroxetine HCl hemihydrate since 1993 as Paxil
®
.  
Two years later, a Canadian generic company Apotex submitted an Abbreviated New Drug 
Application (ANDA) to the US FDA to market a formulation based on the anhydrate form 
of paroxetine HCl (Form II), and filed a certification that its proposed product would not 
infringe GSK’s patent for the paroxetine HCl hemihydrate product. However, GSK 
claimed that Apotex’s Form II naturally converts into the Form I, making it likely that 
there would be some Form I in Apotex’s product, therefore infringing GSK’s patent. 
Although the district court interpreted the claim as requiring the presence of commercially 
significant amounts of the hemihydrate for infringement to take place and found no reason 
to limit the scope in such a way. 
The above case demonstrates the value of fully understanding the relationship between all 
the physical forms of an API. That information can therefore be used to develop the most 
effective and stable product in order to maintain the intellectual property protection for the 
innovator. 
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1.6 Amorphous Systems 
 
Amorphous materials, also known as glasses, can be defined by the lack of long-range 
order between the molecules when compared to the crystalline structure, as described 
earlier. However, they do possess short-range order and each molecule can establish 
interactions with the neighbour molecules through hydrogen bonding, van der Waals or 
electrostatic interactions (Brittain, 2009).  
In considering the importance of the amorphous state in pharmaceutical systems, they can 
be a result of three main circumstances. Firstly, a material may exist intrinsically in a fully 
or partially amorphous state, examples of which include mainly polymers such as 
polyvinylpyrrolidone (PVP), polyethylene glycol (PEG) and microcrystalline cellulose. 
Secondly, glassy drugs can be prepared intentionally to enhance aqueous solubility and 
dissolution behaviour. Common routes that can be used to prepare amorphous solids 
include quench cooling, solvent precipitation, mechanical activation, freeze drying and 
spray drying. Thirdly, crystalline materials can be inadvertently converted to amorphous 
during processing, some examples are milling, granulation and compression (Craig et al., 
1999; Bruno and George, 1997).  
 
1.6.1 Amorphous Solids: Formation and Properties 
 
Familiar routes used to prepare amorphous solids include quench cooling, solvent 
precipitation, mechanical activation, freeze drying and spray drying. However, the most 
common technique to generate glasses is by the rapid cooling from the melt. The latter two 
technologies (freeze drying and spray drying) will be explained in more detail in further 
sections.  
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1.6.1.1 Generation of Amorphous Materials by Cooling from the Melt 
 
Crystals have lower potential energies than glasses and therefore their formation should be 
more thermodynamically favourable. However, glasses are formed due to kinetic reasons. 
More specifically, crystallisation of supercooled liquids often ‘needs some time’ and may 
fail if ‘insufficient’ time is given. If this happens, a supercooled liquid may form a glass 
upon cooling. 
When a liquid is rapidly cooled below its melting point (Tm) no discontinuity in enthalpy or 
volume is observed and the system forms a supercooled liquid, as shown in Figure 1.7. As 
the material is cooled further, there is a stage where the rate of cooling exceeds the rate of 
molecular rearrangement. At this point, the thermodynamic properties deviate from those 
of the supercooled liquid and a glass is formed (Taylor and Shamblin, 1999; Bruno and 
George, 1997). At this temperature, all the translational and rotational motions of the 
‘frozen’ system are dramatically reduced and a change in heat capacity, Cp (which is the 
derivative of enthalpy with respect to temperature, ∂H/∂T) is detected. This is known as the 
glass transition temperature (Tg).  
When the thermodynamic properties (enthalpy, entropy and volume) of a supercooled 
liquid are extrapolated to temperatures below Tg, they converge with those of the 
crystalline materials, shown by the dashed line in Figure 1.7. This hypothetical point is 
known as the Kauzmann temperature (TK) (Kauzmann, 1948). The TK is considered to 
mark the lower limit of the experimental Tg and to be the point at which the configurational 
entropy of the system reaches zero (see Chapter 5). As a result, TK can be a valuable 
indicator for the long-term storage stability of amorphous solids (Bruno and George, 
1997).  
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Figure 1.7: Schematic illustration of how the enthalpy, entropy and volume of a system changes as a 
function of temperature. Upper line denotes the pathway of an amorphous material while the lower 
line denotes the behaviour of a crystalline material (Bruno and George, 1997). 
 
1.6.1.2 The Glass Transition Temperature 
 
As outlined above, the glass transition temperature, Tg, is by definition, the temperature at 
which changes in the physical state of a material take place from a rubbery viscous liquid 
to a glassy mechanical material. Amorphous systems are mainly characterised by their 
thermodynamic instability where the excess in enthalpy and entropy trapped in the glassy 
material tends to be released over time and at temperatures near Tg. Therefore, Tg is a 
parameter often used to determine the physical and chemical stability of an amorphous 
material (Craig et al., 1999).  
To carry out a measurement of Tg value for a pharmaceutical system, thermal approaches 
are commonly employed, such as differential scanning calorimetry (DSC), 
thermomechanical analysis (TMA), dynamic mechanical analysis (DMA) and dieletric 
analysis (DEA). DSC represents the most used method to characterise an amorphous 
system. TMA has been employed in the study of polymeric systems or cast films (Hancock 
et al., 1995), whereby the dimensional changes of an amorphous sample are measured as a 
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function of temperature. By using DMA, the changes in the viscoelastic properties of an 
amorphous material with temperature can be measured (Craig and Johnson, 1995). In the 
case of DEA, a sinusoidal oscillatory electric field is applied to the sample and the 
dielectric permittivity is measured as a function of temperature, showing an abrupt change 
through the Tg (Stickel et al., 1995). 
 
1.6.1.3 Molecular Mobility and Enthalpy Relaxation 
 
Molecular mobility of amorphous systems can be defined as the molecular motions 
associated with glass transition and represents one of the most important aspects for a 
comprehensive approach of the amorphous state (Bhattacharya and Suryanarayanan, 
2009).  
Since the molecular volume within an amorphous solid is larger than that in the 
corresponding crystalline phase, the enhanced molecular mobility in disordered solids 
affects their chemical and physical reactivity. Molecular motions are temperature 
dependent and, as a result minimal in the glassy state (in the sense of a system being below 
Tg) and greater above the glass transition. Another point of concern is the fact that 
amorphous materials are not static solids, but rather dynamic systems. As a consequence, 
their stability is determined by kinetic aspects which governs their transformation towards 
a more stable form (Byrn et al., 1994). For instance, recently numerous studies have been 
devoted to the characterisation of molecular mobility of pharmaceutical amorphous 
systems in order to predict their physical stability. These studies rely largely on the 
measurement of bulk properties, such as relaxation enthalpy or heat capacity (Shamblin et 
al., 2000). 
One means of measuring mobility is to introduce a perturbation to the system (heat) and to 
see how the system returns to the initial state, a process known as relaxation. As the initial 
state is of higher enthalpy, heat is given off during the relaxation process, and this process 
is also known as enthalpy relaxation (Liu et al., 2002). Relaxation can be divided into α 
and β relaxation. The β-relaxation also called Johari-Goldstein relaxation is normally 
correlated to the motion of some constitutional parts of the molecules (i.e., groups of 
atoms), which is not coupled with the motion of the entire molecule. On the other hand,  
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α-relaxation or commonly known as structural relaxation reflects the motion of the whole 
molecule, i.e., changes in atomic/molecular arrangements that happen during the 
spontaneous conversion from the amorphous to crystalline state, in a scale of time and 
temperature influence (Kawakami and Pikal, 2005; Hilden and Morris, 2004). 
The Kohlraush-William-Watts (KWW) equation is generally used to determine relaxation 
constants, which can be used to describe structural relaxation and correlate molecular 
mobility between different systems. First of all, it is necessary to estimate the maximum 
enthalpy recovery at that particular storage temperature, ΔHmax,T (also called enthalpy 
relaxation at time infinity ΔH∞,T), according to Equation 1.1 (Hancock et al., 1995; 
Hancock and Shamblin, 2001), 
            
         
Equation 1.1 
where, ΔCp
Tg
 is the heat capacity change between the glass and the liquid at Tg and T is the 
temperature at which isothermal relaxation is carried out. 
From the maximum enthalpy recovery, it is possible to calculate the relaxation function (φ) 
at a given time (t) and under a defined temperature T, according to Equation 1.2,   
     
   
       
 
Equation 1.2  
where, ΔHt is the measured enthalpy recovery under those defined conditions.  
This expression can then be used to calculate the molecular relaxation time (τ) as a 
meaningful and direct approach for quantifying molecular mobility as shown by  
Equation 1.3 known as the KWW equation, 
        
 
 
    
Equation 1.3 
where, β is the relaxation time distribution parameter, with a value between 0 and 1.  
β is an indication of the homogeneity of the relaxation process. Values near to the unit 
correspond to an exponential function and are an indication of a narrow distribution of 
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states; values close to zero represent a broad distribution of states, and therefore, wide 
distribution of relaxation times. During the ageing experiments, τ increases with time and β 
decreases with time, therefore some authors recommend to use τβ as a stability indicator, 
since it remains more or less invariant and it is less sensitive to experimental error 
(Kawakami and Pikal, 2005; Liu et al., 2002).  
 
1.6.1.4 Physical and Chemical Stability  
 
Amorphous solids are characterised by their intrinsic thermodynamic instability and 
irreversible tendency towards a most stable state. This phenomenon is known as 
recrystallisation and implies the release of the excess of energy stored by the amorphous 
material. The recrystallisation mechanism involves nucleation followed by crystal growth 
and is influenced by the storage conditions such as temperature and relative humidity. 
Molecular aggregation results in the formation of nuclei, followed by a nucleation phase 
that initiates growth, leading consequently to an actual growth phase (Bruno and George, 
1997).  
The molecular mobility in amorphous systems is low at temperatures below the glass 
transition but increases rapidly above it. It has been suggested that in order to reduce 
molecular mobility and therefore extent the physical stability, amorphous materials should 
be stored at a temperature at least 50 
o
C below its Tg (Hancock et al., 1995). However, this 
fact cannot be taken as a guarantee of stability; firstly, molecular mobility exists even 
below the glass transition temperature; secondly, it is not always possible to keep the 
amorphous samples 50 
o
C below the Tg value; thirdly, the stability of amorphous materials 
is system dependent. An example is the study carried out with glassy indomethacin and 
phenobarbital, both of which have similar Tg values and were stored below their Tg 
(Fukuoka et al., 1989). Phenobarbital was found to recrystallise within one week whereas 
indomethacin was stable for several years. Dissimilarities in their structure and the 
hydrogen bonding might be behind the differences observed. The relationship between Tg 
and the physical stability is therefore complex and certainly not straightforward.  
Another aspect to consider on the stability of amorphous materials is the presence of 
residual amounts of water. Water has a very low Tg value around -135 
o
C (Hallbrucker et 
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al., 1989) and can act as plasticiser of amorphous solids by increasing the free volume of 
these materials, hence increasing its molecular mobility and leading to a decrease in Tg 
(Ahlneck and Zografi, 1990). On the contrary, some excipients can act as stabilisers in 
amorphous pharmaceutical formulations and consequently have an antiplasticising effect 
increasing the overall glass transition of the mixed system (Bruno and George, 1997). 
In terms of chemical reactivity, amorphous solids show, in general, greater chemical 
reactivity when compared to crystals. This is due to the enhanced degree of molecular 
mobility and therefore higher potential for intramolecular and intermolecular chemical 
reactions (Brittain, 2009). A well-documented example is the case of cefoxitin sodium 
(Oberholtzer and Brenner, 1979). Amorphous cefoxitin sodium showed a considerably 
higher rate of thermal degradation and colour change compared to its corresponding 
crystalline form.  
One plausible reason for the increased reactivity of amorphous compounds could be related 
to their tendency in absorbing high amounts of water. According to Shalaev and Zografi, 
water can promote chemical reactivity in amorphous systems acting in four different 
possible ways: a reactant, a product, plasticiser or as a reaction medium (Shalaev and 
Zografi, 1996). The versatility of water alone makes it a critical participant in many types 
of reactions. In addition, the ubiquitous nature of water, in combination with its plasticising 
effect, makes water a culprit in the chemical degradation of many amorphous drugs.  
 
1.7 Solid Dispersion Technology 
 
The use of solid dispersions was firstly introduced in the pharmaceutical field in the early 
1960s by Sekiguchi and Obi (Sekiguchi and Obi, 1961). The authors found that the 
formation of eutectic mixtures of drugs with water soluble carriers by the melting of their 
physical mixtures resulted in a significant bioavailability enhancement. An eutectic 
mixture simply consists of two compounds which are completely miscible in the liquid 
state but only to a very limited extent in the solid state (Goldberg et al., 1965). As a result, 
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the faster dissolution rate and thereby improved bioavailability is a consequence of the 
reduced particle size and better wettability of the API in the polymer matrix.  
Currently, the definition of solid dispersion refers to the dispersion of the drug in a 
biologically inert matrix at a solid state prepared by fusion or solvent methods (Chiou and 
Riegelman, 1971). This formulation strategy has been explored for decades in order to 
improve bioavailability of poorly soluble compounds. Figure 1.8 is a schematic timeline 
representation of the different carriers used to prepare solid dispersions. In the early 
beginning crystalline carriers were used such as urea (Goldberg et al., 1966) and sugars 
(Kanig, 1964). These systems have the disadvantage of forming crystalline solid 
dispersions, which did not release the drug as quickly as the amorphous ones, though they 
were thermodynamically more stable. 
Therefore, a second generation of solid dispersions emerged, containing amorphous 
carriers instead of crystalline. Commonly, the amorphous carrier is a synthetic polymer 
such as polyvinylpyrrolidone based polymers (PVP) (Simonelli et al., 1969; Weuts et al., 
2005), polyethyleneglycols (PEG) (Urbanetz, 2006; Bley et al., 2010) or polymethacrylates  
(Huang et al., 2006); natural product based polymers can also be used to prepare solid 
dispersions and are mainly composed by cellulose derivatives, such as 
hydroxypropylmethylcellulose (HPMC) (Konno and Taylor, 2006), ethylcellulose (Desai 
et al., 2006), hydroxypropylcellulose (Repka et al., 1999) or starch derivate, like 
cyclodextrins (Mura et al., 1999b). 
Recently, the third generation of solid dispersions appeared taking advantage of the surface 
activity or self-emulsifying properties of certain carriers or specific materials. These 
systems are designed to achieve the highest degree of bioavailability for poorly soluble 
drugs and to maximise the stability of the prepared solid dispersion system. Examples of 
surfactants selected for this purpose are inulin (Van Drooge et al., 2006), Gelucire 44/14
TM
 
(Yüksel et al., 2003) and poloxamer 407 (Majerik et al., 2007). The association of 
amorphous polymers and surfactants is also a common approach (Ghebremeskel et al., 
2007). The inclusion of surfactants in the formulation containing a polymeric carrier may 
help to prevent precipitation and agglomeration of fine crystalline particles. On the other 
hand, lipid-based formulations have been shown to enhance oral absorption of lipophilic 
drugs, although the exact mechanism is complex and not yet fully understood (Pouton, 
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2000). Finally, the combination of polymers with different physicochemical properties can 
represent a good strategy in increasing the physical stability of solid dispersions when 
compared with single polymer based systems (Yang et al., 2013; Sakurai et al., 2012). 
 
 
 
Figure 1.8: Classification of solid dispersions according to the nature of the carrier selected  
(adapted from (Vasconcelos et al., 2007)). 
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1.7.1 Preparation Methods for Solid Dispersions 
 
1.7.1.1 Melting Methods 
 
1.7.1.1.1. Traditional Melting Methods 
 
The melting method is the oldest and the easiest way to prepare solid dispersions, provided 
the drug and the carrier are miscible in the molten state. This method consists of melting 
the drug within the carrier followed by cooling and pulverisation of the obtained product  
(Lloyd et al., 1997). The time allowed for the formation of the glass in the supercooled 
melt is considered a critical parameter for the stability of the resulting amorphous material. 
The cooling rate of the melt should be chosen depending on the spontaneous tendency of 
each compound to recrystallise, and can be slow at room temperature or fast in an ice bath 
or by immersion in nitrogen liquid. Generally, faster cooling rates lead to the preparation 
of more stable amorphous systems, as the time scale available for molecular reorganisation 
is lower.  
Limitations of this method include the thermal stability of both drug and polymer at the 
melting temperature and the existence of miscibility gaps in the phase diagram that can 
lead to the formation of a product not homogeneously dispersed. Moreover, this method is 
not suitable to a scale-up preparation of solid dispersions. 
 
 Hot Melt Extrusion 1.7.1.1.2
 
Hot melt extrusion (HME) method consists of the extrusion of the drug and carrier, 
previously mixed, at an elevated temperature for a short period of time. The resulting 
product is then collected after cooling at room temperature (Shah et al., 2012). Since this 
technique was used in this work to prepare solid dispersions it will be described in more 
detail in Chapter 2. 
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1.7.1.2 Solvent Methods 
 
 Solvent Evaporation Methods 1.7.1.2.1
 
Solvent evaporation methods were firstly introduced in the 1960s and since then many 
workers have taken up this method for the preparation of solid dispersions (Tachibana and 
Nakamura, 1965). The solvent evaporation method consists of the dissolution of the drug 
and carrier in a volatile solvent that is later evaporated. In this method, the thermal 
decomposition of drugs or carriers can be prevented, since the evaporation of the organic 
solvent occurs at low temperatures. However, it is a prerequisite that both the drug and 
polymer are soluble in the solvent, usually ethanol, chloroform or dichloromethane. 
 
 Freeze Drying 1.7.1.2.2
 
The basic freeze drying process consists in three main steps: freezing, primary drying  
(by sublimation) and secondary drying (by desorption). The drug and carrier are dissolved 
in a common solvent (usually water), which can be immersed in liquid nitrogen until it 
becomes completely frozen (Tang and Pikal, 2004).  
In this first step, two phases are formed: one is the frozen solvent and the other is the 
highly concentrated solute termed as ‘freeze concentrate’. The next step is the primary 
drying which involves the sublimation of the frozen solvent under vacuum and with 
relatively low temperature in order to enhance the sublimation of the solvent. After this 
step, the product still contains a certain amount of water, ranging from 5 to 20%, 
depending on the nature of the formulation. Therefore, in the secondary drying the shelf 
temperature is raised at much higher temperature than in the primary drying step so that 
desorption of the residual solvent occurs at a high rate (Tang and Pikal, 2004; Craig et al., 
1999). 
Besides of its use to prepare rapidly dissolving oral dosage forms, freeze drying has also 
gained considerable application in the processing of pharmaceutical products of biological 
origin including vaccines, peptides and liposomes (Craig et al., 1999). 
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 Spray Drying 1.7.1.2.3
 
Spray drying is a well-established method for processing solutions, emulsions and 
suspensions into powders, efficiently controlling the size, density and morphology of the 
particles. Spray drying is one of the most commonly used solvent evaporation techniques 
in the preparation of solid dispersions. It consists of dissolving or suspending the drug and 
carrier, then spraying it into a stream of heated air flow to remove the solvent. 
Similarly to HME, spray drying will be discussed in more detail in Chapter 2 of this 
dissertation.   
 
 Electrospinning 1.7.1.2.4
 
Electrospinning has gained particular interest in the last five years due to its simple and 
versatile ability to produce nanofibers suitable for the delivery of poorly water soluble 
drugs. During the electrospinning process a solution containing the polymer and API is 
pumped through a thin nozzle with an inner diameter on the order of 100 mm. The nozzle 
simultaneously serves as an electrode, to which a high electric field of  
100–500 kVm is applied. This results in charge being induced within the solution, which 
causes the initiation of a jet. As this jet travels the solvent’s evaporation is accelerated and 
the electrospun fibers can be collected (Greiner and Wendorff, 2007). This process is 
schematically represented in Figure 1.9. As the solvent evaporates, the drug molecules are 
dispersed in the polymer fibers matrix, producing electrospun fibers that can enhance drug 
solubility (Bikiaris, 2011; Ignatious et al., 2010). 
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Figure 1.9: Illustration of the electrospinning procedure (Bikiaris, 2011). 
 
Electrospinning technology has several advantages when compared with other solvent 
based techniques used to prepare solid dispersions: firstly, it is a one-step manufacturing 
process of amorphous solid dispersions that can be easily scalable; secondly, the prepared 
electrospun fibers have a very large area-to-volume ratio organised in a three-dimensional 
continuous web structure, which gives higher available surface area; thirdly, a small 
solvent content was found to remain in the final products (Yu et al., 2010).  
 
1.7.2 Advantages, Disadvantages and Concerns of Solid Dispersions 
 
In recent years, there has been an increased interest in the use of amorphous APIs in 
various formulations, especially when their crystalline forms are shown to exhibit poor 
aqueous solubility. This often compromises dissolution within the gastrointestinal tract and 
may be the rate limiting step to absorption, ending with inadequate oral bioavailability 
(Brouwers et al., 2009). Amorphous forms tend to exhibit high levels of supersaturation in 
aqueous media relative to the crystal, and thus higher apparent solubility. This increase 
arises from the lack of a highly ordered crystal with lattice energies that must be overcome 
to attain adequate solubility of the crystal.  
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As compared to single component amorphous APIs, the presence of a hydrophilic carrier in 
amorphous solid dispersions can contribute to increase the wettability of the drug and at 
the same time act as crystallisation inhibitor improving their physical stability.  
However, despite the advantages of solid dispersion formulations they are not broadly used 
in commercial products, mainly because there is the possibility that during processing 
(mechanical stress) or storage (temperature and humidity stress) the amorphous state may 
undergo crystallisation. Moreover, phase separation between the drug and the polymer can 
also promote crystal growth. This may result in decreased solubility and dissolution rate 
(Pokharkar et al., 2006; Vasconcelos et al., 2007). Therefore, exploitation of the full 
potential of amorphous solids implies a suitable stabilisation in solid state, as well as 
during in vivo performance.  
The first concern when intending to prepare solid dispersions with an API and a polymer is 
to evaluate their degree of miscibility. Approaches such as melting point depression 
(MPD) and solubility parameter (δ) are often used to infer on the miscibility of a system; 
these two methods will be discussed in Chapters 6 and 7. It is also well-recognised that the 
addition of polymers with a high Tg can increase the Tg of the miscible mixture, thereby 
reducing the molecular mobility at regular storage temperatures (Weuts et al., 2005). 
Additionally, drug-polymer specific interactions between functional groups, in general 
through hydrogen bonds, tend to increase the energy barrier against recrystallisation 
(Matsumoto and Zografi, 1999). Finally, specific properties of the polymer such as the 
degree of hygroscopicity can represent a considerable advantage in the stabilisation of 
these systems. The influence of the polymer type in the preparation of amorphous solid 
dispersions of olanzapine, a poorly water soluble antipsychotic drug, will be explored in 
Chapter 7 of this thesis. 
 
1.8 Phase Transformations during Processing 
 
After the identification and thorough characterisation of the most appropriate physical 
form of an API, it is important to ensure that the selected crystal form is retained in the 
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final pharmaceutical product. Stresses induced during production and interactions with 
formulation components can lead to phase transformations. Understanding the effect of 
each processing step on the API physical form is therefore very important in ensuring the 
phase purity of the drug substance used throughout the product development stream 
(Brittain, 2009). 
Generally, the transformations of the materials can be simply classified as solid-solid 
(phase transition, deformation), solid-liquid (melting, crystallisation) or solid-gas 
(sublimation, condensation) (Morris et al., 2001). More specifically in the pharmaceutical 
field, scenarios of amorphisation, crystallisation, polymorphic transitions and incorporation 
or removal of solvents from the crystal lattice are the most relevant physical solid state 
transitions (Figure 1.10). As a result, properties such as stability, solubility, dissolution, 
bioavailability, density, hardness, etc., might be influenced by phase transformations. A 
brief description of the impact of pharmaceutical processes on solid phase transformations 
is presented.   
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Figure 1.10: Schematic representation of possible phase transformations induced during processing (adapted from reference (Hilfiker, 2006)).
Phase Transformations during Pharmaceutical Processing 
Amorphisation  
(reduction in  
long-range order) 
Disorder induced by  
mechanical processing 
Amorphisation due to  
quenching melt 
Vitrification form  
solution 
Crystallisation  
(increase in long-range  
lattice order) 
Heat induced 
Solution mediated 
Plasticiser induced 
Polymorphic transitions 
 (change in lattice structure) 
Solid-solid transition  
Mediated by solution,  
melt or amorphous 
 intermediate 
Change in chemical 
 composition 
Solvation/Desolvation 
Complex formation 
Salt formation/free  
acid or base 
 
Chapter I 
 
81 
 
1.8.1 Milling 
 
Milling is one of the first steps during solid product processing that leads to particle’s 
fracture and size reduction. This might facilitate subsequent processing and enhance 
product performance. Nevertheless, it is important to account that milling normally imparts 
mechanical stress and generates heat and vibrational energy that can induce phase 
transitions such as polymorphic transitions and vitrification via solid state (amorphisation) 
(Zhang et al., 2004).  
Several cases can be found in the literature reporting solid phase transformations during 
milling. One example is the case of ranitidine HCl (Chieng et al., 2006). The authors 
studied the effect of the milling conditions on the polymorphic stability of ranitidine HCl 
Form I. Ranitidine HCl Form I was found to convert to Form II or an amorphous form 
depending on the temperature at which the milling process was carried out. Additionally, it 
is important to bear in mind that crystalline materials can also be converted to amorphous 
solids by continuous grinding via dehydration/desolvation. Carbamazepine dihydrate was 
milled at different environmental humidity conditions and it converted to an amorphous 
phase after the removal of the first mol of water. The amorphous form then transformed 
into the anhydrate after dehydration of the second mol of water (Otsuka et al., 1999). A 
direct polymorphic transition was observed with caffeine metastable Form I that rapidly 
converted to the stable Form II after 3 min of milling time (Pirttimaki et al., 1993). 
 
1.8.2 Wet Granulation 
 
In general, a granulation step may be required in order to improve the flow and 
consolidation properties of a blend as it proceeds into tableting. Commonly, two methods 
are used to prepare suitable granules: (1) wet granulation, that involves an aqueous or 
hydro-alcoholic binder solution (alone or with a polymer) is added to a dynamic powder 
bed and a drying step is followed; (2) dry granulation on the other hand is typically used 
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when the formulation ingredients are sensitive to moisture or elevated drying temperatures 
(Zhang et al., 2004). As a result, wet granulation is more likely to induce phase transitions, 
especially with compounds that tend to form stable hydrates at ambient conditions. 
Therefore, depending on the exposure time to the granulation liquid and drying conditions, 
the final product can be a mixture of an anhydrous, a metastable or even partially or total 
amorphous forms. 
Anhydrous forms of theophylline and carbamazepine were found to be transformed into 
their respective hydrates during aqueous wet granulation (Otsuka et al., 1997; Debnath and 
Suryanarayanan, 2004). Another example is the case of thiamine HCl, a relatively water 
soluble nutritional factor (vitamin B1) that was found to dissolve in the granulation fluid 
(Wostheinrich and Schmidt, 2001). As a consequence, multiple phase changes were 
detected during processing, with conversion into the most stable hemihydrate form during 
storage. 
 
1.8.3 Compression 
 
As with milling, the compression of powders to prepare tablets involves the application of 
significant force, which may cause solid phase transformations in either the API or the 
excipients. Compression can induce dissolution of crystals in adsorbed water or conversion 
to stable/unstable or even amorphous forms. Polymorphic transformations of caffeine, 
sulfabenzamide and maprotiline HCl were studied as function of powder particle size and 
compression forces (Chan and Doelker, 1985). 
 
1.8.4 Freeze Drying 
 
Another process that can result in phase transitions is freeze drying. Lyophilised products 
are often unstable and may also undergo phase conversions during processing. A complex 
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example is mannitol that has a tendency to freeze dry as a combination of crystalline and 
amorphous solids. Therefore, slight variations in the lyophilisation process can result in the 
generation of different solids (Haikala et al., 1997).  
Overall, APIs and excipients are exposed to different kinds of stresses during manufacture 
which can result in phase transformations. The most commonly observed transitions are 
amorphous ↔ crystalline, anhydrate ↔ hydrate and polymorphic conversions.  
The characterisation and identification of such transitions is not always straightforward due 
to the presence of multiple components in the formulation. Therefore it is important to 
perform a thorough physical characterisation of the API throughout the manufacturing line 
as a way to detect and control possible phase transformations during processing. 
 
1.9 Research Objectives 
 
In this thesis, structural characterisation from basic structure of two APIs (olanzapine and 
paroxetine HCl) was carried out and extended through the formulation into solid dispersion 
systems. Furthermore, the structure-property relationship was linked to the experimental 
performance and physical stability. The main objectives of each individual chapter are 
presented in more detail in the preceding Scope and Overview section.    
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2.1 Materials 
 
2.1.1 Paroxetine Hydrochloride 
 
Paroxetine hydrochloride (HCl) is functionally classified as a selective serotonin re-uptake 
inhibitor (SSRI) that enhances serotonergic transmission by blocking the pre-synaptic 
active membrane transport mechanism and therefore increases the serotonergic activity at 
the post-synaptic receptor, as illustrated in Figure 2.1. Paroxetine HCl has been used for 
the treatment of depression, obsessive-compulsive disorder, panic disorder and social 
phobia (Bourin et al., 2001; Johnson, 1992). 
Paroxetine HCl can exist in two different crystal forms, Form I and II. Form I is a 
hemihydrate and the most stable form of paroxetine HCl. Paroxetine HCl Form II had been 
previously classified up to this study as a very hygroscopic anhydrous form (Buxton et al., 
1988). This form was thoroughly studied in this work and results are presented in Chapter 
3 of this dissertation.  
 
 
 
 
 
 
 
 
 
 
Figure 2.1: Mechanism of action of specific serotonin (5-HT) reuptake inhibitors (SSRI)  
(www.cnsforum.com). 
 
Figure 2.2 presents the chemical structure of paroxetine HCl.  
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Figure 2.2: Chemical structure of paroxetine HCl. 
 
Table 2.1 presents a list of general physicochemical properties of the two forms of 
paroxetine HCl, Forms I and II, which will be studied further in the following chapters. 
 
Table 2.1: General physicochemical properties of paroxetine HCl Forms I and II. 
 
Properties Form I Reference Form II Reference 
IUPAC 
Name 
(3S,4R)-3-[(1,3-
Benzodioxol-5-
yloxy)methyl]-4-(4-
fluorophenyl)piperidine 
 
(3S,4R)-3-[(1,3-
Benzodioxol-5-
yloxy)methyl]-4-(4-
fluorophenyl)piperidine 
 
Chemical 
Formula 
C19H20FNO3.HCl.
1
/2H2O  C19H20FNO3.HCl  
General 
Designation 
Stoichiometric hydrate 
(Hemihydrate) 
(Barnes et 
al., 1988) 
Non-stoichiometric 
hydrate* 
Chapter 3 
Molecular 
weight 
(MW) 
374.83 g/mol  365.83 g/mol  
Density (ρ) 1.35 g/cm3 
(Yokota et 
al., 1999) 
1.36 g/cm
3
 
(Howard et 
al., 2003) 
Entries in 
the CSD** 
GODVAW 
GODVAW01 
 EHOXEE  
 
*Note that this is a finding of the current work and the evidence for this assertion is outlined in Chapter 3 
**Cambridge Structural Database 
 
Chapter II 
 
87 
 
2.1.2 Olanzapine 
 
Olanzapine, a thienobenzodiazepine derivative, is a second generation (atypical) 
antipsychotic agent used in the treatment of schizophrenia, depressive episodes associated 
with bipolar disorder and acute maniac episodes (Bhana and Perry, 2001; Bhana et al., 
2001). It has shown in vitro, binding affinity for a broad range of neurotransmitter 
receptors (serotonin 5-HT2A-C, adrenergic, histamine H1 receptors, dopamine D1 and all 
five types of the muscarinic receptors). 
Olanzapine has been suggested to crystallise in more than 25 crystal forms, including 
several anhydrates, hydrates and solvates. Recently, a paper published by Bhardwaj et al. 
determined the crystalline structure of 24 new solvate forms (Bhardwaj et al., 2013).  
The same group calculated the crystal energy landscape of different forms of olanzapine 
and concluded that olanzapine molecules have a packing efficiency no more than 70%, 
which explained the prolific tendency to form solvates.  
In this work olanzapine Form I was used to prepare solid dispersions with different 
polymers via hot melt extrusion (Chapter 7). Form I is an anhydrous form and the most 
stable crystalline form of olanzapine. Its chemical structure and main physicochemical 
properties are presented below in Figure 2.3 and Table 2.2, respectively. 
 
 
 
Figure 2.3: Chemical structure of olanzapine. 
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Table 2.2: Physicochemical properties of olanzapine Form I. 
 
Properties Olanzapine Form I Reference 
IUPAC Name 
2-methyl-4-(4-methylpiperazin-1-yl)-5H-thieno 
[3,2-c][1,5]benzodiazepine 
 
Chemical Formula C17H20N4S  
General Designation Anhydrate Form I 
(Reutzel-Edens et al., 
2003) 
Molecular weight 
(MW) 
312.43 g/mol  
Density (ρ) 1.30 g/cm3 
(Reutzel-Edens et al., 
2003) 
Entries in the CSD 
UNOGIN 
UNOGIN01 
(Reutzel-Edens et al., 
2003, (Wawrzycka-
Gorczyca et al., 
2004a) 
Recrystallisation 
from solvents 
Can be recrystallised from anhydrous solvents 
such as ethyl acetate, toluene, propyl acetate, 
isopropyl acetate, butyl acetate, tetrahydrofuran 
and acetone. As well as from desolvation of 
several low alcohol solvates viz., methanol, 
ethanol and propanol and from dihydrates  
B, D and E 
(Bunnell et al., 1996, 
1998; Wawrzycka-
Gorczyca et al., 
2004a; Bunnell et al., 
2001; Reutzel-Edens 
et al., 2003a) 
Entries in the CSD 
UNOGIN 
UNOGIN01 
(Reutzel-Edens et al., 
2003, (Wawrzycka-
Gorczyca et al., 
2004a) 
Others 
Adopts mirror-related conformation (conformer 
A and B) 
(Reutzel-Edens et al., 
2003) 
 
Table 2.3 below presents a resume of several polymorphic and pseudopolymorphic forms 
of olanzapine described in the literature, their properties and preparation methods. 
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Table 2.3: Principal characteristics and properties of other forms of olanzapine. 
Solid State 
Classification 
Designation Principal Features 
Anhydrates 
Form II 
 
 Considered to be metastable and not well suited for commercial use in pharmaceutical formulations; 
 Prepared from desolvation of methanol solvate and crystallised from acetonitrile and dichloromethane 
(Reutzel-Edens et al., 2003a; Bunnell et al., 1997); 
 Single crystals of this form were isolated in a recent work (Bhardwaj et al., 2013), which allowed to finally 
obtain its crystal structure; 
Form III 
 
 Prepared by dissolving Form I or II in aqueous acid solution (HCl, H2SO4, CH3COOH) followed by a 
precipitation of olanzapine from the resultant salt using a methanolic solution (Hamied et al., 2002); 
 Reutzel-Edens et al. (2003) stated in their work that the attempts to prepare pure Form III were not 
successful. However the desolvation in mild conditions of CH2Cl2 and CHCl3 solvates result in Form III free 
of Form II, but still not yield to a pure Form III; 
 
Hydrates 
 
Dihydrates B, D  
and E 
 
 The structure of three dihydrates (B, D and E) and its relative stability has been reported by  
Reutzel-Edens et al. (2003). In their work, the dihydrates B and E showed a lower dehydration temperature 
(≈ 25 oC) in comparison to the dihydrate D (≈ 50 oC);  
 The hydrates B and E are considered to be channel hydrates; 
 Dihydrate D is considered to be the most stable, having a more organised crystal packing and therefore a 
higher dehydration temperature; 
 Refcodes of the dihydrates of olanzapine deposited in the CSD: AQOMAU (dihydrate D), AQOMAU01 
(dihydrate B) and AQOMAU02 (dihydrate E); 
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Higher hydrate 
 
 Crystallise from EtOAc-toluene-water mixtures at temperatures lower than 55 oC and dichloromethane-
water mixtures; 
 It is a metastable form containing 2-2.5 mol of water; 
 It converts to the dihydrate E within few minutes after being isolated from the crystallisation solution; 
 Two hydrate forms are reported in the CSD: AQOMEY (Reutzel-Edens et al. 2003) and AQOMEY01; the 
last entry, is described to be submitted into CSD by (Wawrzycka-Gorczyca et al. 2007), however no 
information is available in the published paper; 
Two 
components 
(solvent-
olanzapine) 
solvates 
Ethanol and  
1-propanol solvate 
 
 Its desolvation leads to Form I (Bunnell et al. 1997); 
Methanol solvate 
 
 The desolvation of this solvate lead to Form I (Bunnell et al., 1997); 
 Its structure has been reported (Wawrzycka-Gorczyca et al., 2004b) and deposit into the CSD (UNOGOT); 
 Accordingly to the solved structure, the methanol molecules are localised in channels; 
Dichloromethane 
solvate 
 
 It has been firstly prepared (Larsen, 1997) by dissolving olanzapine in CH2Cl2 at 30 
o
C and keeping the 
mixture isothermal for 30 min, followed by a rapid cooling in an ice-bath; 
 The structure of this form solved later in 2007 and submitted to the CSD with the refcode WEXQAS 
(Wawrzycka-Gorczyca et al., 2007); 
 It is described to crystallise in a ratio of 1:2 solvent-drug molecules; 
 The intermolecular hydrogen bonds N-H…N found in Form I, were also reported for this structure; 
 It is an unstable form and its desolvation results in olanzapine Form I; 
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Three 
components 
(water-
solvent-
olanzapine) 
solvates 
 
Methanol solvate 
monohydrate 
 
 The structure of this solvate was solved (Capuano et al., 2003) and submitted to the CSD  
(refcode: ELEVOG); 
 The piperazine ring adopts a chair conformation with the methyl group in a equatorial position; 
Dimethylsulfoxide 
solvate monohydrate 
 
 The solved structure (Polla et al., 2005) showed a water:DMSO proportion of 1:0.40 and to be isostructural 
to others solvates, viz., methanol solvate and methanol solvate monohydrate; 
 Refcode in CSD: CAYTUS; 
 It completely desolvates upon heating (weight loss = 13%) and melts as olanzapine Form I; 
Methanol solvate 
dihydrate 
 
 Its structure has been solved (Wawrzycka-Gorczyca et al., 2007); 
 It is described to crystallise in a ratio of 2:1:2 olanzapine:ethanol:water, respectively; 
 As previously mentioned, olanzapine molecules are arranged into dimers which are hydrogen bonded to 
water and ethanol molecules; 
 Refcode in the CSD: WEXQEW; 
Butan-2-ol solvate 
monohydrate 
 
 The crystalline structure showed that the olanzapine dimers are linked through bridges established by the 
water molecules (Wawrzycka-Gorczyca et al., 2007); 
 The stoichiometry of this three component solvate is 1:1:1 (olanzapine:butan-2-ol:water) and its refecode in 
CSD is WEXPUL; 
Isopropanol solvate 
dihydrate 
 
 It is described to crystallise with a stoichiometry 2:1:2, olanzapine:isopropanol:water, respectively  
(Kotar-Jordan et al., 2011); 
 It can be converted into to a methylene chloride solvate and then to olanzapine Form I; 
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2.1.3 Polyvinylpyrrolidone  
 
Soluble polyvinylpyrrolidone (PVP), also known as Povidone, is obtained by free-radical 
polymerisation of vinylpyrrolidone in water or 2-propanol (Bühler, 2005), yielding the 
chain structure shown in Figure 2.4. 
 
 
 
 
 
Figure 2.4: Chemical structure of PVP. 
 
PVP is classified as an extremely hygroscopic substance, which is attributed to the 
electronegative groups of the carbonyl group in the pyrrolidone structure able to establish 
hydrogen bonding with water (Callahan et al., 1982).  
Differentiation between the different grades of PVP homopolymers is made based on their 
molecular weights and relative viscosity in water. Therefore, it is possible to calculate a  
K-value for each grade according to the Ph. Eur. and USP monographs. Within the PVP 
homopolymers family, higher K-values are related to higher molecular weight and 
therefore higher viscosity (Bühler, 2005). 
In terms of pharmaceutical applications, PVP is commonly used as adhesive and binder, 
particularly important in tableting and also incorporated in the film-coating of tablets, in 
transdermal systems and in medicinal sprays (Bühler, 2005). PVP has been extensively 
reported in the literature to have good stabilising effects on amorphous APIs (Khougaz and 
Clas, 2000; Tantishaiyakul et al., 1999, 1996). Therefore, in this work, PVP K30 was used 
as a carrier in solid dispersion formulations, as a means of stabilising amorphous 
olanzapine prepared via hot melt extrusion. The physicochemical and general properties of 
PVP K30 are described in Table 2.4. 
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Table 2.4: Physicochemical properties of PVP K30. 
 
Properties PVP K30 Reference 
IUPAC Name Polyvinylpyrrolidone  
Chemical Formula (C6H9NO)n  
General Designation Povidone  
Molecular weight (MW) 31 700 – 51 400 g/mol (Bühler, 2005) 
Glass transition 
temperature (Tg) 
≈ 160 oC (Bühler, 2005) 
Density (ρ) 1.16 g/cm3 (Chokshi et al., 2005) 
 
2.1.4 Polyvinylpyrrolidone Vinyl-Acetate 
 
Polyvinylpyrrolidone vinyl-acetate (PVPVA), also known as Copovidone, is manufactured 
by free-radical polymerisation of 6 parts of vinylpyrrolidone and 4 parts of vinyl-acetate in  
2-propanol. Figure 2.5 below shows the chemical structure of the repeating units of 
PVPVA 6:4. 
 
 
Figure 2.5: Chemical structure of PVPVA 6:4. 
 
 
Chapter II 
 
94 
 
Table 2.5 lists the main physicochemical properties of PVPVA 6:4. 
 
Table 2.5: Physicochemical properties of PVPVA 6:4. 
 
Properties PVPVA 6:4 Reference 
IUPAC Name 
Polyvinylpyrrolidone 
vinyl-acetate 
 
Chemical Formula (C6H9NO)6(C4H6O2)4  
General Designation Copovidone  
Molecular weight (MW) 45 000 – 70 000 g/mol (Bühler, 2005) 
Glass transition 
temperature (Tg) 
≈ 105 oC (Bühler, 2005) 
Density (ρ) 1.17 g/cm3 (Chokshi et al., 2005) 
 
The applications of PVPVA, in line with PVP, rely mainly on its good binding and  
film-forming properties, its affinity to hydrophilic and hydrophobic surfaces. Because of 
these properties, it is commonly used as a processing aid in the production of granules and 
tablets, as a binder in direct compression, in film coatings on tablets, as a protective layer 
and sub-coat for tablet cores and as a film-forming agent in sprays. In addition, the 40% 
replacement with the lipophilic vinyl-acetate functional groups makes this co-polymer to 
be relatively less hygroscopic which has resolved some processing and handling issues of 
the homopolymer system (Bühler, 2005).  
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2.1.5 Soluplus® 
 
Soluplus
® 
(SLP) is a polymeric solubiliser with an amphiphilic chemical structure. Due to 
its dual character, SLP shows excellent solubilising properties for poorly soluble APIs and 
therefore it was particularly developed for the formulation of solid dispersions (Shamma 
and Basha, 2013). For use in hot melt extrusion approaches, the Tg of this polymer was 
adjusted to approximately 70 
o
C in order to enable extrudability at lower temperatures 
compared to the already known polymers (Reintjes, 2011).  
SLP has a polyethylene glycol (PEG) 6000 backbone with one or two side chains 
consisting of vinyl-acetate randomly copolymerised with vinyl-caprolactam (13% PEG 
6000/57% vinyl-caprolactam/30% vinyl-acetate) as shown in Figure 2.6.  
 
 
 
Figure 2.6: Chemical structure of Soluplus
®
. 
 
Table 2.6 displays the main physicochemical properties of Soluplus
®
. 
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Table 2.6: Physicochemical properties of Soluplus
®
. 
 
Properties Soluplus
®
 Reference 
IUPAC Name 
Polyethylene 
glycol/vinyl-
caprolactam/vinyl-acetate 
 
Chemical Formula (C21H39NO8)m   
Molecular weight (MW) 118 000 g/mol (Reintjes, 2011) 
Glass transition 
temperature (Tg) 
≈ 70 oC (Reintjes, 2011) 
Density (ρ) 1.20 g/cm3 (Djuris et al., 2013) 
 
2.1.6 Raw Materials Sourcing  
 
As a resume, Table 2.7 lists the suppliers of all APIs, polymer carriers and other chemicals 
used in this study. 
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Table 2.7: Sources of chemicals used in this study. 
 
Category Substance Supplier 
APIs and 
Polymers 
Paroxetine HCl Form I Afine (China) 
Paroxetine HCl Form II Huahai Pharmaceuticals (China) 
Olanzapine Form I Myjoy Ltd. (India) 
PVP K30 BASF (Germany) 
PVPVA 6:4 BASF (Germany) 
Soluplus
®
 BASF (Germany) 
DSC Standards 
n-Octedacane Sigma Aldrich (UK) 
Benzoic acid Sigma Aldrich (UK) 
Indium Sigma Aldrich (UK) 
Tin Sigma Aldrich (UK) 
Sapphire disc TA Instruments (US) 
DVS Standard Sodium Bromide Sigma Aldrich (UK) 
Salts used for 
Stability Test 
Sodium Chloride Fischer Scientific (UK) 
Magnesium Nitrate Hexahydrate Fluka (Germany) 
Calcium Chloride BDH Laboratory (UK) 
Potassium Acetate Alfar Aesar (UK) 
Phosphorus Pentoxide Alfar Aesar (UK) 
Solvents Methanol Sigma Aldrich (UK) 
Karl Fischer 
Reagents 
Hydranal
®
 Solvent Fluka Analytical (US) 
Hydranal
®
 Titrant Fluka Analytical (US) 
Hydranal
® 
Standard Fluka Analytical (US) 
Materials used to 
Prepare 
Dissolution Media 
Hydrochloride Acid Sigma Aldrich (UK) 
Potassium Dihydrogen Orthophosphate Fischer Scientific (UK) 
Sodium Phosphate Dibasic Sigma Aldrich (UK) 
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2.2 Preparation of Solid Dispersions 
 
2.2.1 Spray Drying 
 
Spray drying (SD) is a technique used to dry aqueous or organic solutions, suspensions or 
pastes into a dry particle form. The use of drying of products from an atomised liquid 
stream was firstly reported by Percy in 1872 (Percy, 1872). Since that time, and due to 
significant equipment development, SD became a versatile technique with application in 
several different areas, ranging from food, ceramics and fertilisers to the pharmaceutical 
industry. 
In the pharmaceutical industry, SD has been used from simple drying operations to the 
process of peptides and vitamins and has particular importance for the production of 
particles with optimal properties for inhalation therapy (Vidgren et al., 1987). In this work, 
SD was selected to prepare amorphous solid dispersions due to the main advantage of the 
very fast solvent evaporation that leads to rapid viscosity increase and permits kinetic 
trapping of the API in the carrier matrix (Paudel et al., 2012). 
A typical spray drying process consists of four basic steps ( u chi, 2003): 
1. Atomisation of the liquid feed 
2. Mixing of the liquid with the drying gas 
3. Evaporation of the liquid 
4. Separation of the dried particles from the gas 
 
Atomisation transforms the liquid stream into fine droplets by applying a force. The more 
energy supplied during this step, the smaller the droplets and consequently the smaller the 
spray dried particles produced.  
The liquid spray is subsequently mixed with the drying gas. Normally, compressed air is 
the medium of choice; however, if organic solvents are being used then an inert gas such as 
nitrogen should be used to minimise the risk of explosion. The drying gas needs to have 
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the right temperature and humidity, which must be adjusted accordingly to the nature of 
the sample. For instance, if the solvent is water, higher temperatures would be required 
compared to organic solvents.  
The contact between the droplet and the heated gas resulted in the evaporation of the 
solvent from the saturated vapour film at the droplet surface. The design of the drying 
chamber and the gas flow allows the droplets to reside in the chamber until the desired 
moisture content is achieved and then the product is immediately discharged from the 
chamber. The last step in the SD process is the collection of the particles, which requires 
the separation of the dried droplets from the drying gas stream, most commonly via a 
cyclone. 
Reviews have been published in recent years concerning the fundamentals of spray drying 
(Cal and Sollohub, 2010; Sollohub and Cal, 2010; Vehring et al., 2007) and exploring the 
influence of process and formulation parameters on the quality of the resulting spray dried 
products (Corrigan, 1995; Paudel et al., 2012).  
The main steps involved in the spray drying process and referred above are identified in 
Figure 2.7. In this study a Bu chi Mini Spray Dryer B-290 ( u chi, Switzerland) was 
used. 
 
 
 
Figure 2.7: Bu  chi Mini Spray Dryer B-290, a laboratory-size model (Bu  chi brochure).  
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2.2.2 Hot Melt Extrusion 
 
Hot melt extrusion (HME) is a processing technique widely applied in the plastic, rubber 
and food industry. In the past few years, an extensive number of studies have shown the 
potential of this technology in the pharmaceutical field for manufacturing a variety of 
dosage forms and formulations such as granules, pellets, tablets, implants, transdermal 
systems and ophthalmic inserts (Breitenbach, 2002). HME is a continuous manufacturing 
process in which a blend of API, thermoplastic polymeric carrier and other processing aids, 
including plasticisers and antioxidants, is heated and softened inside the extruder barrel 
and then pressurised through a die into granules, cylinders or films (Crowley et al., 2007; 
Repka et al., 2007).  
The extrusion process can be categorised as either ram extrusion or screw extrusion. Screw 
extrusion consists of one or two rotating screws inside a heated barrel, while ram extrusion 
operates with a positive displacement ram capable of generating high pressures to push 
materials through the die. Ram extrusion has limited melting capacity that causes poor 
temperature uniformity in the extrudate compared to screw extrusion and for that reason is 
not used for HME (Crowley et al., 2007). Screw extruders used for pharmaceutical 
applications typically consist of two screws (twin screw) and can be categorised, 
depending on the direction of rotation of the screw, as co-rotating or counter-rotating.  
Figure 2.8 displays a schematic representation of a typical lab scale extruder. An extruder 
can be divided into three main zones: the feeding, the melting or compression and the 
metering zone. The different zones of the barrel are pre-set to specific temperatures prior 
the extrusion process. The API and polymer are premixed and fed into the extruder via a 
hopper. The feedstock is further transported along the length of the barrel, where it is 
melted, plasticised, mixed and compressed. The material transfer should be efficient in 
order to maintain an increase in pressure in the compression zone and the metering zone. 
The primary function of the metering zone is to ensure thickness, consistent flow and 
steady delivery rate through the die (Breitenbach, 2002).  
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Figure 2.8: Illustration of a typical HME equipment (www.particlesciences.com). 
 
Overall, HME offers the possibility of continuous process and thus efficient scale up. 
Moreover, it is a solvent free processing technique and therefore it is environment friendly 
and cost effective. However, it also has some drawbacks, such as the limitation to process 
heat or mechanical sensitive drugs. 
Based on these characteristics, HME has been successfully applied on the design and 
manufacture of delivery systems for poorly soluble drugs (Tho et al., 2010; Lakshman et 
al., 2008; Feng et al., 2012). Basically, the solubility enhancement occurs through 
dispersion of the poorly soluble API in a polymeric (or lipid) carrier matrix essentially 
forming a solid dispersion. Several aspects must be considered in order to obtain an 
adequate solubilisation in melt extrusion, which depends on the materials (drug and carrier 
properties), process (processing temperature, screws rotation speed, residence time) and 
equipment (design and operating conditions). 
In this work, a Thermo Scientific HAAKE MiniLab II (Thermo Scientific, UK) equipped 
with co-rotating twin screws, was used. A die of round shape with a diameter of 2 mm was 
attached to the extruder.  
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2.3 Characterisation Techniques 
 
2.3.1 Differential Scanning Calorimetry   
 
2.3.1.1 Principles of Operation 
 
Differential scanning calorimetry (DSC) is a well-established method of thermal analysis 
within the pharmaceutical sciences. DSC technique consists in applying a heat signal to a 
sample and consequently measuring the response in terms of the energy and temperature 
associated with the relative events, such as melting, crystallisation, glass transition and 
decomposition reactions of the materials. The temperature profile may be a heating, 
cooling or an isothermal program (Craig and Reading, 2007). 
There are two different types of DSC instruments according to the operating principles: 
heat flux and power compensation. The two types differ on the design of the DSC cell and 
the algorithms used to convert the measured temperature difference into differential power 
(heat flow). Power compensation DSC involves two separated furnaces, one for the sample 
and a second for the reference. The temperature difference between the two furnaces is 
kept similar by supplying an electric power to the sample furnace. In heat flux DSC, the 
sample and the reference are placed symmetrically inside the furnace and share a common 
heat source. As a result, the heat flow signal is derived from the temperature difference 
between the sample and the reference and is measured by the thermocouples which are 
connected in a back-to-back arrangement.  
The DSC used in the experiments carried out in this thesis (TA Instruments, US) operates 
by heat flux and the above descriptions are schematically represented in Figure 2.9. 
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Figure 2.9: Schematic representation of a heat flux DSC showing the sample (S) and the  
reference (R) pan location within the same furnace (www.anasys.co.uk). 
 
The differential heat flow measured during DSC experiments can be expressed by, 
  
  
 
  
 
 
Equation 2.1 
where, dQ/dt represents the heat flow (where Q is heat and t is time), ΔT is the temperature 
difference between the furnace and the sample and R is the thermal resistance of the heat 
path between the furnace and the crucible.  
When a material is heated, the heat flow signal is determined by the heat capacity (Cp) of 
the material. Heat capacity is defined as the amount of energy required to raise the 
temperature of the sample by 1K and can be expressed by, 
  
  
     
  
  
 
Equation 2.2 
where dT/dt is the heating rate. 
 
2.3.1.2 Experimental Variables 
 
An inert atmosphere is essential in all DSC experiments which can be achieved by purging 
an inert gas into the cell. The selected gas is usually nitrogen however, helium can also be 
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used. A constant purge gas, in general with a flow rate of 50 mL/min, enhances the heat 
transfer between the cell and the sample pan. Moreover, ensures that any volatile 
compounds, including water vapour, are removed from the contact with the measuring 
sensor and, at the same time, minimise long term damage of the DSC cell.  
To ensure an accurate performance of the instrument, routine calibrations processes must 
be carried out each time any experimental parameter changes (heating rate, pan type). The 
cell constant calibration (enthalpy calibration) is conducted by heating indium through its 
melting transition (Tm = 156.6 
o
C) and the temperature calibration is performed by using 
high purity materials, such as n-octadecane (Tm = 28.2 
o
C), benzoic acid (Tm = 122.4 
o
C) 
and tin (Tm = 231.9 
o
C). 
Another important factor to consider is the sample size. As the sample mass increases there 
is an increase in the thermal gradient across the sample. With conventional DSC, large 
sample masses are recommended if precise heat capacity data is required as this increases 
the ΔT and heat flow signals. However, a sample size between 3-5 mg is generally 
recommended. 
Finally, the type of pan selected is of great importance and should be carefully chosen 
depending on the properties of the sample and on the type of data extrapolated from the 
DSC run. For example, when analysing solid dispersions the presence of water influences 
the measured Tg and therefore as a way to dry the sample upon heating, pans with a hole in 
the lid (pinhole pans) are often used. Open pans (pans without lids) can also be used for 
this purpose, though the linearity of the baseline might be compromised. In contrast, when 
dealing with suspensions, liquid formulations or samples that must be kept in their 
hydrated state, hermetically sealed pans must be used. In the present Thesis, these three 
different types of pans (pinhole, open and hermetic) were used depending on the desired 
experimental measurements in each case.  
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2.3.1.3 Modulated Temperature Differential Scanning Calorimetry 
  
 Principles of Operation 2.3.1.3.1
 
Modulated temperature differential scanning calorimetry (MTDSC) is an extension of the 
conventional DSC technique in which a sinusoidal modulation is superimposed on the 
linear temperature ramp combined with a mathematical procedure designed to separate 
different types of sample behaviour (deconvolution) (Coleman and Craig, 1996; Craig and 
Reading, 2007; Gill et al., 1993). This allows the direct measurement of heat flow and 
changes in heat capacity simultaneously, as expressed by Equation 2.3, 
  
  
   
  
  
        
Equation 2.3 
where, f (t,T) is a function of time and temperature and it is used to express the response 
associated with the physical or chemical transformation. 
The first term on the right hand side of the Equation 2.3 describes the heat flow associated 
with the heat capacity of the sample and represents reversing processes. On the other hand, 
the second term is related to the enthalpy of the reaction and it is often identified as an 
irreversible event. As a result, events such as glass transition are accurately measured in 
the reversing heat flow signal whereas irreversible processes which are kinetically 
hindered, for example relaxation and crystallisation, are observed in the non-reversing heat 
flow signal.  
Overall, MTDSC technique gives three signals in a single heating run, allowing the heat 
capacity, kinetic and total heat flow components to be delineated. This technique has been 
of undoubted use for the study of amorphous systems. 
 
 Experimental Variables 2.3.1.3.2
 
MTDSC experiments depend on three parameters: the underlying heating rate, the 
temperature modulation amplitude and the reciprocal period. In general, MTDSC implies 
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the use of much slower heating rates, typically varying from 1-5 
o
C/min, compared with 
the 10-20 
o
C/min heating rates employed in conventional DSC. The combination of low 
underlying heating rates with large modulation amplitudes, generally selected from the 
range ± 0.1 to ± 1 
o
C, enables an increase in sensitivity without any compromise of 
resolution. The modulation period is normally selected within 30-80 sec. However, an 
important requirement is to have at least six modulation cycles throughout the duration of 
each thermal event in order to enable the complete separation of cycle and underlying 
processes (Coleman and Craig, 1996).  
The baseline and temperature calibration of the MTDSC cell does not differ from that of 
the conventional DSC although an additional step for the calibration of the heat capacity is 
needed. This will allow a correct measurement of the sample heat capacities and an 
adequate separation of the total, reversing and non-reversing heat flow signals. The heat 
capacity calibration is performed by scanning a material with known heat capacity, such as 
sapphire.  
DSC and MTDSC studies were carried out on a DSC Q1000 and Q2000 series TA 
Instruments (US) with an integrated cooling system (RCS) attached. The purge gas used 
was nitrogen with a flow rate of 50 mL/min.  
 
2.3.2 Hot Stage Microscopy 
 
Hot stage microscopy (HSM) consists in an optical microscope fitted with a hot stage 
accessory, and therefore combines the best properties of microscopy and thermal analysis. 
This analytical technique enables the characterisation of the physical properties of 
materials as a function of temperature such as melting, solid state transformations, 
recrystallisations, etc.  
High resolution colour cameras and image manipulation software are nowadays powerful 
accessories of HSM, which enable to record thermal events happening during the 
heating/cooling cycle of the sample (Vitez et al., 1998). 
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In this thesis, HSM studies were performed using a microscope Leica DM L52 (Germany) 
with a 20x lens connected to a hot stage plate Mettler Toledo FP82HT (UK) and a FP90 
central processor. 
 
2.3.3 Thermogravimetric Analysis 
 
Thermogravimetric analysis (TGA) is a technique where the change in weight of the 
sample is measured as a function of temperature (non-isothermal experiments) or time 
(isothermal experiments).  
Water content and chemical decomposition of solid drugs and pharmaceutical excipients 
are the two main applications of this technique in the pharmaceutical arena. Moreover, it 
can be used to determine the stoichiometry of solvates (calculated from the weight loss per 
known amount of original sample) and at the same time give an indication on the strengths 
of the water binding on the basis of the temperature at which the solvent is lost. Finally and 
in the same field of the study of solvates, vital information can be obtained when 
combining DSC and TGA techniques with a view to differentiating between solvent loss 
and melting. 
TGA instruments are generally equipped with high precision balances that allow accurate 
measurements of the sample weight during heating. A purge gas with an optimised flow is 
also required to establish a stable environment around the sample and the furnace.  
In this work, experiments were carried out using a Hi-Res TGA 2950 TA Instruments (US) 
equipment. Nitrogen gas was used at a flow rate 60 mL/min and 40 mL/min through the 
furnace and TGA head, respectively. A more modern equipment Q5000 series also from 
TA Instruments equipped with an autosampler device was also used in some of the 
experiments. In this case, the furnace was also blanketed with dry nitrogen but with a flow 
rate of 10 mL/min and 25 mL/min to the balance and furnace/sample areas, respectively. 
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2.3.4 Dynamic Vapour Sorption 
 
Dynamic vapour sorption (DVS) analysis is a technique in which a sample is subjected to 
varying conditions of humidity and temperature, and the response of the sample is 
measured gravimetrically.  
Measurements of the equilibrium water content of a solid as a function of RH (constant or 
variable) at a certain temperature are commonly used to assess the hygroscopicity of 
pharmaceutical solids. More specifically, DVS experiments are also helpful in 
differentiating different types of hydrates. Therefore, compounds that have the tendency to 
form stoichiometric hydrates show stepwise jumps in their weight whereas  
non-stoichiometric hydrates present a gradual increase in weight as the water is 
continuously incorporated into the structure, as it is presented in Chapter 3. Apart from 
this, the DVS technique has also been used to study and quantify amorphous systems 
(Buckton and Darcy, 1995; Mackin et al., 2002). Overall, from a pharmaceutical 
perspective, a thorough understanding of the effects of water (bonded or adsorbed onto the 
surface) on the structure of APIs and excipients is essential for its formulation and 
development.  
DVS instruments operate in a closed system at a controlled temperature and either ambient 
or controlled pressure. The sample is placed on a sensitive microbalance inside the 
humidity chamber and exposed to a continuous flow of air or nitrogen.  
In this work, DVS experiments were performed on a Sorption Analyzer Q5000, TA 
Instruments (US). All samples were tested using quartz pans and at a constant nitrogen 
flow of 10 mL/min. The instrument was calibrated according to the deliquescence point of 
sodium bromide (57.6% RH). 
 
2.3.5 Attenuated Total Reflection–Fourier Transform Infrared  
 
Fourier transform infrared (FTIR) is a spectroscopic non–destructive, non–invasive 
technique that provides information about the molecular composition, structure and 
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interactions within a sample based on its chemical bonds. Infrared (IR) spectroscopy is 
used for identification, characterisation, quantification, structure elucidation, reaction 
monitoring, quality control and quality assurance.  
With IR spectroscopy, the sample is irradiated with a polychromatic light in the IR region 
(4000 to 400 cm
-1
) and a photon of light is absorbed when the frequency (energy) of the 
absorbed light matches the energy required for a particular bond to vibrate within the 
sample. In order for a vibration to be IR active, the molecular dipole moment must change 
during the vibration. Any IR light that has not been absorbed is transmitted to the sample 
to a detector. The fraction of transmitted light allows the absorbed frequencies to be 
determined.  
The difficulties associated with the analysis of solid samples in the conventional IR 
spectroscopy that involved the preparation of KBr disks was overcome by the use of 
attenuated total reflection (ATR) mechanism applied to the FTIR. ATR is based on the 
principle of the reflection of radiation when it passes from a denser to a less dense 
medium. During this process the beam acts as if it has penetrated a small distance into the 
less dense medium. Samples are generally placed on opposite sides of a transparent 
crystalline material of high refractive index, generally diamond. The penetration depth into 
the sample is usually just a few microns (0.5-5 μm) thus a good contact between the 
sample and the crystal surface must be ensured (O'Neil and Edwards, 2011). 
The FTIR studies presented throughout this thesis were carried out using a Bruker Optics 
IFS 66/S (UK) spectrometer with an ATR accessory fitted to a heating system (SPECAC, 
UK). Spectra were collected from 4000 to 550 cm
-1
 with a total of 64 scans at a resolution 
of 2 cm
-1
, unless otherwise stated.   
 
2.3.6 X-Ray Powder Diffraction 
 
X-ray powder diffraction (XRPD) is a gold standard technique in the characterisation of 
pharmaceutical materials in the solid state. It is mainly used for fingerprinting and 
quantification analysis due to its high sensitivity to small chemical changes.  
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Basically, X-rays are generated by heating a filament (the cathode) which works as a 
source of electrons. These electrons are then accelerated and strike a target (the anode) that 
is usually Cu, Mo, Cr or Ag and produces a characteristic X-ray spectrum (Gilmore, 2011). 
When X-rays pass through the sample they interact with the electron cloud of atoms in the 
molecules and the intensity and position of the emergent X-rays are recorded by a detector. 
Additional equipment can be fitted to the conventional XRPD in order to proportionate 
analyses under the effect of temperature or humidity. This is of great importance when 
studying polymorphic and pseudopolymorphic transitions. 
Variable humidity XRPD (VH-XRPD) is commonly used to investigate the structure of 
variable hydrates. The amount of water present in a variable hydrate is typically a function 
of the RH environment of the sample. Since the XRPD peak positions are directly related 
to the dimensions of the unit cell, subtle changes in the size of the unit cell due to the 
presence of water may be evaluated by comparison of XRPD patterns collected for the 
species under different RH environments. 
Variable temperature XRPD (VT-XRPD) on the other hand permits the direct 
identification of a crystalline phase as a function of temperature, especially important in 
the study of thermal stability of pharmaceutical hydrates. 
In this thesis, general XRPD analysis of solid dispersion systems and polymers were 
performed using a Thermo ARL Xtra (Thermo Scientific, UK) model equipped with a 
copper X-ray Tube (1.540563 Å). The samples were exposed to an X-ray beam with a 
voltage of 45 kV and a current of 40 mA. All XRPD experiments were performed at 2θ 
and step scan of 0.01
o
. The scanning range was based on the characteristics peaks of each 
sample. 
The changes in the crystal structure of paroxetine HCl Form II as a function of humidity 
(Chapter 3) were evaluated using a XRPD, Philips XPERT Pro (Netherlands) equipped 
with a relative humidity generator (RH-200, L&C, Germany) and a temperature control 
unit (TUC 50, Anton Paar, Austria). Patterns were collected from scans in the range of 2θ 
from 5.0
o
 to 50.0
o
 with a step size of 0.0010°, at different RHs.  
The dehydration study of paroxetine HCl Form I (Chapter 4) was studied in situ using a  
VT-XRPD Bruker D8 Advance (Bruker, UK) fitted with a TTK450 (Anton Paar, Austria) 
chamber. The temperature was controlled by a Temperature Control Unit TCU 100  
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(Anton Paar, Austria) and the applied heating rate was set by default to 0.167 K/s. Spectra 
were collected from 4.0° to 30.0° at 2θ under nitrogen purge with a flow rate of 
approximately 50 mL/min.  
 
2.3.7 Scanning Electron Microscopy 
 
Scanning electron microscopy (SEM) enables specimens to be examined at much higher 
magnification and resolution than it is possible using a light microscope. In SEM, a beam 
of electrons is produced at the top of the microscope by an electron gun. The electron beam 
follows a vertical path through the microscope, which is held within a vacuum. The beam 
travels through electromagnetic fields and lenses, which focus the beam down toward the 
sample. Once the beam hits the sample, electrons are ejected from the sample. Detectors 
collect these backscattered electrons and secondary electrons and convert them into a 
signal that is sent to a screen similar to a television screen. This produces the final image. 
SEM photographs were taken using a JSM 4900LV SEM (JOEL, Japan) mounted with a 
tungsten filament with an acceleration voltage of 5-20 kV. To improve conductivity prior 
to examination, samples were coated with gold using a Polaron SC7640 sputter gold coater 
(Quorum Technologies, UK). 
 
2.3.8 Karl Fischer Titration 
 
Karl Fischer titration (KFT) is a classic titration method that determines the water content 
in a sample.  
KFT is based on a quantitative reaction of water with iodine (I2) and sulfur dioxide (SO2) 
in the presence of a lower alcohol (ROH) such as methanol and an organic base (RN) such 
as pyridine, as shown in the following reactions: 
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There are two types of Karl Fischer titrators: volumetric and coulometric. The main 
difference between the two is that with the volumetric method, the titrant is added directly 
to the sample by a burette. Conversely, with the coulometric method, the titrant is 
generated electrochemically in the titration cell.  
When performing KFT several aspects must be taken into consideration to prevent 
misleading results. First of all, the choice of the reagents is of great importance especially 
when dealing with aldehydes and ketones. These compounds can react with the standard 
methanol reagents and form water. Therefore, methanol-free reagents must be used in these 
particular cases. Another aspect is regarding the time and the speed of stirring the sample 
inside the titration vessel. Too low a stirring speed can lead to irregular titration and over 
titration may occur whereas a speed too high can generate bubbles in the solution and 
falsify the measured values. Moreover, the influence of atmospheric moisture in the 
titration process must also be accounted. Moisture can enter not only the titration vessel 
but also the titrant bottle leading to a decrease in the titrant concentration. 
KFT was performed using a DL38 (Mettler Toledo, UK) volumetric titrator with 
Hydranal
®
 solvent and Titrant
®
 5. The titrant concentration was determined daily by using 
di-sodium tartrate dihydrate, which has a water content of 15.66%. 
 
2.3.9 Dissolution Studies 
 
Dissolution testing of pharmaceutical solids is one of the most important tests in drug 
product development and manufacturing as well as in regulatory assessment of the drug 
product quality. It provides information on the rate and extent of drug absorption and at the 
same time assesses the effect of drug substance properties and formulation principles on 
the release profile of the drug substance (Lee et al., 2008). 
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The dissolution process of solids consists of two main steps. At first, the molecules at the 
solid-liquid interface are wetted and solvated and detached from the solid surface. 
Secondly, the solvated molecules diffuse away from the interface to the bulk solution. It is 
described that it is the diffusion rate of the molecules in the media and/or the wetting and 
solvation of the surface molecules that defines the dissolution profile of a certain 
compound (Hörter and Dressman, 2001).  
The dissolution rate (δM/δt) of a solid in a liquid can be described by the well-known  
Noyes-Whitney equation as presented below. 
  
  
    
 
 
         
Equation 2.4 
where M is the mass, t is the time, A is the surface are of the undissolved solid in contact 
with the solvent, D is the diffusion coefficient (m
2
/s), h is the thickness of diffusion layer, 
Cs is the solubility, Cb is the concentration in the bulk solution and Cs-Cb is the 
concentration gradient. The above Equation 2.4 assumes that the surface area and thickness 
of the hydrodynamic diffusion layer remain constant. 
Dissolution experiments were carried out using a BP Apparatus I, Copley CIS 8000 
dissolution bath (Copley Scientific, UK) paddle method. Each vessel was filled with  
900 mL of dissolution medium, the temperature was set at 37.0 
o
C and a rotation speed of 
50 rpm was used. The concentration of each API through the dissolution tests was assessed 
spectrophotometrically at the respective wavelength of maximum absorbance, λmax, using a 
Perkin-Elmer Lambda XLS (Perkin Elmer, US) spectrophotometer. Calibration curves 
were constructed for each API in the respective dissolution media. 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
3 IDENTIFICATION AND CHARACTERISATION OF 
STOICHIOMETRIC AND NON-STOICHIOMETRIC HYDRATE 
FORMS OF PAROXETINE HCL: REVERSIBLE CHANGES IN 
CRYSTAL DIMENSIONS AS A FUNCTION  
OF WATER ABSORPTION 
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Abstract 
 
Paroxetine hydrochloride (HCl) is an anti-depressant drug, reported to exist in the 
anhydrous form (Form II) and as a stable hemihydrate (Form I). In this study, the hydration 
behaviour of paroxetine HCl Form II was investigated with a view to understanding both 
the nature of the interaction with water and the interchange between the Forms II and I as a 
function of both temperature and water content. In particular, new evidence is presented 
for both the structure and the interconversion process to be more complex than previously 
recognised.  
A combination of characterisation techniques was used, including thermal (differential 
scanning calorimetry (DSC) and thermogravimetric analysis (TGA)), spectroscopic 
(attenuated total reflectance-Fourier transform infrared (ATR-FTIR)), dynamic vapour 
sorption (DVS) and X-ray powder diffraction (XRPD) with variable humidity, along with 
computational molecular modeling of the crystal structures.  
The total amount of water present in Form II was surprisingly high (3.8% w/w, 0.8 mol of 
water/mol of drug), with conversion to the hemihydrate noted on heating in hermetically 
sealed DSC pans. XRPD, supported by ATR-FTIR and DVS, indicated changes in the unit 
cell dimensions as a function of water content, with clear evidence for reversible expansion 
and contraction as a function of relative humidity (RH). This data suggested that 
paroxetine HCl Form II is not an anhydrate but rather a non-stoichiometric hydrate. 
However, no continuous channels are present and, according to molecular modeling 
simulation, the water is moderately bonded to the crystal, which is in itself an uncommon 
feature when referring to non-stoichiometric hydrates. Overall, therefore, it is suggested 
that the anhydrous form of paroxetine HCl is not only a non-stoichiometric hydrate, but 
also one that shows highly unusual characteristics in terms of gradual unit cell expansion 
and contraction despite the absence of continuous channels. These structural features in 
turn influence the tendency of this drug to convert to the more stable hemihydrate. The 
study has implications for the recognition and understanding of the behaviour of 
pharmaceutical non-stoichiometric hydrates. 
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3.1 Introduction 
 
Polymorphism and pseudopolymorphism are well studied phenomena within the 
pharmaceutical arena, with the most widely studied manifestation of the latter being 
hydrate formation. Indeed, the possible interaction with water during certain processing 
steps (freeze drying, spray drying or wet granulation) as well as contact with atmospheric 
humidity upon storage renders hydrate formation extremely common (Koradia et al., 2011; 
Giron et al., 2002). Typically, such materials are considered to be stoichiometric, with a 
precise and defined molecular ratio between the water and host in the crystal lattice, 
although undefined incorporation is also possible, these being known as non-stoichiometric 
or variable hydrates (Griesser, 2006; Khankari and Grant, 1995). For stoichiometric 
hydrates, the water may play a crucial role in the stabilisation of the molecular network and 
therefore dehydration may result in a disordered or amorphous state (Kobayashi et al., 
2009; Vogt et al., 2006; Guguta et al., 2006). In contrast, non-stoichiometric hydrates may 
reversibly gain or lose water while retaining the same crystalline structure (isomorphic 
dehydrates), with the water molecules entering and leaving the crystal lattice in a manner 
determined by the environmental relative humidity (RH) (Stephenson et al., 1998). This 
therefore presents issues for the formulator in that differentiation from simple surface 
adsorption may be challenging, with the well-known indicators of hydrate formation (e.g. 
powder X-ray diffraction and thermogravimetric analysis) not yielding the same 
unequivocal identification of lattice alteration as is usual for stoichiometric hydrates. On 
this basis the possible existence of non-stoichiometric hydrates is not fully appreciated 
within the pharmaceutical field, with an accompanying lack of the development of 
characterisation tools for their identification and structural elucidation.  
Hydrates can also be classified based on their crystal structures (Vippagunta et al., 2001).  
In Class I, or isolated site hydrates, water has a well-defined isolated location and therefore 
hydrates of this class are often stoichiometric. In Class II, channel or planar hydrates, water 
is packed inside the crystalline structure so as to form continuous channels or planes. Class 
III refers to ion coordinated hydrates, in which water molecules are coordinated to metal 
ions. Class II hydrates are, in general, non-stoichiometric, while Class III hydrates can be 
either stoichiometric or non-stoichiometric. 
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Differentiation between hydrate formation and non-specific hygroscopicity may be 
challenging. Water can interact with crystalline materials in several ways (adsorption, 
absorption, deliquescence and hydrate formation), all of which may have a large impact on 
the solid state properties, processing and handling of drugs (Ahlneck and Zografi, 1990). 
This difficulty is exemplified by the study of Reutzel (Reutzel, 1998) on the muscarinic 
agonist, LY297802 tartrate. The considerable hygroscopicity for this material was found to 
be, in fact, due to non-stoichiometric hydrate formation whereby, rather than simple 
surface sorption, water migrates between hydrogen-bonding sites located in crystal lattice 
channels.  
In this work, the hydration behaviour of paroxetine HCl was investigated. Paroxetine HCl 
is a potent and selective inhibitor of the neuronal re-uptake of serotonin  
(5-hydroxytryptamine, 5-HT) and is currently clinically approved for the treatment of 
depression, social phobia, obsessive-compulsive, post-traumatic stress and general anxiety 
(Bourin et al., 2001). This molecule is of particular interest due to the confusion associated 
with its physical forms with three nomenclature systems being used to describe them. 
Initially, Barnes et al. (Barnes et al., 1988) described in their patent the preparation of 
paroxetine HCl hemihydrate and, in Example 8 of the same document, the preparation of 
paroxetine HCl anhydrate. Less than one year later, Buxton et al. (Buxton et al., 1988) 
further investigated the above forms and named the hemihydrate as Form I and the 
anhydrate as Form II. Form I is described as a non-hygroscopic hemihydrate with a 
melting point (m.p.) of 143 °C, which represents the most stable form and is currently 
included in commercially available pharmaceutical formulations, while Form II is 
described as a hygroscopic anhydrate with a m.p. of 118 °C and a moisture content 
controlled by environmental humidity. More recently, Ward and Jacewicz (Ward and 
Jacewicz, 2000) described the preparation of three new anhydrate forms of paroxetine HCl, 
named as A, B and C. They suggest that paroxetine HCl Form A (m.p. 123-125 °C) can be 
distinguished from the anhydrate Form II by the crystal shape, as reported by Buxton et al. 
(Buxton et al., 1988). However, the data available (infrared and thermal analysis) suggests 
that in terms of internal structure these two forms (A and II) are probably, but not 
definitely, equivalent. The reported characteristics of the other two forms, B (m.p. at  
137 °C) and C (m.p. at 161 °C) do not comply with those of the form investigated here and 
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no such transitions were seen in the present study, hence these forms do not impinge on the 
present study.   
This therefore leads to an immediate issue of nomenclature, as three classifications are 
currently in use (anhydrate/hemihydrate, I and II, A, B and C). In this work, the 
nomenclature Form I (hemihydrate) and II (anhydrate) was chosen for the sake of 
simplicity. However, as it will be demonstrated, the notion of Form II as being a true 
anhydrate is challenged in this work, hence it is avoided the use of this term other than to 
point out its nominal description so as to avoid confusion.  
In this investigation a combination of thermal analysis, variable humidity powder XRD 
with associated modeling, attenuated reflection FTIR and dynamic water sorption studies 
was used to examine the interplay between the Form II and hydrated forms, with a view to 
clarifying the physical structures and transformation processes associated with exposure of 
Form II to water.  
 
3.2 Materials and Methods 
 
3.2.1 Materials 
Paroxetine HCl Form II was purchased from Huahai Pharmaceuticals (China) and was 
used as received as well as, pre-dried over phosphorus pentoxide (P2O5), Alfa Aesar (UK), 
as stated. The correspondence to the nominally anhydrous form was confirmed using 
thermal and spectroscopic analysis, as outlined below.   
 
3.2.2 Methods 
3.2.2.1 Thermal Analysis  
Standard differential scanning calorimetry (DSC, Q1000 TA Instruments) was performed 
at heating rates of 5, 10, 20 and 50 
o
C/min. Modulated temperature DSC (MTDSC, Q1000 
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DSC TA Instruments) analysis was performed using a heating rate of 2 
o
C/min, amplitude  
± 0.318 
o
C and a period of 60 seconds. Scans were carried out within the temperature range  
0 °C to160 °C except for the collection of the Form I prepared in situ DSC whereby the 
runs were stopped at 125 
o
C. Pinhole, hermetically sealed and open pans (pinhole pans 
without lid) were used as stated.  
Thermogravimetric analysis (TGA, Hi-Res 2950 TA Instruments) was performed in open 
aluminium pans with a heating rate of 10 
o
C/min, from 30 
o
C to 300 
o
C. 
 
3.2.2.2 Karl Fischer Titration (KFT) 
KFT (Mettler Toledo DL38) were carried out by accurately weighing between 40 to 41 mg 
of bulk and pre-dried samples. The bulk sample was kept under ambient conditions and the 
dried sample was stored at P2O5 for 7 days prior to testing. The reagents used were Titrant
® 
5 and Hydranal
®
 solvent. Each determination was repeated five times (n = 5). 
 
3.2.2.3 Attenuated Total Reflection-Fourier Transform Infrared (ATR-FTIR)  
The infrared spectra of the samples were collected using a Bruker Optics IFS 66/S 
spectrometer, with 64 scans being acquired for each sample from 4000 cm
-1 
to 550 cm
-1
 
with a resolution of 2 cm
-1
. Variable temperature ATR-FTIR experiments were carried out 
by connecting a temperature controller to the diamond ATR top-plate. A constant heating 
rate of 2 
o
C/min was employed. 
 
3.2.2.4 Dynamic Vapour Sorption (DVS) 
DVS (SA Q5000 TA Instruments) experiments were performed at a constant temperature 
set at 30 
o
C. The sample previously stored over P2O5 for 7 days was equilibrated at 0% RH 
for 2h inside the DVS chamber before starting the sorption/desorption experiments. The 
starting relative humidity was 10% RH, which was firstly increased to 30% RH, and then 
at 10% RH/step to 90% RH. Desorption was studied by reducing the relative humidity 
from 90% to 25% RH, then to 15%, 5% and 1% RH. At each target RH, the isothermal 
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sorption procedure was performed for 40 minutes (min). Note that for RHs higher than 
10%, no mass change was detected after 40 min in any of the steps. 
 
3.2.2.5 X-Ray Power Diffraction (XRPD) and Variable Humidity XRPD (VH-XRPD) 
Spectra of raw and prepared Form I in situ DSC were collected using XRPD (Thermo-
ARL Xtra, Thermo Scientific) from 5.0
o
 to 40.0
o
 at 2θ. 
VH-XRPD (Philips XPERT Pro) patterns were collected from scans in the range of 2θ 
from 5.0
o
 to 40.0
o
 with a step size of 0.0010°, at different RH using a relative humidity 
generator (RH200). The temperature was controlled by using temperature control unit 
(TUC 50, Anton Paar). The RH steps and equilibration time were the same as in the DVS 
experiment. Unit cell parameters were determined by Pawley refinement of the collected 
patterns using the program TOPAS-Academic (Coelho, 2007). A specimen displacement 
parameter was included in the refinement to account for the macroscopic expansion or 
displacement of the sample in response to environmental changes. The value of the 
displacement parameter varied between 0.63 and 0.67 mm, which would, in itself, cause 
very little change in the powder pattern (≈ 0.02o shift of peak positions around 2θ = 20o). 
 
3.2.2.6 Computational Modeling of Crystal Structures 
Lattice energy minimisations were performed using the rational function optimisation 
method implemented in the GULP package (Gale, 2005). The force field used comprised 
of the Dreiding parameter set (Mayo et al., 1990) and AM1-BCC charges (Jakalian et al., 
2002). The initial (P21) symmetry of the crystal structure was maintained during the 
minimisations. The starting configurations were generated from the experimental structure 
by assuming either full or zero occupancy for the water molecule. 
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3.3 Results and Discussion 
 
3.3.1 Differential Scanning Calorimetry (DSC) 
 
Initially, the thermal behaviour of paroxetine HCl Form II was explored using standard and 
modulated DSC. Three types of pans, pinhole, hermetic and open, were used to examine 
the influence of water on the thermal behaviour while modulated measurements were used 
in order to aid identification of any non-obvious thermal events that may arise such as 
glass transitions. Figure 3.1 presents data for paroxetine HCl Form II at 10 °C/min in 
pinhole and open pans. A single endotherm melting point was detected in both cases with 
an onset temperature of 117.1 ± 0.7 °C in pinhole and 121.8 ± 0.3 °C in open pans. This is 
in good agreement with the reported values from Buxton et al. (Buxton et al., 1988)  
(118.3 °C) for Form II and also from Ward and Jacewicz (Ward and Jacewicz, 2000)  
(123-125 °C) for Form A. The 'bowing' endotherm seen for the open pan systems is 
associated with water loss which will be expected to occur over a relatively narrow 
temperature range, and hence be thermally visible, due to the unrestricted nature of the 
water evaporation on heating for an anhydrous form; this notion will be revisited later. 
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Figure 3.1: Standard DSC analysis (10 °C/min) of paroxetine HCl Form II  
in pinhole pans and open pans. 
 
It is apparent that the melting event of paroxetine HCl Form II is influenced by the 
experimental conditions, with a difference of almost 5 °C in the onset melting temperature 
seen using different pan types. This indicates the inherent difficulties in establishing the 
‘correct’ value for the melting point of this form; again an explanation for this difference 
will be shown later. 
When using hermetically sealed pans, a distinct thermal profile was obtained (Figure 3.2). 
The melting response was detected at 111.8 ± 0.6 
o
C, followed by an exotherm (possibly 
associated with recrystallisation, Trec) at 118.1 ± 0.6 °C and finally an endotherm at  
139.8 ± 0.5 °C corresponding to the reported melting of the Form I, as per previous studies 
(Barnes et al., 1988). It is therefore reasonable to conclude that the Form II is forming the 
hydrate form on heating, using the associated water to form the stoichiometric hydrate.  
This is a highly unusual behaviour pattern and, up to this study, there are no previous 
reports to this effect. 
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Figure 3.2: MTDSC analysis (total heat flow, 2 
o
C/min) of paroxetine HCl Form II  
in hermetically sealed pans.  
 
This observation was confirmed by using XRPD and the results are shown in Figure 3.3. 
The diffractogram of paroxetine HCl Form I is presented for comparison with the 
recrystallised product obtained after heating paroxetine HCl Form II in the DSC furnace in 
hermetically sealed pans. The DSC runs were stopped at 125 °C (after the recrystallisation 
step) and samples were collected for the XRPD experiments. The data obtained confirmed 
that the form obtained after recrystallisation is, in fact, the stoichiometric hemihydrate, 
paroxetine HCl Form I.  
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Figure 3.3: XRPD data comparing the form obtained after the recrystallisation of paroxetine HCl  
Form II when heated in hermetic sealed pans in the DSC furnace (top) and  
paroxetine HCl Form I (bottom). 
 
Furthermore, when using higher heating rates (HRs) the recrystallisation signal 
disappeared and, at 50 
o
C/min, no melting of the Form I was detected (Figure 3.4). 
The melting peak of Form II showed a broader appearance, as is usual when increasing 
heating rate due to thermal lag effects. However it is also suggested that the 
recrystallisation to Form I is kinetically hindered and hence does not take place at higher 
heating rates. Moreover, samples run in hermetically sealed pans at 2 
o
C/min but pre-dried 
over P2O5 also showed no evidence of transformation to the Form I (data not shown), 
further supporting the hypothesis that the conversion involved sorbed water becoming 
stoichiometrically bound on heating. 
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Figure 3.4: Influence of the heating rate on the transformation between Form II and Form I of 
paroxetine HCl. Standard DSC runs at 5, 10, 20 and 50 
o
C/min (downwards) were performed in 
hermetically sealed pans. 
 
3.3.2 Thermogravimetric Analysis (TGA) 
 
Given the role of sorbed water (using the term loosely) that has been identified above, it 
was clearly essential to have some measurements of both the quantity and binding 
characteristics of the water present. The TGA signal (Figure 3.5) showed a water weight 
loss process completed by approximately 140 
o
C. A continuous weight loss was observed 
from the starting temperature until approximately 90 
o
C and after that an evident sharper 
drop in the weight was noticed, between 100 
o
C and 130 
o
C, which corresponds, in total, to 
a weight loss of 4.45 ± 0.26%. The last and higher drop in the weight around 260 
o
C is due 
to the decomposition of the sample. These processes are shown in the derivative signal for 
clarity.  
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Figure 3.5: TGA curve of paroxetine HCl Form II, showing the weight loss and  
associated derivative loss curve.  
 
In general, when a stoichiometric hydrate is present, the water molecules are incorporated 
in the crystal lattice and the water loss signal shows a sharp discontinuity, typically 
between 80 and 140 
o
C. Alternatively, when the water molecules are simply present on the 
crystal surfaces (adsorbed water), the water loss signal tends to be broader and appears 
over a wider and lower temperature range, frequently between 60 to 90 
o
C (Craig and 
Reading, 2007). The behaviour shown here appears to demonstrate a steady water loss, 
typically associated with sorbed water, followed by a sharper loss corresponding to the 
melting of Form II, indicating release of any remaining water on breakdown of the crystal 
structure.  
On the other hand, the TGA trace of Form I at the same heating rate (data not shown) did 
not show a continuous weight loss, but rather a sharp drop in weight in a narrow 
temperature range between 100 and 130 
o
C. This is in good agreement with the typical 
dehydration behaviour of stoichiometric hydrates. The weight loss at this temperature 
corresponds to 2.60 ± 0.15% (0.55 ± 0.02 mol of water per mol of drug), which matches 
well the designation of Form I as a hemihydrate.  
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3.3.3 Karl Fischer Titration (KFT) 
 
The water content of untreated and dried samples was determined by Karl Fischer titration 
under ambient humidity (53% RH) and temperature (25.5 
o
C). The untreated sample was 
found to have a water content of 3.83 ± 0.05% w/w, which corresponds to 0.80 ± 0.01 mol 
of water per mol of paroxetine HCl. The water content of the sample previously dried over 
P2O5 for 7 days was calculated as 1.65 ± 0.17% w/w, 0.33 ± 0.03 mol of water per mol of 
paroxetine HCl.  
These results are surprising in that they are high for such a relatively non-polar low 
molecular weight material; indeed, the amount of water in the dry sample is quite high for 
a material stored for 7 days at 0% RH. However, as the measurements were performed 
under atmospheric conditions, the time between weighing and measurement may have 
been sufficient for some moisture sorption. Even so, this implies quite considerable 
hygroscopicity. This may be a result of high surface adsorption or, alternatively, molecular 
internalisation of water, i.e. non-stoichiometric hydrate formation. On this basis a series of 
spectroscopic and water sorption studies were performed in order to investigate the 
possibility of such hydrate formation. 
 
3.3.4 Attenuated Total Reflection-Fourier Transformer Infrared (ATR-FTIR) 
 
Infrared spectroscopy is a potentially useful tool to distinguish between the two forms of 
paroxetine HCl (Form II and Form I) by analysing the spectrum between 3700-3200 cm
-1
 
corresponding to the OH stretching region. This area is also useful to monitor temperature-
dependent transitions between those forms. The spectrum of Form II, as shown in  
Figure 3.6, has two main bands at 3633 cm
-1
 and 3395 cm
-1
, which can be assigned to 
stretching vibrations involving weakly and strongly H-bonded water H atoms, respectively. 
If paroxetine HCl Form II was a true anhydrate, it should not show any OH vibration at 
high wavenumbers, as no water would be present in the crystal lattice. In contrast, Form I 
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shows a double band at 3401 cm
-1
 and 3339 cm
-1
, which correspond to two strong H-bonds 
in different chemical environments. 
Some misinterpretations can be easily made in this region due to the presence of a 
secondary amine, as it was shown in Figure 2.2. The NH stretching in secondary amines 
usually appears as a single band in the range between 3380-3205 cm
-1
. However the HCl 
salt formation can cause a considerable attenuation of the normal NH stretching band and 
displace it towards lower frequencies (2760 and 2690 cm
-1
) (Nakamoto et al., 1955; 
Heacock and Marion, 1956). Owing to the complexity of the spectra in this region, 
especially due to the overlapping of the aromatic ring vibrations, a clear and precise 
assignment of the NH band is hard to make.  
 
 
 
 
Figure 3.6: ATR-FTIR spectra of paroxetine HCl Form II (top) and Form I (bottom). 
 
The assignment of the OH stretching bands presented in this section for paroxetine HCl 
Forms I and II is consistent with their respective structural models and H-bonding.  
Since these will be described in more detail in the molecular modeling section, only a brief 
discussion, relevant to differences in the ATR-FTIR spectra, will be presented here.  
The water molecules in Form II can establish two different types of hydrogen bonding: a 
very weak one to an oxygen from the dioxole ring, which appears as a free OH band with a 
sharp appearance at a high wavenumber (3633 cm
-1
); and a strong one to a chloride ion, 
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which appears as a broad band at a lower wavenumber (3395 cm
-1
), an indication of 
stronger hydrogen bond formation (Tang et al., 2002). In Form I the water molecules can 
establish three strong hydrogen bonds. In two of them the water molecules donate their 
hydrogen atoms to chloride ions, giving the double band observed at 3401 and 3339 cm
-1
. 
The third hydrogen bond is formed with the protonated ammonium nitrogen as the donor 
and water as the acceptor.  
By using variable temperature ATR-FTIR spectroscopy with a constant heating rate of  
2 
o
C/min, it was possible to observe the pseudopolymorphic transformation between the 
Form II and the Form I (Figure 3.7). It should be noted that the sample holder is such that, 
while the sample is not sealed hermetically, water movement is nevertheless partially 
restricted rendering these results only partially comparable to the DSC data. Nevertheless, 
the data set provides a useful corroborative perspective by which the transformation may 
be further studied.  
 
 
 
 
Figure 3.7: Variable temperature ATR-FTIR spectra of paroxetine HCl Form II, measured using a 
constant heating rate of 2 
o
C/min. 
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Initially, the spectra show the response associated with the Form II (from top to bottom). 
However, when the temperature reached 50 
o
C, a small shoulder started to appear in the 
region of the hydrogen-bonded OH (3339 cm
-1
) and the intensity of the free OH stretching 
band started to decrease. These observations, together with the initial description of those 
bands, suggest that a new intermolecular hydrogen bond between the OH group from the 
water molecules and the chloride ion starts to become established, which results in a split 
of this band characteristic of the Form I. Changes in the spectrum can also be observed in 
the region at 2500-3000 cm
-1
.  
Overall, not only does Figure 3.7 clearly show transformation between the Form II and the 
Form I but also indicates that, at temperatures as low as 50 
o
C, the interaction between the 
drug and water is specific and intrinsic to the crystalline lattice structure, rather than being 
a simple surface adsorption process. While the highest temperatures clearly indicate Form I 
formation, the intermediate temperatures indicate a mixture between Form II and the  
Form I, which again is supportive of the suggestion of non-stoichiometric hydrate 
formation. 
 
3.3.5 Dynamic Vapour Sorption (DVS) 
 
The hydration behaviour of paroxetine HCl Form II under defined humidity and 
temperature conditions was investigated. Pre-treatment of the sample included drying over 
P2O5 for 7 days, plus an additional drying step of 2 h at 30 
o
C and 0% RH inside the DVS 
chamber to ensure that any residual water was dried off prior to starting, as confirmed by 
the achievement of a constant weight. Figure 3.8 shows the DVS data for paroxetine HCl 
Form II. During the sorption cycle a weight gain of 3.53% was observed from 10 to  
90% RH, which corresponds to 0.73 mol of water per mol of drug, with 81% of the total 
water uptake taking place between 10 and 30% RH. From 40 to 90% RH the change in 
weight is significantly smaller.  
The high absolute amounts of water gained, together with the reversibility of the uptake 
and desorption, again supporting the existence of a non-stoichiometric hydrate. More 
specifically, the reversibility of the sorption process and the relatively rapid time scales 
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over which the process takes place is, in general, a property of channel hydrates. Several 
non-stoichiometric hydrates have been identified to have such water channels at a 
molecular level (Stephenson and Diseroad, 2000; Ahlqvist and Taylor, 2002; Kumar and 
Bansal, 2011), which enables the water molecules to move easily both within the structure 
and between the solid and its environment without causing any structural disruption. On 
this basis it was considered essential to examine the X-ray powder diffraction profile as a 
function of both temperature and humidity in order to elucidate whether paroxetine HCl 
Form II shows similar structural characteristics.   
 
 
 
Figure 3.8: Dynamic vapour sorption data for paroxetine HCl Form II.  
Sorption and desorption cycles are superimposable. 
 
3.3.6 Variable Humidity X-Ray Powder Diffraction (VH-XRPD) 
 
The crystal structures of two paroxetine HCl hydrate forms have been determined 
previously: the Form I (Yokota et al., 1999) and a form with the composition paroxetine 
HCl ∙ 0.8 H2O (Howard et al., 2003). The latter structure has been submitted to the 
Cambridge Structural Database (Allen, 2002) as a private communication (reference code 
EHOXEE), so no detailed information about the origin or preparation of the sample is 
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available. However, the powder diffraction pattern calculated for paroxetine HCl ∙ 0.8 H2O 
matched the experimental diffraction pattern measured for the Form II, confirming that 
they represent the same crystal structure. While the drug : water ratio of 1 : 0.8 suggests a 
non-stoichiometric hydrate, the water molecules of this Form II are located in isolated 
voids (Figure 3.9) an observation which is usually associated with stable stoichiometric 
hydrates. It also noted that this ratio of water to drug is very similar to the saturation value 
found from the DVS studies hence it is possible to conclude that the structure given in 
(Howard et al., 2003) represents the equivalent of a hydrated form of paroxetine HCl but, if 
this hypothesis is correct, that form is in fact a non-stoichiometric hydrate. 
 
 
 
 
 
 
 
 
 
Figure 3.9: Crystal structure of Form II with the water-containing voids highlighted in brown.  
Generated from data presented in (Howard et al., 2003). 
 
To establish the nature of Form II, variable humidity powder X-ray experiments  
(VH-XRPD) were performed. If Form II is a variable hydrate then the crystal structure 
should change continuously with changing RH. If Form II is not a variable hydrate and the 
gradual change of mass seen in the DVS experiments is caused by the adsorption of water 
on the surface, hence the powder diffraction pattern should remain the same. 
The results showed that the peak positions shifted in response to changes in RH  
(Figure 3.10 and Figure 3.11). In accordance with the DVS results, most of the change 
occurs at low RH (below 30%), after which the peak shifts are very small. No 
appearance/disappearance of peaks was observed in the 1-90% RH range suggesting that 
humidity alone is insufficient to induce the transformation between Form II and the  
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Form I; however changes in humidity are capable of causing changes in the lattice 
spacings, indicating that the lattice is expanding to allow entry of the water. 
 
 
 
Figure 3.10: Shifts in the diffractogram peaks upon increasing RH.  
Only a part of the full XRPD diffractogram (5.0 to 40.0°) is shown to make the peak shifts visible. 
 
 
 
 
Figure 3.11: XRPD patterns of paroxetine HCl Form II during desorption of water. 
 
The peak shifts indicate changes in the dimensions of the unit cell, namely expansion upon 
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during sorption and desorption fall on the same trend line, demonstrating that the 
transformation is reversible with no apparent hysteresis. The remarkable similarities 
between the unit cell volume vs RH (Figure 3.12) and the mass vs RH (Figure 3.8) curves 
confirm that vapour sorption occurs predominantly by incorporating water molecules into 
the crystal structure, i.e., that the ‘anhydrate’ Form II is in fact a variable hydrate. 
 
 
 
Figure 3.12: Changes in the unit cell volume of paroxetine HCl Form II according to variation  
in relative humidity (RH). 
 
The gradual peak shifts in the XRPD pattern are again characteristic of non-stoichiometric 
channel hydrates e.g., risedronate (Redman-Furey et al., 2005), cefazolin and cromolyn 
sodium (Stephenson and Diseroad, 2000), where water molecules can move in (sorption) 
and out (desorption) of the crystal while its basic structure remains the same. As a typical 
example, the crystal structure of cromolyn sodium (Cox et al., 1971; Chen et al., 1999) 
contains wide channels, which readily explains why water can move within the lattice 
without disrupting it.  
However, in paroxetine HCl Form II the water molecules are located in small 
voids/pockets instead of channels, so dehydration without disruption is unexpected. The 
only other example of a variable hydrate with no continuous solvent channels and with an 
isomorphic desolvate known up to this study is the `monohydrate' form of vitamin B1  
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(Te et al., 2003). It has been suggested that dehydration/hydration of this material occurs 
through a cooperative deformation mechanism, which allows retention of structural 
information (Chakravarty et al., 2009a;b). A unique feature of paroxetine HCl Form II is 
that it reaches equilibrium at each RH within minutes. Such a fast equilibration is more 
characteristic of surface water than of hydrates, which explains why this material is 
currently believed to be a hygroscopic anhydrate form. 
 
3.3.7 Crystal Structure Models 
 
The experimental crystal structure of the Form II is incomplete, because the H atom 
positions of the water molecule have not been determined. The O atom from water appears 
to be involved in an extremely short CH∙∙∙O bond (dH∙∙∙O = 2.26 Å), which is probably an 
experimental error arising from the high uncertainty with which the water O coordinates 
could be determined from powder diffraction data. To obtain a more detailed description of 
the structure, models of both a monohydrate and an isostructural dehydrate were generated 
computationally from the experimental structure. In the initial configuration of the 
monohydrate model, one of the missing H atoms was placed to point towards a nearby 
chloride ion, which is well within H-bonding distance of the water molecule  
(dO∙∙∙Cl = 3.14 Å in the experimental structure). The other water H atom was pointing in an 
arbitrary direction enclosing a bond angle of 109.5
o 
with the first one. The initial 
configuration for the anhydrate was generated by simply removing the water O atom from 
the experimental structure. The final computational models were then obtained by 
geometry optimisation starting from these initial configurations.  
The unit cell volumes for the fully hydrated and the anhydrate models are 948 Å
3
 and  
915 Å
3
,
 
which are in good agreement with the highest and lowest unit cell volumes found 
in the VH-XRPD experiments, 939 Å
3 
and 905 Å
3
,
 
respectively (see Appendix A,  
Table A1). 
As expected, the two structures remain highly similar both to each other and to the 
experimental structure (Figure 3.13). In contrast to most channel hydrates, the dehydrate 
form does not contain residual voids, i.e. it is non-porous. The fact that such a simple 
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computational protocol gave a non-porous model highlights the possibility of a smooth and 
continuous transition between the hydrated and dehydrated states of Form II, and it is 
consistent with the experimentally observed retention of the same overall structure even 
when the RH is reduced to 1%. 
 
 
Figure 3.13: Comparison of the hydrate (left) and anhydrate (right) models of Form II. The anhydrate 
model is presented as a space-filling model to show the lack of unoccupied space in the structure. 
 
In general, the water molecules of non-stoichiometric hydrates are weakly bound and can 
be removed without significant changes in the rest of the structure. The model of 
paroxetine HCl Form II shows (Figure 3.14) that each water molecule hydrogen bonds to a 
chloride ion (strong acceptor) and to an oxygen atom in the dioxole ring of the drug 
molecule (weak acceptor). 
 
 
 
 
 
 
 
 
Figure 3.14: Hydrogen-bonding environment of the water molecule in paroxetine HCl Form II. 
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Consequently, removal of a water molecule from Form II requires breaking of at least one 
strong hydrogen bond in addition to some structural rearrangement to allow movement of 
the water molecule between adjacent cavities. These requirements make the quick 
hydration/dehydration of Form II rather surprising. Note, however, that the water 
molecules of the Form I are involved in three strong hydrogen bonds, formed with two 
chloride ions and with a protonated ammonium nitrogen, respectively, so the higher 
stability of the Form I is readily explained (Figure 3.15). 
 
 
 
 
 
 
 
 
 
Figure 3.15: Hydrogen-bonding environment of the water molecule in Form I. 
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3.4 Conclusions 
 
The distinction between strong hygroscopic behaviour and hydrate formation is sometimes 
very opaque and can lead to misinterpretations. In this study, it was shown that the 
hygroscopic nature of paroxetine HCl has led to incorrect classification of this material as 
an anhydrate. The evidence for this is as follows. First, the large amount of water content 
determined by using TGA, KF titration and DVS raise doubts regarding the anhydrate 
classification of this drug. In general, the water adsorbed on the surface of an API is 
around 1%, but paroxetine HCl Form II has a water uptake more than three times higher 
than this. The rapid and extensive water uptake into the structure at low RH (≈ 30%) in 
itself indicates that paroxetine HCl Form II is likely to be a non-stoichiometric hydrate. 
This is also supported by the thermal analysis (DSC) data that indicated that the sorbed 
water associated with this form, on heating slowly under hermetic conditions, become 
incorporated into the crystal structure of the drug to form the Form I. This is in itself very 
unusual behaviour, but is consistent with the notion of the water being incorporated into 
the structure rather than simply sorbed onto the surface.    
Secondly, to support the non-stoichiometric hydrate hypothesis, variable humidity XRPD 
studies were performed. It was observed that on increasing the RH, shifts in the peak 
positions of the XRPD diffractogram were evident until 30% RH, which is in accordance 
with the observations in DVS. During desorption, the shifts in the peaks followed the 
decrease in the RH. In both cases there were no changes to the crystalline pattern, showing 
that the water sorption process led to changes in lattice spacing but no fundamental change 
to the lattice arrangement. 
In most recorded cases, this water sorption behaviour is characteristic of a specific 
subgroup of non-stoichiometric hydrates, the channel hydrates, where the existence of 
connecting pathways allows the smooth departure of the water without any structural 
deformation. However, the analysis of the structure of Form II indicates that the water in 
not located in channels but in small voids and also is not weakly bonded to the crystalline 
structure, as expected, which makes the hydration/dehydration of this material an 
uncommon feature. The location of the water within the structure together with the energy 
supply, explains the pseudopolymorphic transformation observed either in the MTDSC, 
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when hermetic sealed pans were used, as well as, in variable temperature ATR-FTIR 
experiments.  
As a conclusion, this work suggested that the classification of paroxetine HCl Form II 
should be reviewed, since the designation as an anhydrate form is no longer reliable. Also 
the non-standard behaviour for this non-stoichiometric hydrate in that the water is not 
present in channels but in pores, rendering the absence of hysteresis on sorption and 
desorption, along with the change in lattice dimensions, it was found extremely unusual. 
However, the broader implications of the study lie with the notion that differentiation 
between a hygroscopic anhydrate and a non-stoichiometric hydrate may be extremely 
difficult and hence the question naturally arises as to whether such non-stoichiometric 
systems are more common than is generally appreciated. Such knowledge is of 
considerable relevance to pharmaceutical performance, both in terms of quality control of a 
system which changes its crystal structure reversibly in different humidity environments 
but also in terms of physical and possibly chemical stability.  
 
  
 
 
 
 
 
 
 
4 AN INVESTIGATION INTO THE DEHYDRATION BEHAVIOUR OF 
PAROXETINE HCL FORM I USING A COMBINATION OF 
THERMAL AND DIFFRACTION METHODS:  
THE IDENTIFICATION AND CHARACTERISATION  
OF A NEW ANHYDROUS FORM 
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Abstract 
 
As already described in Chapter 3, paroxetine HCl can exist as a non-stoichiometric 
hydrate (Form II) or as a stoichiometric hemihydrate (Form I); the latter is considered to be 
the stable form and its structure is well-known. However, little work has been performed to 
investigate its dehydration behaviour, hence the generation of the anhydrous form via 
dehydration of paroxetine HCl Form I was investigated. A combination of thermal 
(standard differential scanning calorimetry (DSC) and modulated temperature DSC 
(MTDSC), thermogravimetric analysis (TGA) and hot stage microscopy (HSM)) and 
diffraction (variable temperature X-ray diffraction, VT-XRPD) techniques were used. Karl 
Fischer titration (KFT) and scanning electronic microscopy (SEM) were used to determine 
the water content and collect microphotographs of the crystals, respectively. Dehydrated 
Form I was prepared using ultra-dry conditions and the resulting product compared to 
dehydrated Form II. DSC indicated that the two dehydrated forms of Form I and II had 
distinct melting points. TGA experiments allowed the calculation of the activation energy 
for the dehydration of Form I, which varies between 86–114 kJ/mol. Pawley refinement of 
the VT-XRPD data suggested that Form I dehydrates to an isostructural anhydrate, since 
the unit cell parameters of this new form were very similar to those of Form I with only a 
smaller volume as consequence of dehydration. Comparison with dehydrated Form II 
indicated that these two forms represent different crystal entities, hence a new anhydrous 
form of paroxetine HCl has been identified.  
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4.1 Introduction  
 
Hydrates are often the most physically stable form of an active pharmaceutical ingredient 
(API) under conditions of relative humidity (RH) typically found on storage, hence their 
use remains extremely widespread. Nevertheless, their dehydration and rehydration 
behaviour is often complex, with multiple forms possible which render thorough 
investigation of such interchanges necessary for both practical and regulatory reasons. The 
dehydration process occurs when the water activity of the surrounding environment is 
lower than the water activity in the solid compound (Cui and Yao, 2008). Once the water is 
removed from the crystal structure packing, different structural consequences may occur 
(Petit and Coquerel, 1996): 
(a) breakage of the crystal lattice, followed by a rearrangement into a new anhydrous 
form (Leung et al., 1998); 
(b) the crystal structure remains the same after dehydration forming an 
isomorphic/isostructural dehydrate (Hirayama et al., 2000; Suzuki et al., 2012; Te 
et al., 2003; Stephenson et al., 1998);  
(c) partially or totally disordered state followed by a collapse into an amorphous phase 
(Chen et al., 1999; Vogt et al., 2006). 
Isostructural dehydrates (b) are associated with high free energy, which may be reduced by 
re-incorporation of solvent molecules into the lattice, rendering this type of compounds 
highly hygroscopic (Hilfiker, 2006). Dehydration is not always a straightforward process 
and a mix of phases can be obtained with a combination of more than one of the 
aforementioned mechanisms taking place. An example is the case of eprosartan mesylate 
dihydrate (Sheng et al., 1999) whereby after losing the first water molecule, the 
monohydrate dehydrates and collapses into an amorphous state, followed by 
recrystallisation into an anhydrate form of eprosartan mesylate. Another case is the 
dehydration of trehalose dihydrate whereby the product obtained is highly dependent on 
the dehydration conditions employed (Willart et al., 2002). More specifically, fast 
dehydration produces an amorphous phase, whereas a slow dehydration produces a 
crystalline phase (α-polymorph) of anhydrous trehalose. 
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Thermal analysis techniques such as differential scanning calorimetry (DSC) and 
thermogravimetric analysis (TGA) are widely used to evaluate the dehydration behaviour 
and the solid state stability of pharmaceutical hydrates. Two main approaches can be used 
to evaluate solid state kinetics (Khawam and Flanagan, 2006a): the sample is held at a 
constant temperature for a specified period of time (isothermal methods), or heated at a 
constant heating rate (non-isothermal methods). For both methods, it is possible to 
calculate the conversion fraction (α) where isothermal methods produce α-time data 
(Equation 4.1) and non-isothermal methods produce α-temperature data (Equation 4.2), 
  
     
     
 
Equation 4.1 
where, m0 is the initial sample weight, mt  is the sample weight at the time, t, and m∞ is the 
final sample weight. 
  
     
      
 
Equation 4.2 
where, mT  is the sample weight at temperature, T. The extent of conversion, α, increases 
from 0 to 1 as the process progresses and kinetic analysis (isothermal or non-isothermal) 
can be performed either by model-fitting or model-free methods (Khawam and Flanagan, 
2006a).  
Model-fitting approaches involve expressions (Appendix B, Table B3) to which the 
experimental data (isothermal or non-isothermal) is fitted. The model that gives the best 
fitting (R
2
 closer to 1) is selected to calculate the kinetic triplet which involves: the 
activation energy, Ea (kJ/mol), as the energy barrier to overcome dehydration (for the 
present study), the pre-exponential factor, A (min
-1
) and the kinetic model (Khawam and 
Flanagan, 2006a). Model-fitting methods assume a single value of Ea for the overall 
reaction process, thereby implying a single reaction mechanism and do not provide an 
adequate interpretation of complex kinetic reactions (Vyazovkin et al., 2011). Another 
approach used to calculate the kinetic parameters of a dehydration reaction is by using 
model-free methods. As the designation implies, model-free methods are applied without 
any modelistic assumptions and therefore irrespectively of the underlying reaction model. 
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As a result, they are capable to quantify the dependence of the Ea at each conversion 
fraction, α, and thus are also known as isoconversional methods. Model-free methods 
enable to highlight the complexity of the kinetic reactions, which allows a more accurate 
determination of the Arrhenius parameters (Khawam and Flanagan, 2006a).  
Paroxetine HCl Form I is a stoichiometric hydrate with half mol of water per mol of drug, 
as shown by its chemical structure in Figure 4.1. 
 
 
 
Figure 4.1: Chemical structure of paroxetine HCl Form I. 
 
Barnes et al. (Barnes et al., 1988) reported the preparation of paroxetine HCl Form I and 
described this form as being extremely stable, with the removal of the water from the 
crystalline structure being possible under extreme desiccant conditions, with a quick 
rehydration to the hemihydrate form. A decade later, Ibers (Ibers, 1999) published the 
crystal structure of paroxetine HCl Form I, which indicated that the water molecules are 
linked to a N-H
...
O via a hydrogen bond 2.772(6) Ǻ in length. The author suggested that 
this was the bond associated with dehydration and should be easily cleaved, hence 
theoretically dehydration should occur readily. It is now believed that the water molecules 
of the Form I are involved in three strong hydrogen bonds, formed with two chloride ions 
and with a protonated ammonium nitrogen, respectively, explaining the observed stability 
of Form I (shown in Chapter 3). Though the crystal structure of paroxetine HCl Form I is 
now well-known, an important gap in the understanding of this form is related to its 
dehydration behaviour (Farjas et al., 2010).  
Paroxetine HCl can also exist in Form II, as shown in Chapter 3, identified as being a  
non-stoichiometric hydrate. Form II retains the same crystal structure when dehydrated 
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forming an isostructural dehydrate with only expansion and contraction on the crystal 
lattice volume, respectively.  
In an effort to better understand the interplay between hydrated and anhydrous forms, a 
thorough investigation into the dehydration behaviour of paroxetine HCl Form I was 
carried out using a combination of thermoanalytical techniques (standard differential 
scanning calorimetry (DSC) and modulated temperature DSC (MTDSC), 
thermogravimetric analysis (TGA) and hot stage microscopy (HSM)) and high resolution 
variable temperature X-ray powder diffraction (VT-XRPD). The water content of the 
sample was determined by Karl Fischer titration (KFT) and the morphology of crystals was 
observed under scanning electron microscopy (SEM). The purity of the sample obtained 
after the dehydration of Form I was determined using high performance liquid 
chromatography (HPLC). Additionally, the activation energy, Ea, needed to dehydrate 
Form I was calculated using non-isothermal model-free (Ozawa-Flynn-Wall) approaches; 
isothermal model-fitting (Standard) methods were used in order to identify the best kinetic 
model as a means of describing this dehydration process. The work presented in this 
chapter aims to examine whether dehydration from two significantly distinct hydrate forms 
leads to the same anhydrate for this material. This question is particularly pertinent given 
the unusual nature of the non-stoichiometric Form II and, as will be shown, the very 
unstable nature of the Form I anhydrate, hence little precedent exists to determine whether 
the Form I (hemihydrate) will yield the same dehydrated form.    
 
4.2 Materials and Methods 
 
4.2.1 Materials 
Paroxetine HCl Form I was purchased from Afine (China) and was used as received or 
after being kept over phosphorus pentoxide (P2O5), Alfa Aesar (UK) or in a static oven, as 
stated. For HSM observations, Form I was recrystallised from methanol by solvent 
evaporation method. 
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4.2.2 Methods 
4.2.2.1 Thermal Analysis  
Standard differential scanning calorimetry (DSC, Q2000 TA Instruments) analysis was 
performed at heating rates of 2, 5, 10, 20 and 50 
o
C/min. Modulated temperature DSC 
(MTDSC, Q2000 TA Instruments) analysis was conducted using a heating rate of  
2 
o
C/min, amplitude ± 0.318 
o
C and a period of 60 seconds. Scans were carried out within 
the temperature range 0 °C to 170 °C. Pinhole, hermetically sealed and open pans (pinhole 
pans without lid) were used as stated.  
Thermogravimetric analysis (TGA, Q5000 TA Instruments) of paroxetine HCl Form I was 
performed in aluminium open pans by weighing approximately 5 mg of sample with 
controlled particle size between 63-106 μm. Nitrogen purge at a constant rate, 25 mL/min, 
was maintained during each run. Non-isothermal experiments were performed at heating 
rates of 1, 2, 3, 4 and 5 °C/min from 30 °C until 300 °C. Isothermal studies were carried 
out at 75, 80, 85, 90 and 95 °C with each sample been rapidly heated to the set temperature 
at a 50 °C/min and kept isothermal until a constant weight change was achieved.  
Hot stage microscopy (HSM, Leica DM L52) studies were conducted by placing Form I 
between a slide and a cover slip inside a hot stage chamber (FP82HT, Mettler Toledo) 
connected to a FP90 central processor. The sample was heated up at 2 
o
C/min from 30 to  
150 
o
C and the observed thermal events were digitally captured (Studio 86 Design Capture 
Software).  
 
4.2.2.2 Karl Fischer Titration (KFT) 
KFT (Mettler Toledo DL38) for water determination of Form I was carried out by 
weighing between 40 to 50 mg of the untreated bulk sample. 
 
4.2.2.3 Scanning Electron Microscopy (SEM) 
SEM (JSM5900 LV) was used to acquire microphotographs on the untreated Form I and 
after being kept isothermal in TGA for 1 h at 90 and 110 
o
C. To improve conductivity prior 
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examination, samples were coated with gold using a Polaron SC7640 sputter gold coater 
(Quorum Technologies). 
 
4.2.2.4 High Performance Liquid Chromatography (HPLC) 
HPLC (Agilent HP 1100 Series System) was carried out using a Supelco Ascentis Express 
C18 (Sigma). Mobile phase consisted of 0.1% TFA in water and 0.085% TFA in 
acetonitrile and a flow rate of 2.0 mL/min was used. The samples were analysed at  
255.9 nm. 
 
4.2.2.5 Variable Temperature X-Ray Power Diffraction (VT-XRPD) 
VT-XRPD experiments (Bruker D8 Advance, Bruker) data sets were collected from 5.0° to 
30.0° at 2θ under nitrogen purge with a flow rate of approximately 50 mL/min and 99.9% 
purity. The sample was placed in an Anton-Paar TTK450 (Anton-Paar) chamber at 25 
o
C. 
The temperature was controlled by a Temperature Control Unit TCU 100 (Anton-Paar) and 
the applied heating rate was set by default to 0.167 K/s. Diffractograms were recorded 
during heating at 25, 50, 75, 100 and 110 
o
C, and cooling at the same temperatures as 
during heating. The sample was maintained under isothermal conditions for different 
periods of time at each temperature, according to the knowledge provided by preliminary 
studies. 
Unit cell parameters were determined by Pawley refinement of the collected patterns using 
the software TOPAS-Academic (Coelho, 2007). The initial values of the cell parameters 
for the refinement at 25 
o
C were taken from the single crystal structure of Form I. 
Refinements of powder patterns at higher temperatures were initiated from cell parameters 
refined in the previous heating or cooling step. The pattern recorded at 100 °C during 
cooling was indexed in TOPAS-Academic and the refinement was based on the cell 
parameters from indexing. 
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4.3 Results and Discussion  
 
4.3.1 Thermoanalytical Investigation of the Dehydration Process  
 
The thermal behaviour of paroxetine HCl Form I was investigated by DSC using three 
types of pans: pinhole, hermetic and open. As presented in Figure 4.2, the type of pan used 
has a profound effect on the thermal response observed. As expected, it was found that the 
accurate melting point of Form I has to be measured in hermetic pans (in order to avoid 
dehydration) and has an onset temperature of 142.0 ± 0.2 °C, which matched the reported 
value in the literature (Barnes et al., 1988). However, when pinhole and open pans were 
used, the onset melting temperature of Form I was shifted to lower temperatures and 
appeared as a broad and poorly resolved profile. 
 
 
 
Figure 4.2: DSC traces of paroxetine HCl Form I at 10 °C/min in hermetic, pinhole and open pans. 
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The effect of the heating rate (HR) (2, 5, 10, 20 and 50 
o
C/min) was tested using the three 
types of pans (data not shown). In pinhole pans, as the heating rate increased, the peaks 
became broader and at 50 °C/min the melting event was shifted closer to the melting of the 
hydrate Form I. The results obtained at different HRs with hermetic pans were the same at 
all the heating programs used. With open pans, a significant dependence on heating rate 
was observed, with slower rates indicating a distinct endotherm which we associate with a 
dehydration process (supported by TGA studies as discussed later).  
Figure 4.3 shows the DSC responses of paroxetine HCl Form I and II in open pans  
(2 
o
C/min) so as to highlight the differences in behaviour between the two forms studied 
under identical conditions. First of all, the water loss was detected at different temperature 
ranges for the two forms. In the case of Form II, the water loss started from the beginning 
of the run, while for Form I the loss occurred roughly between 50 and 100 ºC. The onset 
melting temperature was detected at 111.9 ± 0.4 ºC for Form I and at 117.5 ± 0.4 ºC for the 
Form II, resulting in a difference of almost 6 ºC between the onset melting points of these 
two forms, while the peak melting temperatures differed by almost 3 
o
C. At this early stage 
of the investigation these results, while not conclusive, indicated that there may be 
differences in the anhydrate forms generated from the dehydration of the two hydrate 
forms.   
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Figure 4.3: Standard DSC traces of paroxetine HCl Form I and II when heated in open pans  
at 2 ºC/min. 
 
After this, the conditions required to dehydrate Form I were investigated, working on the 
assumption that the anhydrate could be identified by a melting point onset of circa 112 
o
C. 
Surprisingly, the only means of producing this form was within the DSC, with storage over 
P2O5 or oven drying both resulting in only partial dehydration (Table 4.1). Preliminary 
studies indicated that a functioning water filter on the nitrogen supply was also essential 
(data not shown), further reinforcing the hypothesis that the environment must be 
extremely dry to allow dehydration of Form I to occur. This also led to the consideration 
that physical isolation of the anhydrate was extremely difficult, as any exposure to 
humidity resulted in reconversion. Consequently, all the subsequent studies involve the 
assessment of the structure within the instrument used to generate the anhydrate.  
In contrast, Form II was completely dehydrated inside the DSC, when held isothermally in 
the oven or stored over P2O5. Complete dehydration of Form II was confirmed by the 
detection of a single endotherm event corresponding to the melting of the dehydrated  
Form II (≈ 117 oC). Overall, this set of comparative experiments suggested that the 
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dehydration of Form II is a much simpler process than the dehydration of Form I, able to 
happen over a wider range of conditions with a more stable product being generated.   
 
Table 4.1: Dehydration studies of paroxetine HCl Form I and Form II performed at  
different drying conditions. 
 
* 
Measurements were made in hermetic pans. All the experiments were performed at 2 
o
C/min. 
 
Another important aspect in this study was to ensure that the complete dehydration of 
paroxetine HCl Form I was not associated with any amorphisation of the sample. 
Therefore, a heat-cool-heat procedure was set up at 2 
o
C/min using open pans; MTDSC 
was used to identify particular transitions such as Tg in case the sample becomes 
amorphous after dehydration. As presented in Figure 4.4 it is possible to observe a typical 
water loss signal for Form I in the 1
st
 heating cycle. On cooling, no thermal events were 
detected either in total or reversing heat flow. Surprisingly however, on the 2
nd
 heating 
cycle a broad endothermic transition between 40 and 60 
o
C was noticed. The first 
assumption made was that this transition could be a glass transition event as consequence 
of amorphisation after dehydration. However, the transition was not observed on the 
reversing heat flow signal, which then excluded this hypothesis. The possibility of this 
transition being an artefact was eliminated, with the same results being obtained either 
Sample 
Experimental drying 
procedure 
T
m onset
 (°C) ΔH
melting 
(J/g) T
m
 
peak
 (°C) 
Form I 
 
DSC open pans  111.9 ± 0.4 50.4 ± 1.4 120.4 ± 0.1 
*
Oven 100 ºC/24 h 136.7 ± 0.8 85.2 ± 0.2 140.9 ± 0.1 
*
P2O5/48 h 138.9 ± 0.9 91.5 ± 2.4 141.1 ± 1.5 
Form II 
 
DSC open pans  117.5 ± 0.4 53.1 ± 1.0 123.1 ± 0.1 
*
Oven 100 ºC/1 h 116.6 ± 0.2 56.2 ± 2.0 120.1 ± 0.3 
*
P2O5/48 h 117.2 ± 0.9 53.2 ± 0.2 120.5 ± 1.7 
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using pans from different batches or the same procedure carried out using different DSC 
instruments.  
 
 
 
Figure 4.4: Dehydration of paroxetine HCl Form I inside DSC through heat-cool-heat cycling 
procedure in open pans. MTDSC was used with a HR of 2 
o
C/min, modulation amplitude of 0.318 
o
C 
and a period of 60 sec.  
 
At this point, the most likely explanation for the transition was water evaporation. 
However, as the DSC cell is a closed system, the only possible source of moisture would 
be the nitrogen purge gas. To confirm this possibility the same cycling procedure was 
carried out in pinhole pans, which would partially restrict the exposure of the sample to the 
nitrogen gas. Under these conditions, the endothermic transition was not observed in the 
2
nd
 heating cycle (data not shown). These observations suggest that even with a water 
filter, the system is sufficiently hygroscopic to pick up water, probably via surface sorption 
as there was no evidence of regeneration of the hydrate form. This further demonstrates the 
experimental difficulties associated with handling such a hygroscopic sample. 
The thermal behaviour of paroxetine HCl Form I under heating was confirmed by using 
hot stage microscopy (HSM). However, the crystals of paroxetine HCl Form I as received 
1st heating cycle
2nd heating cycle
-0.08
-0.06
-0.04
-0.02
0.00
0.02
0.04
[ 
  
  
  
  
  
  
] 
R
e
v
 H
e
a
t 
F
lo
w
 (
W
/g
)
 –
 –
 –
 –
 
-0.28
-0.18
-0.08
0.02
0.12
H
e
a
t 
F
lo
w
 (
W
/g
)
0 20 40 60 80 100 120 140
Temperature (°C)
Size:  3.1800 mg DSC
File: Paroxetine HCl Form I open pans 5cycl...
Operator: fatima
Run Date: 25-Jul-2012 19:19
Instrument: DSC Q2000 V24.4 Build 116
Exo Up Universal V4.5A TA Instruments
 
Chapter IV 
 
153 
 
120 oC 121 oC 
124 oC 133 oC 
were not big enough for a clear observation under HSM, therefore paroxetine HCl Form I 
was recrystallised in methanol (solvent evaporation method) and crystals with a greater 
size were obtained. The DSC traces and the water content measured by TGA confirmed the 
recrystallised form to be Form I. 
From the microphotographs collected at different temperatures, as shown in Figure 4.5, 
paroxetine HCl Form I dehydrated upon heating and at around 120 
o
C some surface 
melting of the crystal can be observed. The overall melting process happened over a broad 
range of temperature (≈ 13 oC) with the offset melting temperature being detected at 
around 133 
o
C. It should be noted that the environment inside the hot stage furnace is 
obviously different from the DSC cell and as a result, the complete dehydration of the 
sample was not achieved. These facts are fairly understood, firstly due to the non-
hermetically conditions provided by the HSM furnace and secondly the inexistence of 
nitrogen purge which makes the dehydration of this form harder to happen. In a broader 
view, however, these results support the DSC data and the idea of the dehydration of  
Form I followed by the melting of the anhydrous form. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5: Microphotographs of paroxetine HCl Form I heated at 2 
o
C/min.  
Scale bar represents 150 µm. 
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Given the above results, it was considered important to evaluate the strength of the 
interactions between the water and the drug within the hydrate, which may be achieved 
using TGA. In Figure 4.6, the DSC and TGA thermograms of paroxetine HCl Form I have 
been overlaid. For a particular slow HR of 2 
o
C/min, the water loss commenced at around 
50 
o
C and occurred continuously until approximately 115 
o
C; the loss can be divided in 
two main temperature regions. The first one between 50-95 
o
C covered the majority of the 
water loss and the second one near the endothermic melting event, as observed from the 
DSC curve.  
 
 
 
Figure 4.6: DSC (
____
) and TGA (
_ _ _
) thermographs for paroxetine HCl Form I in open pans at  
2 
o
C/min. The derivative weight curve (-
.
-
.
-) is presented for clarity. 
 
The water content of the raw Form I was determined by KFT to be 2.71 ± 0.25% w/w. This 
value was in a good agreement with the designation of this form as hemihydrate,  
0.56 ± 0.05 mol of water per mol of drug and matched the total weight lost measured by 
TGA. In addition, HPLC was used to confirm that dehydration and subsequent melting 
process did not yield to any degradation of the sample. Analyses were performed on the 
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untreated paroxetine HCl Form I and on the sample heated in the TGA until 130
 o
C. No 
sign of degradation was found on the heated sample (purity of 99.6%) when compared to 
the raw Form I (purity of 99.5%). 
A closer inspection of the derivative curve shows that, at a HR of 2 
o
C/min, part of the 
water (0.61% of the 2.59%) could only be released at high temperatures, i.e., near the 
melting point of the dehydrate Form I. However, this idea is not supported by the 
isothermal experiments, as shown in Figure 4.7. For example, when the sample was kept at 
90 
o
C, the dehydration was completed after 30 min. The TGA isothermal experiments are 
also important to access the dehydration conditions when performing VT-XRPD, though a 
direct correspondence could not be made due to the environmental differences between the 
two techniques. Moreover, this set of data was also fundamental to calculate the activation 
energy (Ea) for dehydration, as described earlier in the Introduction of this chapter. 
 
 
 
Figure 4.7: Representation of the conversion fraction (α) versus time obtained from  
TGA isothermal data at the different temperatures. 
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4.3.2 Dehydration Kinetics 
 
The dehydration kinetics of paroxetine HCl Form I was studied using  
model-free and model-fitting approaches. Model-free analysis were performed using  
non-isothermal data, allowing the calculation of the Arrhenius parameters as a function of 
the conversion fraction, α. Model-fitting approaches were carried out using isothermal data 
that yields to the evaluation of a suitable kinetic model that better defines the overall 
reaction.  
Based on the graphical shape of the isothermal curves, as shown previously in Figure 4.7, 
the dehydration rate decreases as the reaction proceeds and thereby the kinetic model for 
this reaction is known as decelerating. There are three other major groups of kinetic 
models described in the literature as accelerating, linear and sigmoidal (Vyazovkin et al., 
2011). Non-isothermally, plots of α vs. temperature are not distinctive in their shapes as 
they are isothermally and thereby not used to preclude on the kinetic model of the solid 
state reaction (Khawam and Flanagan, 2006b). 
 
Model-Free Analysis 
The activation energy for the dehydration of paroxetine HCl Form I was calculated using a 
non-isothermal isoconversional method developed by Ozawa, Flynn-Wall (Ozawa, 1965; 
Flynn and Wall, 1966) and therefore commonly referred to as the OFW method, which can 
be expressed by the Equation 4.3 
         
   
     
      
  
  
       
Equation 4.3 
where, β is the heating rate, g(α) is the integral reaction model and R the gas constant.  
Plotting log β versus 1000/T at each α yields Ea from the slope and from the intercept of 
the linear equation, the frequency factor, A, can be obtained. However the determination of 
A requires modelistic assumptions and as consequence, model-free methods usually only 
focus on the calculation of Ea at each value of α (Khawam and Flanagan, 2006a). An 
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example for the calculation of the Ea at a specific conversion fraction is presented in 
Appendix B (Table B2 and Figure B2).  
Figure 4.8 shows the variation of the Ea as a function of α. By analysing in more detail the 
dependence of Ea with α through the kinetic reaction, a decrease in the Ea from 114.1 to 
99.2 kJ/mol within 0.15 ≤ α ≤ 0.40 can be observed, followed by an approximately 
constant value of 85.9-96.2 kJ/mol in the range 0.45 ≤ α ≤ 0.75. The initial decrease of the 
Ea vs. α is characteristic of reversible reactions and could indicate a departure from the 
initial equilibrium (Vyazovkin et al., 2011). After this nearly constant period, the Ea started 
to increase gradually until an abrupt high value (211.8 kJ/mol) when α = 0.9. This increase 
in the Ea for the final conversion fractions can be linked to the observations in TGA, 
showing that the removal of the final fractions of water took place at higher temperatures, 
therefore requiring more energy. However, one should also bear in mind that a loss of 
linearity and a higher error are expected at the final points of α, weakening the correlation 
with the TGA results. Nevertheless, this variation of Ea with α indicates that the process is 
kinetically complex and a single-step rate equation cannot describe the whole reaction. 
Attempts to analyse isothermal data using model-free methods were unsuccessful since 
good correlations could just be obtained for high values of conversion (α ≥ 0.40) since the 
rate of the reaction is faster in the beginning (decelerating model). As a result, there is a 
significant extent of conversion during the heat-up time even using a heating rate of  
50 
o
C/min to quickly reach the desired isothermal temperature.    
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Figure 4.8: Activation energy, Ea, plotted as a function of the extent of conversion, α, for the 
dehydration of paroxetine HCl Form I under non-isothermal conditions.    
 
Model-Fitting Analysis 
 
Model-fitting methods of isothermal data were performed within the conversion region 
where Ea is approximately constant (0.45 ≤ α ≤ 0.75), as determined previously by  
model-free analysis. The data was fitted to the integral form, g(α), of 17 models listed in 
Appendix B Table B3.  
Two different models were found to have the best fit for the dehydration kinetics of 
paroxetine HCl Form I: F2 (Ea = 71.8 ± 2.4 kJ/mol, R
2
 = 0.9968) and D3 (Ea = 74.3 ± 2.2 
kJ/mol; R
2
 = 0.9974). Each model affords a similar value of Ea, however from the shape of 
the isothermal curves, the reaction follows a deceleratory model, as mentioned above. 
Therefore, D3 (three dimensional diffusion model) provides a good description of the 
dehydration kinetics over this range of conversion.  
The acquired knowledge up to this stage allowed to understand the thermal behaviour of 
Form I when exposed to different dehydration conditions and carefully set up the XRPD 
experiments, as follow, which are essential to provide information on the structure of the 
dehydrated form.  
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4.3.3 Structural Studies using VT-XRPD 
 
VT-XRPD experiments were performed in a closed system constantly purged with dry 
nitrogen gas in order to mimic the conditions inside the DSC and TGA furnace. A change 
in the XRPD pattern started to be apparent after 1 h at 75 
o
C, with some of the diffraction 
peaks becoming broader. The changes were clearly observed as the temperature increased  
(Figure 4.9). After 5 h isothermal treatment at 100 
o
C, the existing peaks became less sharp 
and new peaks appeared which may be associated with the departure of the water 
molecules and the concomitant appearance of a new phase. This phenomenon was more 
evident when the temperature increased to 110 
o
C and the sample was kept isothermal for 
12 h. After that time, and analysing the spectrum at lower angles, it is possible to 
distinguish the new peaks that appeared (*) and the peaks from the hydrated Form I that 
started to disappear (
#
). However, at higher angles the discrimination between the two 
phases is more difficult due to the overlap between some of the peaks. Pawley refinement 
(Coelho, 2007) using the unit cell parameters of Form I gave a good fit to the experimental 
patterns at temperatures below 75 °C, but at 100 and 110 oC the fit was very poor due to 
the presence of more than one form (Appendix B, Figure B1 and Table B1). 
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Figure 4.9: VT-XRPD diffractograms collected on paroxetine HCl Form I at 25, 50, 75, 100 and 110 
o
C 
(upwards). Peaks identified with (*) correspond to the new anhydrous form and those identified with 
(
#
) are related to the initial Form I. 
 
On cooling, it was possible to index the pattern collected after 1 h at 100 
o
C. Pawley 
refinement with the new unit cell parameters gave a good fit to the diffraction pattern. The 
refined cell parameters (a = 14.400(2) Å, b = 10.5362(15) Å and c = 12.7706(13) Å) were 
found to be very similar to those of the hemihydrate Form I at 75 °C (a = 14.655(5) Å,  
b = 10.191(3) Å and c = 13.039(5) Å), but with a smaller unit cell volume. The space 
group of the new anhydrous form was found to be P21, the same as Form I. A similar 
pattern to the one collected at 100 
o
C was maintained on further cooling down to 50 
o
C 
(Figure 4.10). When the temperature dropped to 25 
o
C the pattern changed significantly, 
which might be ascribed to the re-entry of water molecules into the crystal structure. At 
this stage, the fitting using the anhydrous unit cell parameters became very poor, as the 
pattern started gradually to revert to the initial Form I. 
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Figure 4.10: VT-XRPD patterns of paroxetine HCl Form I collected during cooling from 110 
o
C to  
25 
o
C (upwards). At 25 
o
C, the diffractograms were collected after 1, 2 and 6 h isothermal  
at that temperature.  
 
Figure 4.11 depicts the changes in the unit cell volume as a function of temperature. It is 
clear that during heating the unit cell volume increased slightly, as expected for thermal 
expansion. The unit cell volume of the new form at 50 °C was found to be 56 Å
3
 smaller 
than that of Form I at the same temperature, which is consistent with dehydration 
(Appendix B, Table B1). After 6 h at 25 
o
C, the unit cell volume was found to be the same 
as the hydrate Form I, indicating that full rehydration took place. 
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Figure 4.11: Changes in the unit cell volume of paroxetine HCl Form I during heating at 25, 50, 75 and  
100 
oC (♦); during cooling of the anhydrous form (●) at the same temperatures as during heating; and 
after cooling at 25 
o
C for 6 h (□). Note that the refinement at 100 oC on heating and after 1 h at 25 oC  
on cooling gave a poor fitting, thus these results are less reliable. 
 
From these observations, Form I is likely to dehydrate to an isostructural anhydrous form, 
which explains its extremely high instability and propensity to interact with water, as no 
major changes in the structure were needed for the rehydration to occur.  
Furthermore, SEM microphotographs (Figure 4.12) taken on the raw Form I (a) and 
compared with Form I (b) held isothermal for 1 h at 90 
o
C in TGA, did not show any 
differences in their crystal appearance. This fact is not surprising and can be readily 
explained by the higher hygroscopic behaviour of this new anhydrous form able to 
rehydrate using the residual moisture present in the nitrogen gas (XRPD experiments 
during cooling). Therefore, differences related to dehydration would be hard to observe 
under SEM. A sample held at 110 
o
C for 1 h (c) had a partially glassy appearance under 
SEM. This is due to surface melting of the dehydrated sample kept under these isothermal 
conditions and subsequent cooling. Thermogravimetric analysis is primarily designed for 
dynamic heating rates and the offset is not affected by heating rate but the actual 
temperature may be different in the isothermal experiment. As a result, these observations 
are expected since the onset melting point of the dehydrated Form I  
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is ≈ 112 oC, matching well with the possibility of small variations in temperature when 
isothermal experiments are performed in TGA. 
 
 
 
Figure 4.12: SEM pictures of raw paroxetine HCl Form I (a), isothermal for 1 h 
 at 90 
o
C (b) and isothermal for 1 h at 110 
o
C (c) in TGA. 
 
Finally, by comparing the pattern obtained for the dehydrated Form II at 30 
o
C/1% RH 
(data presented in Chapter 3) and the pattern collected in this study at 50 
o
C for the 
dehydrated Form I, it is possible to see that these two crystalline patterns are different 
(Figure 4.13). As Form II forms an isostructural anhydrate when dehydrated, only shifts on 
the diffraction peaks were observed without any changes in terms of 
appearance/disappearance of peaks. Attempts to fit the pattern of dehydrated Form I using 
the unit cell parameters of the dehydrated Form II were unsuccessful, reinforcing the 
hypothesis that these two dehydrated forms are structurally different.  
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Figure 4.13: VT-XRPD pattern of the dehydrated Form I at 50 
o
C on cooling (bottom) and VH-XRPD 
pattern of the dehydrated Form II (top) collected at 30 
o
C/1% RH (data presented in Chapter 3). 
 
Figure 4.14 is a schematic representation of the relationships between hydrated and 
dehydrated forms of paroxetine HCl. Form II dehydrated to an isostructural anhydrous 
form that rehydrated back at 10-30% RH (Chapter 3). The dehydration of Form I was a 
more complex process implying a completely dry environment and high temperatures. The 
dehydrated Form I was found to be very unstable with quickly reconversion to the hydrate 
Form I when RH ≈ 1%. The two dehydrated forms of Form I and II were structurally 
different and therefore a new form of paroxetine HCl has been found.  
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Figure 4.14: Representative scheme of the relationship between the two forms of paroxetine HCl. 
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4.4 Conclusions 
The combination of thermal and diffraction techniques allowed investigation of the 
dehydration behaviour of paroxetine HCl Form I and, consequently, suggested the 
existence of a new anhydrous form as a result of this process. Dehydration was firstly 
observed when Form I was heated in pinhole or open pans in the DSC. However, the 
melting peak temperature observed for the dehydrated Form I (120 ºC) was fairly close to 
the melting of the isostructural dehydrate Form II (123 ºC), which made the differentiation 
between these two dehydrated forms difficult using thermal techniques.  
Therefore, VT-XRPD experiments were performed in a closed system blanket with dry 
nitrogen gas (99.9% purity) in similar conditions as those observed in the DSC and TGA 
furnace. The changes in the XRPD pattern started to be observed as the temperature 
increased, with the appearance of new diffraction peaks after the sample being kept 
isothermal for 5 h at 100 
o
C. The Pawley refinement showed that the unit cell parameters 
of the new anhydrous form were very similar to the hydrate Form I, the main difference 
being a smaller unit cell volume, as a result of dehydration. Therefore, it is possible to 
conclude that Form I dehydrates to an isostructural dehydrate form. 
During cooling, as a result of the temperature drop, residual moisture in the N2 source (in 
theory nearly 1%) and probably not completely hermetically sealed VT chamber, the 
pattern started gradually to revert to the initial Form I after 1 h at 25 
o
C. Pawley refinement 
using the pattern collected after 6 h at 25 
o
C showed that the unit cell had the same volume 
as the hydrate Form I confirming that the new anhydrous form fully rehydrated to Form I. 
The structural rehydration observed during cooling in the VT-XRPD experiments was 
supported by the results obtained when the sample was cycled inside the DSC in open 
pans, with the dehydrate Form I picking up moisture from the nitrogen gas. 
The dehydration kinetic studies of Form I were conducted using non-isothermal TGA data 
with a view to estimate the Ea required to dehydrate Form I. Model-free analysis were used 
to calculate the Ea for dehydration of Form I, which varies between 86-114 kJ/mol. This 
value of Ea is much higher than the reported value (60 kJ/mol) for stable hydrates under 
ambient conditions, supporting again the great stability observed for the hydrate Form I 
(Shimanovich et al., 2012).  
 
Chapter IV 
 
167 
 
The significance of these findings lies not only in the identification of a new structure for 
an important drug molecule, but also in highlighting the complexity of dehydration and 
rehydration behaviour of low molecular weight molecules. The Form I anhydrate was 
extremely difficult to produce and isolate due to the high resistance to dehydration and 
extreme affinity for water. The anhydrate is extremely unstable and hence is not a viable 
candidate for commercial use. However, taken in the context of the unusual hydration 
behavior of Form II highlighted in Chapter 3, this drug also serves as a potentially highly 
important model for understanding the relationship between chemical structure and 
hydration behaviour. In particular, the current study has highlighted the extreme affinity of 
the Form I dehydrate for water, which is in itself of interest in understanding hydrate 
formation and stability.       
Overall, the work presented in this chapter have shown that the dehydration of paroxetine 
HCl Form I is a complex and uncommon process for a stoichiometric hydrate. The 
prepared anhydrous form is structurally different from the dehydrated Form II, thereby a 
new anhydrous form of paroxetine HCl has been identified. Moreover, the structure of the 
new anhydrous form was found to be very similar to the hydrate Form I, which supported 
its high instability and tendency to quickly rehydrate. These findings are of considerable 
relevance on the understanding of the solid state relationships of paroxetine HCl. 
Furthermore, the study presents new insights into the behaviour of hydrates with high 
resistance to dehydration, with the possibility of new forms being identified and enhanced 
understanding of the driving factors determining hydrate formation and stability.   
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Abstract 
 
Increased interest in molecular time scales below the glass transition temperature, Tg, has 
arisen from the need to identify the conditions at which the stability of glassy materials is 
maximum and unwanted changes, such as recrystallisation, are improbable. In this study, a 
series of well-known kinetic and thermodynamic parameters have been used to 
characterise amorphous paroxetine HCl and predict its physical stability. These predictions 
were asserted with the experimental results obtained after the amorphous sample was 
stored under different relative humidity (RH) environments at room temperature.  
A combination of thermal (standard differential scanning calorimetry (DSC), modulated 
temperature DSC (MTDSC) and thermogravimetric analysis (TGA)), spectroscopic 
(attenuated total reflection-Fourier transform infrared (ATR-FTIR)) and diffraction (X-ray 
powder diffraction (XRPD)) techniques were used to characterise the freshly prepared and 
aged amorphous samples. Aqueous solubility and dissolution studies were also performed.  
Parameters such as heat capacity, configurational thermodynamic quantities and fragility 
parameters classified amorphous paroxetine HCl as a moderate fragile glass with a 
considerable degree of molecular mobility associated. The calculated relaxation time using 
Adam-Gibbs-Vogel approach was found to be a reasonably good predictor of the stability 
of amorphous paroxetine HCl. These observations were reflected in the stability of this 
form. Firstly, amorphous paroxetine HCl recrystallised to the most stable Form I during the 
solubility experiments. Secondly, the stability studies showed that the recrystallisation of 
this form was greatly influenced by the presence of humidity. High RH environments  
(75% RH) led to a full recrystallisation within 1 to 3 days, while the same observation was 
detected after 30 days under 53% RH. The storage conditions were also found to affect the 
pathway of recrystallisation of amorphous paroxetine HCl, which happened directly to 
Form I at 53% RH or via metastable Form II at 75% RH, as confirmed by FTIR. This study 
elucidated the importance of taking advantage of the theoretical predictors in the study of 
amorphous systems, although the complete understanding of its physical stability and 
recrystallisation behaviour remains beyond these predictions.  
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5.1 Introduction  
 
Thermodynamic properties such as excess of free energy, enthalpy and entropy are 
responsible for the advantageous uses of amorphous materials, namely the enhancement of 
aqueous solubility and dissolution rate of poorly soluble drugs. Amorphous compounds are 
highly disordered systems, thus the energy barrier to be overcome for dissolution is lower 
than that associated with the equivalent crystalline materials. However, due to high 
reactivity and instability to mechanical and thermal stresses above their glass transition, the 
incorporation of amorphous materials in formulated products is restricted; some examples 
of amorphous drugs marketed are: Kaletra
®
 (ritonavir and lopinavir), Sporanox
®
 
(itraconazol) and Prograf
®
 (tracolimus). There are many routes to transform a crystal into 
an amorphous phase being the most representative the mechanical activation (e.g. milling), 
via solution (e.g. spray drying, freeze drying, and precipitation by the addition of  
anti-solvents) and quench cooling after melting. 
A crucial decisive factor regarding whether an active pharmaceutical ingredient (API) can 
be formulated as an amorphous material is its physical stability during the processing 
operation, dissolution testing as well as during its self-life. Therefore, several kinetic and 
thermodynamic parameters were used in this study to predict the stability of amorphous 
paroxetine HCl, as presented next.  
The fundamental characterisation of an amorphous material implies the measurement of 
the glass transition temperature, Tg, at which the material changes on cooling from a liquid 
or rubbery state to a brittle or glassy state (Craig et al., 1999). This phenomenon is known 
as vitrification. By contrast, devitrification describes the process of conversion from the 
metastable amorphous state to the more stable crystalline state, as a consequence of 
mechanical stress and/or effect of temperature and humidity (Ambike et al., 2004). The 
determination of the Tg is essential to evaluate the physical and chemical stability of 
amorphous compounds. 
Another important concept to take into consideration is known as relaxation and reflects 
the changes in atomic/molecular arrangements that happen during the spontaneous 
conversion from the amorphous to crystalline state, in a scale of time and temperature 
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influence (Kawakami and Pikal, 2005; Hilden and Morris, 2004). In amorphous drug 
studies, the structural relaxation is often referred to as enthalpy of relaxation which is a 
common parameter used to measure the extent of stability. Normally, in the pharmaceutical 
field, the bulk enthalpy relaxation is measured using calorimetric methods, such as 
differential scanning calorimetry (DSC) and recently MTDSC. Lately, attempts have been 
made in order to measure surface relaxation by using inverse gas chromatography, with a 
view to understanding molecular mobility at the surface (Ke et al., 2012). The enthalpy lost 
during a certain time and at a determined temperature below Tg is regained during the 
heating run in the DSC and is shown as an endothermic peak at Tg. As a result, the 
enthalpy relaxation is also known as enthalpy recovery. The increase in enthalpy recovery 
over the ageing time can be used as a direct measure of molecular mobility, which is the 
main aspect governing the physical stability of glassy systems (Surana et al., 2004).  
 
Kauzmann Temperature 
The Kauzmann temperature, TK, is the temperature at which the configurational entropy of 
the glassy material vanishes (often called as entropy crisis); the degree of mobility at this 
point is reduced and can be considered to be similar to the most ordered crystalline state 
(Shamblin et al., 1999). TK is considered as the theoretically lowest glass transition 
temperature possible, where the molecular mobility of the amorphous materials becomes 
negligible. TK is an important parameter to inform the researcher regarding the likely 
stability of a pharmaceutical compound, since at this temperature or below, the metastable 
amorphous materials are expected to have the maximum stability. In practice, however, the 
storage at T < TK is often not possible from an industrial perspective.  
The estimation of TK can be made either using entropy, TKS (Equation 5.1) or enthalpy, TKH 
(Equation 5.2) of fusion. However, the entropy-based calculation is considered to be the 
most accurate approach to calculate the correct TK value  (Shamblin et al., 1999), 
 
   
  
 
  
(   
   
         
) 
Equation 5.1 
 
Chapter V 
 
172 
 
 
   
  
 
  
(
   
         
) 
Equation 5.2 
where, ΔHm is the enthalpy change at melting, Tm is the melting temperature and Cp conf  
is a the configurational heat capacity. 
The Cp conf is controlled by the temperature dependence of the configurational entropy, 
which is consequently a measure of the temperature dependence of non-vibrational 
molecular mobility. It can be calculated from the heat capacity of the supercooled liquid 
(Cp
l
) and the crystal (Cp
c
) by using the following expression, 
          
      
  
Equation 5.3 
Fragile glasses are expected to have large Cp conf  values due to their rapid configurational 
entropy change with the temperature, whereas strong glass formers have small 
configurational heat capacities, because their configurational entropy changes slowly with 
temperature (Angell, 1991). 
 
Zero Mobility Temperature 
The zero mobility temperature, T0, is defined as the temperature where extrapolated 
thermodynamic properties of a supercooled liquid are equal to those of the crystal and can 
be expressed by the Equation 5.4, 
       (  
    
 
) 
Equation 5.4 
where, m represents the index of fragility and mmin the minimum value possible for that 
index, these parameters will be discussed in detail later.  
T0 is often reported to have the same meaning as TK, as it represents the temperature where 
the configurational entropy is zero (Shamblin et al., 1999). There are however some 
exceptions, as reported previously for sucrose and sorbitol, where the entropy TK was 
considerably higher than T0 (Shamblin et al., 1999; Zhou et al., 2002).  
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Relaxation time 
The relaxation time, τ, can be calculated by using the Vogel-Tamman-Fulcher (VTF) 
equation, in case the storage temperature, T, is higher than the Tg, following the  
Equation 5.5, 
       
   
    
 
Equation 5.5 
where, τ0 denotes a constant taken as the time scale of atomic vibrations, 10
-14
 seconds, and 
D is Angells strength parameter, as further described. 
On the other hand, it is also possible to describe the relaxation time of an amorphous 
material below its Tg by introducing a new parameter into the Equation 5.5 called the 
fictive temperature, Tf. The new expression is referred as Adam-Gibbs-Vogel (AGV) 
equation and appears as shown in Equation 5.6, 
        
   
          
 
Equation 5.6 
Tf establishes a relationship between the glass and the supercooled liquid and it is defined 
as the temperature at which the glassy system has the same thermodynamic properties as 
the equilibrium system (Shamblin et al., 1999). Tf can be calculated from the heat 
capacities and the Tg of the glass, (Graeser et al., 2009a; Graeser et al., 2009b), using the 
following Equation 5.7 and Equation 5.8, 
 
  
 
   
  
  
     
 
 
Equation 5.7  
    
  
     
 
  
    
     
   
       
 
Equation 5.8 
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γCp is a thermodynamic parameter used to characterise fragility of pharmaceutical glass 
formers, with values between 0 (for fragile systems) and 1 (for strong materials)  
(Hodge, 1996). 
 
Fragility 
The viscosity of a supercooled liquid changes with temperature (more drastically at the Tg) 
and this relationship can be described by the well-known Arrhenius equation (Macedo and 
Litovitz, 1965), 
     
   
   
Equation 5.9 
where, η is the viscosity, A is the pre-exponential factor, Ea the activation energy, R is the 
universal gas constant and T is the absolute temperature. 
Fragility indicates how fast structural relaxation increases as a glass becomes closer to the 
glass transition region (Yu, 2001). According to Angell (Angell, 1988, 1991), fragility can 
be portrayed plotting the log viscosity (η) against Tg/T. From this plot, strong liquids show 
a linear relationship (Arrhenius behaviour), whereas fragile glasses have a behaviour that 
deviates from linearity (non-Arrhenius behaviour). Therefore, weak glasses having  
non-Arrhenius behaviour can undergo structural rearrangements as a function of 
temperature, showing higher mobility through the Tg. Based on this property, strong 
systems feature m < 40 and fragile systems m > 75. 
The fragility index can be calculated using the activation energy of the structural relaxation 
at the glass transition (Wang et al., 2002; Crowley and Zografi, 2001), as described by  
Equation 5.10, 
  
    
         
 
Equation 5.10 
where, ΔETg is the activation energy for structural relaxation at temperatures around Tg. 
Significant changes in ΔETg with temperature are characteristic of fragile systems and their 
viscosity deviates from the Arrhenius behaviour; on the opposite, for strong systems, the 
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ΔETg changes slightly with the temperature, which follows Arrhenius behaviour  
(Angell, 1988).  
Due to the scanning rate dependence of the Tg, it is possible to determine the ΔETg from a 
plot of ln (q) against 1/Tg, as represented by Equation 5.11, 
      
       
  
    
 
 
Equation 5.11 
where, q represents the cooling/heating rate and (- ΔETg/R) is the slope of the plot ln (q) 
versus 1/Tg.  
The minimum possible fragility value, mmin, has been calculated to be 16 and corresponds 
to the relaxation of the unrestricted material at Tg, which exactly conforms to the Arrhenius 
behaviour (Mao et al., 2006).  
 
Strength Parameter 
The fragility of a material can be connected to the strength parameter, D, by the  
Equation 5.12 (Graeser et al., 2009b), 
  
          
 
      
 
Equation 5.12 
For strong glass formers, D values are larger (> 30) whilst for fragile glass formers D 
values are quite small (< 10). 
 
Glass Forming Ability 
Some other parameters can be used to deduce on the physical stability of glassy materials. 
The Glass Forming Ability (GFA) is defined as the ease of vitrification of a liquid on 
cooling. The minimum cooling rate required to vitrify a material is known as the critical 
cooling rate, Rcrit, and it is a widely used factor to measure GFA (Baird et al., 2010).  
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The same authors investigated the crystallisation tendency of 51 organic molecules, by 
using DSC, from the undercooled melt state. In the end of their study, they managed to 
divide them into three different groups:  
Class I – crystallisation observed upon cooling from the supercooled liquid; 
Class II – crystallisation detected during reheating above Tg; 
Class III – no crystallisation detected either during cooling or reheating. 
 
An additional parameter to assess the GFA is the reduced glass transition temperature Trg 
defined in Equation 5.13,  
    
  
  
 
Equation 5.13 
Presuming that the viscosity has a constant value at the Tg, materials with higher Trg values 
would be expected to have higher viscosity between Tg and Tm and therefore be more 
resistant to crystallisation. The increase in viscosity enlarges the timescale for molecularly 
rotational and translational motions. As a result, the closer Trg value to 1, the higher is the 
GFA of the material. 
The aim of this chapter is to characterise amorphous paroxetine HCl using the 
aforementioned glassy parameters and establish a possible relationship with the physical 
stability observed experimentally for this material. Amorphous paroxetine was prepared 
via quench cooling from its hydrochloride (HCl) Form II. Stability studies were carried out 
under different relative humidities (RHs) at room temperature for 60 days and evaluated 
using modulated temperature DSC (MTDSC), thermogravimetric analysis (TGA), infrared 
spectroscopy (ATR-FTIR) and X-ray powder diffraction (XRPD). 
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5.2 Materials and Methods 
 
5.2.1 Materials 
Crystalline paroxetine HCl Form II was purchased from Huahai Pharmaceuticals (China) 
and was used as received or after being dried over P2O5 as stated. Form II is described to 
be a non-stoichiometric hydrate with a melting point of circa 120 
o
C (as shown in  
Chapter 3). Storage environments with different relative humidities (RHs) were prepared 
using salt solutions of sodium chloride (75% RH, Fischer Scientific, UK); magnesium 
nitrate hexahydrate (53% RH, Fluka, Germany); calcium chloride (33% RH, BDH 
Laboratory, UK) and potassium acetate (22% RH, Alfar Aesar, UK). Phosphorus 
pentoxide (P2O5) was used as desiccant and was purchased from Alfar Aesar (UK). 
 
5.2.2 Methods 
5.2.2.1 Preparation of Amorphous Paroxetine HCl  
Quench cooled paroxetine HCl was prepared by melting the crystalline paroxetine HCl  
Form II in an aluminium foil placed over a hot plate. The molten sample was kept 
isothermal at that temperature for 2 min to ensure a complete melting. After that, the 
sample was cooled down rapidly by immersion in nitrogen liquid. For the determination of 
Cp, the amorphous paroxetine HCl was prepared in situ the DSC. 
 
5.2.2.2 Thermal Analysis 
Differential scanning calorimetry (DSC, Q1000 TA Instruments) analysis was done at 
different heating rates (HRs): 2, 5, 10, 20 and 50 
o
C/min in pinhole pans. Modulated 
temperature DSC, (MTDSC, Q1000 TA Instruments) analysis was performed with a HR of  
2 
o
C/min and a modulation of ± 0.318 
o
C every 60 seconds. Hermetic pans were used for 
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the analyses of fresh and aged samples while standard crimped pans were used for the Cp 
measurements.  
Thermogravimetric analysis, (TGA, Hi-Res 2950 TA Instruments) with a HR of 10 
o
C/min 
from room temperature to 300 
o
C was used to determine the water content of the samples. 
 
5.2.2.3 X-Ray Powder Diffraction (XRPD) 
XRPD (Thermo-ARL Xtra, Thermo Scientific) spectra were collected from 5.0
o
 to 40.0
o
 at 
2θ. 
 
5.2.2.4 Attenuated Total Reflection-Fourier Transform Infrared (ATR-FTIR)  
The infrared spectra of the samples were collected using a Bruker IFS 66/S 
spectrophotometer (Bruker Optics Ltd.), with 64 scans being acquired for each sample 
from 4000 cm
-1 
to 550 cm
-1
 with a resolution of 2 cm
-1
.  
 
5.2.2.5 Solubility Measurements 
Solubility measurements were performed by adding an excess of drug to distilled water 
and stirring for 24 and 72 h at 25 
o
C. After each time period, the samples were centrifuged 
and filtered through a 0.45 μm filter (Henwood et al., 2001; Sugano et al., 2007). The 
solutions were then suitably diluted with distilled water and assayed 
spectrophotometrically (Lambda XLS UV/VIS, Perkin-Elmer) at 293 nm. 
 
5.2.2.6 Dissolution Studies 
Dissolution studies were carried out in 900 mL of 0.1M HCl at 37.0 ± 0.5 
o
C on a Copley 
CIS 8000 dissolution bath (Copley Scientific) with a rotation speed of 50 rpm using the BP 
paddle method. Sixty milligrams (60 mg) of each sample were used. At predetermined 
intervals, 10 mL of solution was withdrawn and filtered through a 0.45 μm filter. 
Subsequently, the filtrate was analysed spectrophotometrically (Lambda XLS UV/VIS, 
Perkin-Elmer) at 293 nm. All the dissolution experiments were done under sink conditions. 
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5.2.2.7 Physical Stability  
Stability experiments were carried out at 25 
o
C under different RHs, 0, 22, 33, 53 and 75%. 
The range of humidity atmospheres were obtained by using saturated salt solutions, then 
stored in proper desiccators and left to equilibrate for a minimum of 24 h prior to storage 
of the samples. 
 
5.3 Results and Discussion 
 
5.3.1 Thermodynamic and Kinetic Parameters on the Classification of Paroxetine 
HCl as a Glass Former  
 
In the first instance, several thermodynamic and kinetic parameters were obtained for the 
amorphous paroxetine HCl prepared in situ the DSC. The values presented in Table 5.1 
were obtained directly from the MTDSC measurements or calculated using the expressions 
presented in the Introduction section. Standard crimped pans were used to ensure a good 
contact between the material and the bottom of the pans. The heat capacities of 
supercooled liquid, glass and crystalline paroxetine HCl Form II were obtained by 
deconvolution of the total heat flow curve into the non-reversing and reversing (heat 
capacity) signals; the Tg value was estimated at the midpoint of half-height of the stepwise 
change in the Cp, in the reversing signal. Each calculated parameter is to be described in 
more detail in later context. 
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Table 5.1: Thermal and kinetic parameters obtained for amorphous paroxetine HCl. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Heat Capacity Change (ΔCp) and Configurational Heat Capacity (Cp conf)  
 
The changes in the heat capacity at Tg provides a way to infer information on the physical 
stability of glassy materials. In general, high ΔCp is characteristic of fragile glasses and this 
is due to high molecular motions at Tg, while strong glasses have small ΔCp changes at 
glass transition temperature. The increase in the configurational heat capacity, Cp conf  can 
also be used to classify the materials between strong and fragile liquids. Amorphous 
paroxetine HCl showed a ΔCp and Cp conf  of 0.31 and 0.47 J/g 
o
C, respectively.  
Parameter Value 
Tg ± s.d. (
o
C) 71.1 ± 0.6 
ΔCp ± s.d. (J/g 
o
C) 0.31 ± 0.10 
Cp conf  (J/g 
o
C) 0.47 
TKS (
o
C) 48.8 
Tg - TKS 22.2 
T0 (
o
C) 19.7 
Trg 0.6 
m 107.3 
D 6.5 
γCp (J/g 
o
C) 0.66 
Tf 67.9 
τ (AGV) (seconds) 3.26 x 106 
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Figure 5.1 shows the measurement of ΔCp and Cp conf  for amorphous paroxetine HCl using 
the reversing heat capacity against temperature. Clearly, the higher molecular mobility of 
the supercooled liquid is reflected in the higher heat capacities at all temperatures, whereas 
the crystalline heat capacities vary almost linearly with temperature.  
 
 
 
Figure 5.1: Heat capacity data as a function of temperature for crystalline Form II and  
amorphous paroxetine HCl.  
 
Kauzmann Temperature (TK), Zero Mobility Temperature (T0) and Fictive  
Temperature (Tf)  
 
The Kauzmann temperature was calculated from an entropy (TKS) base instead of enthalpy 
(TKH) base, since the Adam-Gibbs model states that is the configurational entropy that 
mostly influences the molecular mobility. As consequence, the TKS is considered to be the 
closest to the entropy crisis temperature and therefore all further calculations involving TK 
referrers to TKS instead of TKH (Andronis and Zografi, 1998). TK for amorphous paroxetine 
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HCl was calculated according to Equation 5.1 and had a value of 48.8 
o
C which was just  
≈ 22 oC below its Tg. 
The fact that TK gets closer to Tg in fragile liquids leads to a relationship between these two 
parameters, TK/Tg which is determinant of the deviation of glass from Arrhenius behaviour. 
The ratio lies between 0 (strong) and 1 (fragile). For amorphous paroxetine HCl,  
TK/Tg = 0.7 categorising it into a moderate fragile system which is also supported by the 
fact that Tg - TKS < 50 
o
C (Kaushal and Bansal, 2008).    
Another aspect is related to the equivalence between TK and T0. Even though both 
parameters refer to the temperature where the mobility of glassy materials is minimal and 
therefore the stability is maximum, T0 unlike TK has a viscosity base from the VTF 
equation. While a majority of organic molecules, have an identical value between T0 and 
TK, amorphous paroxetine HCl has a T0 lower (19.7 
o
C) than TKS (48.8 
o
C), which implies 
that glassy state of paroxetine HCl is greatly influenced by the effect of configurational 
entropy.  
The fictive temperature, Tf, corresponds to the temperature when the glass and the 
equilibrium-supercooled liquid have the same configurational entropy, in other words, it 
makes possible the description of the glassy state in comparison to a reference state. Tf can 
be used as an alternative approach to predict molecular mobility, with a temperature 
dependence bounded by the two extremes of γCp, within the range 0 < γCp < 1. In the 
present work, the γCp was calculated as 0.66 J/g 
o
C and Tf is just 3.2 
o
C below Tg,, which 
shows the excess of entropy trapped in the glass formation below its Tg and is a 
characteristic of fragile glasses/non-Arrhenius behaviour. For glassy paroxetine HCl, Tf is 
mathematically bound to the limits TK < Tf < Tg. 
 
Reduced Glass Transition Temperature, Trg 
 
Assuming that the viscosity at Tg is constant, higher Trg values reflect higher viscosity 
between the glass transition temperature and the melting temperature. Therefore, the closer 
value of Trg to 1, the more resistant is the material to recrystallisation and higher the glass 
forming ability. Amorphous paroxetine HCl has a value of 0.6, and its behaviour during 
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the cycling runs in the DSC is not in agreement with the classification into three different 
classes made by (Baird et al., 2010). From that classification, the materials are divided into 
groups accordingly to the behaviour during cooling after melting and during the reheating 
cycle, as referred earlier in the Introduction section. Follow up this categorisation, 
amorphous paroxetine HCl can be included in the Class 3 (materials with high glass 
forming ability), since it did not show any crystallisation upon either cooling to below Tg 
or upon reheating up. 
However, it is worth mentioning that this classification was found to have several 
limitations in predicting the glass forming ability of numerous compounds (Baird et al., 
2010). 
 
Fragility Index, m, and Strength Parameter, D 
 
Fragility of amorphous paroxetine HCl was measured in situ DSC by heat-cool-heat cycles 
at different RHs (2, 5, 10, 20 and 50 
o
C/min). To avoid recrystallisation from paroxetine 
HCl Form II to paroxetine HCl Form I during the first heating cycle, the starting paroxetine 
HCl Form II was dried in P2O5 over 24-48 h prior to running in DSC and pinhole pans 
were used to allow any residual water to evaporate. As shown in Chapter 3, the 
pseudopolymorphic transformation from Form II to Form I happened when the DSC 
experiments were performed in hermetically sealed pans at slow heating rates.  
For a better comparison, the Tg was measured in the total heat flow of the second heating 
for all the heating rates. Figure 5.2 shows the scanning rate dependence of the Tg, where ln 
(q) is plotted against the temperature. 
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Figure 5.2: Plot of ln (q) (where q is heating/cooling rate) against the inverse glass transition (K) of 
amorphous paroxetine HCl. 
 
Based on the scanning rate dependence of the Tg it is possible to obtain the activation 
energy of structural relaxation at Tg, ΔETg as presented earliest by the Equation 5.11. From 
the slope of the plot, it is possible to calculate the value of ΔETg/R and by using the 
Equation 5.10 the fragile index, m can be obtained.  
For amorphous paroxetine HCl, m, was calculated as 107.3, which classifies the drug as a 
fragile material. The same indication was given by the strength parameter, D, which is 
related to the dependence of the relaxation time constant on the temperature, and has a 
value of 6.5. 
 
Relaxation Time, τ 
 
The relaxation time, τ, was estimated to be 3.26 x 106 seconds (≈ 38 days). Since the 
storage temperature was below Tg, the AGV approach (Equation 5.6) was used instead of 
the VTF equation. The predicted value was in good agreement with the experimental 
physical stability results, as it will be shown later, when considering the samples stored at 
53% RH as being those having an environment closer to the normal ambient humidity. 
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5.3.2 Characterisation of Freshly Prepared Amorphous Paroxetine HCl  
 
5.3.2.1 Thermal Response of Amorphous Paroxetine HCl  
 
For the solubility, dissolution and stability studies, amorphous (quench cooled, QC) 
paroxetine HCl was prepared by cooling from the melt in nitrogen liquid. The freshly 
prepared sample was analysed with MTDSC in hermetic pans. It showed a single glass 
transition event at 51.2 
o
C and no signal of recrystallisation or melting was observed, the 
results presented in Table 5.2. The differences in the Tg and ΔCp between the sample 
prepared in situ the DSC and the sample prepared by quench cooling method in nitrogen 
liquid, were probably due to the exposure to atmospheric humidity conditions which led to 
the adsorption of water molecules and thus lowered the Tg. The enthalpy of relaxation 
(ΔHrelax) was measured in the non-reversing signal. 
 
Table 5.2: Thermal properties and water content of the freshly prepared amorphous  
paroxetine HCl. 
 
 
 
 
 
 
 
 
5.3.2.2 ATR-FTIR and XRPD Characterisation of Amorphous Paroxetine HCl  
 
Paroxetine HCl Form II has two bands in the 3700-3200 cm
-1
 range that can be assigned to 
O-H groups in different chemical environments (as shown in Chapter 3). In the fully 
Parameter Value 
Tg ± s.d. (
o
C) 51.2 ± 0.6 
ΔCp ± s.d. (J/g 
o
C) 0.28 ± 0.06 
ΔHrelax ± s.d. (J/g) 2.5 ± 0.7 
Water content ± s.d. (%) 0.87 ± 0.13 
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amorphous QC sample, these two bands were missed and in the rest of the spectrum some 
peaks appeared broadened or simply disappeared, which is characteristic of this kind of 
state (data not shown). These results were confirmed by the XRPD data that showed the 
absence of crystalline peaks from the starting paroxetine HCl Form II within the range 5
o 
to 
40
o
, 2θ and the appearance as halo pattern (data not shown). 
 
5.3.3 Drug Performance Assessment  
 
5.3.3.1 Solubility Measurements 
 
Assessing the aqueous solubility of amorphous materials can represent a challenge and a 
practical problem to the formulator. The primary and most frequent obstacle is the high 
tendency for amorphous materials to suffer phase transformation towards a thermodynamic 
more stable form during the experimental measurement process (Murdande et al., 2011).  
In this work, as presented in Figure 5.3, the aqueous solubility of amorphous paroxetine 
HCl was determined after 24 and 72 h isothermal stirring time. The measured apparent 
solubility of the glassy paroxetine showed, in both sampling times, a lower value than the 
crystalline starting material paroxetine HCl Form II, but still higher than the aqueous 
solubility of paroxetine HCl Form I. This low apparent solubility can be ascribed to the 
recrystallisation, in the media, to the more stable and less soluble crystalline hydrate form, 
paroxetine HCl Form I. 
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Figure 5.3: Solubility in water of two crystalline (Form I and II) and quench cooled (QC) forms of 
paroxetine HCl. 
 
The residues, collected after centrifugation from the solubility experiments and after dried 
over night at room conditions, were analysed using XRPD and ATR-FTIR, as presented in 
Figure 5.4 and Figure 5.5, respectively. Accordingly, to the results obtained, both 
paroxetine HCl Form II and the QC amorphous form, recrystallised during the solubility 
experiments. However, the decrease in the solubility is higher for the QC sample than for 
the Form II.  
In this type of dynamic solubility experiments, an initial supersaturation condition is 
required and therefore phase separation/recrystallisation events can occur (Grant and 
Brittain, 1995). This phenomenon is clearer for the glassy sample. This could probably be 
ascribed to the higher energy state of the amorphous material that once in contact with 
water led to a higher solubility of the glassy sample in the early beginning. As the 
experiment progressed in time, the excess of amorphous sample in solution started to 
precipitate out. The new form obtained (paroxetine HCl Form I) has a lower water 
solubility and as result the ‘amorphous’ solubility is nearly 2/3 when compared to the 
starting material. 
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Figure 5.4: XRPD data of paroxetine HCl Form I and the solubility residues,  
collected after centrifugation from the solubility measurements of Form II and quench cooled (QC).
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.5: ATR-FTIR spectra of the solubility residues (am rphous QC paroxetine HCl, Form II and 
Form I) collected after the solubility experiments (72 h stirring at 25 
o
C) and  
paroxetine HCl Form I (upwards). 
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Even though the residue obtained from the paroxetine HCl Form II solubility experiments 
corresponded as well to the stable Form I, the solubility of this form still being higher 
when compared to the Form I. This can be readily explained because the recrystallisation 
just took place in the excess of sample added to prepare a saturated solution. Therefore, the 
lower solubility of paroxetine HCl Form II in comparison with the amorphous sample 
made the amount of Form II required to create a supersaturation solution lower than in the 
case of the amorphous sample. 
 
5.3.3.2 Dissolution Studies 
 
In contrast to the aqueous solubility results, the dissolution studies showed a clear 
enhancement on the extent of the dissolution rate of the drug, when the amorphous form 
was compared to the crystalline forms (Figure 5.6). The difference can be explained by the 
immediate dissolution of the amorphous form once it contacts the dissolution medium and 
there is no time for recrystallisation to occur.  
 
  
 
Figure 5.6: Dissolution profiles of Form I, Form II and quench cooled (QC) paroxetine HCl  
in 0.1M HCl. 
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5.3.4 Response of Amorphous Paroxetine HCl Below Tg and Under Different 
Humidity Conditions 
 
Ageing experiments represent a crucial step during the development of any amorphous 
API, establishing a physical and chemical stability profile. Even though, below Tg, 
translational molecular motions are slower than above Tg, they still occur and can 
obviously influence the life time of these materials. 
In this study, since the Tg of QC paroxetine HCl was found to be 51.2 
o
C, its stability 
behaviour was studied at room temperature (≈ 25 oC), so well below Tg and under the 
influence of different RHs environments. 
 
5.3.4.1 Recrystallisation Behaviour of Paroxetine HCl from the Amorphous State  
 
The samples stored in 0% RH did not show, during all the experimental time (2 months), 
any signal of recrystallisation, being only possible to identify during the heating cycle in 
the DSC, a glass transition phenomena. On the opposite, the samples stored at 75% RH 
were completely recrystallised after 24 h, accordingly to DSC data, into the most stable 
paroxetine HCl Form I, with an onset melting temperature around 140 
o
C. 
Apart from the samples stored under these two extreme humidity conditions (0 and  
75% RH), all the others showed a glass transition event, which reduces as the relative 
humidity increases, followed by a recrystallisation exotherm and in the end a fusion 
endotherm, as can be observed below in Figure 5.7. It was also noticed that the shape of 
the recrystallisation peaks and the temperature at which the recrystallisation occurred, 
changed with the storage humidity. As the humidity increased the exotherm peak became 
sharper and appeared at lower temperatures, in contrast to what happened with the  
22% RH samples that showed a broad appearance at much higher range of temperatures.  
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Figure 5.7: MTDSC heating cycle traces of amorphous quench cooled paroxetine HCl aged at 25 
o
C  
under different RHs, as stated, for 48 h; hermetic pans were used.  
 
5.3.4.2 Water Content 
 
The water content was measured by TGA and the results are presented in Figure 5.8. For 
the samples stored under 0, 22 and 33% RH the amount of water remained nearly constant 
for all samples. The water content can also be used as a measure of the recrystallisation 
extent, as shown by the samples stored at 53% RH. These samples showed higher water 
content until 14 days of storage with a decrease afterwards, indicating that most of the 
sample was recrystallised after that period. These results are in agreement with the DSC 
experiments where the ΔHrec decreased significantly after 30 days of storage as a meaning 
of isothermal recrystallisation prior the DSC test, as shown later in this study. In fact, the 
amorphous-crystalline transition reveals a great reduction in the water sorption capacity of 
the crystalline material when compared with the amorphous state.  
For the samples stored at 75% RH, the amount of water remained constant since the first 
day of storage (2.19–2.87% w/w) due to its nearly complete recrystallisation. In addition, 
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the amount of water measured for this sample at 75% RH agreed with the identification of 
the recrystallised material as paroxetine HCl Form I (water content = 2.63% w/w). 
 
 
 
Figure 5.8: Water content of the amorphous paroxetine HCl, over time and  
under different storage conditions at 25 
o
C. 
 
5.3.4.3 Glass Transition Temperature 
 
The increase in the humidity storage conditions decreases the Tg values. The water 
molecules have the ability to plasticise amorphous materials, reduce the viscosity and at 
the same time enhance molecular mobility. Indeed, the presence of small amounts of 
absorbed water makes a high contribution in the molecular mobility of these systems, 
which can induce in the last instance the recrystallisation to happen. However, when glassy 
materials transform into the crystalline form in presence of moisture, the water sorption 
capacity usually decreases or slow down, as reported above. 
As predicted and shown in Figure 5.9, the QC samples stored under 53% RH showed the 
lowest Tg for the four RHs presented. At 75% RH it was not detected any glass transition 
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there is a slight increase in the Tg, certainly due to the dry of small quantities of water 
eventually present prior to storage. 
 
 
 
Figure 5.9: Changes in the Tg of quench cooled paroxetine HCl over time and  
under different RHs conditions. 
 
5.3.4.4 Recrystallisation Temperature  
 
The increase in the humidity, lead the amorphous materials to devitrify and promote the 
nucleation to happen. The transformation from glass to rubber, facilitate the crystal seeds 
to grow, what can be observed by the decrease in the recrystallisation temperature, Trec at 
higher humidity. Indeed, as shown in Figure 5.10 the samples at 53% RH, showed the 
lowest recrystallisation temperature. This can be explained by the presence of higher 
nucleation seeds what facilitates the recrystallisation process and thereby lower 
temperature is needed for the crystal formation. 
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Figure 5.10: Recrystallisation temperature (onset values) profiles  
for the samples stored under 22, 33 and 53% RH for 60 days.  
 
5.3.4.5 Enthalpy of Recrystallisation 
 
In Figure 5.11 is presented the variation on the enthalpy of recrystallisation, ΔHrec, for the 
different samples stored under different humidity environments.  
McGarvey et al. (McGarvey et al., 2003) studied the non-isothermal behaviour of 
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and initial water content of the samples. They observed that samples with higher water 
content showed lower enthalpy and recrystallisation temperatures. These results are 
partially in agreement with the findings in this study. In fact, the recrystallisation 
temperature decreased as the RH increased, although the ΔHrec did not follow the same 
trend.  
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have the lowest. Surprisingly the 53% RH samples have an enthalpy of recrystallisation in 
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water vapour at this humidity was not high enough to devitrify large amounts of glass and 
therefore low ΔHrec upon heating. The explanation for what happen with the samples at 
33% and 53% RH, has probably to be with different disorder stages of the glass under 
these conditions.  
 
 
 
Figure 5.11: Enthalpy of recrystallisation at different storage conditions up to 60 days. 
 
The 53% RH samples overcome through a rubbery state after a short time of storage, the 
molecular mobility is then reduced and the energy barrier created by the enhancement in 
the viscosity reduces the tendency for the crystals to growth even though the initial amount 
of crystal seeds is high, thus, lower value of ΔHrec. This was just observed during the first  
13 days of storage. After that the ΔHrec of the 53% RH samples showed a big drop, even 
below the 22% RH ones, since most of the sample completely recrystallised.  
For the samples at 33% RH, the higher ΔHrec by comparison with the 53% RH samples, 
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obtained by Graeser et. al (Graeser et al., 2008), when they compared amorphous 
simvastatin prepared by two different techniques (cryomilling and quench cooling). 
 
5.3.4.6 ATR-FTIR Analysis 
 
ATR-FTIR was used to monitorise the isothermal recrystallisation of QC paroxetine HCl. 
The samples stored at low RH (0, 22 and 33%) remained amorphous during the total 
experimental time without any characteristic crystalline peak being observed. Though, an 
interesting observation was detected for the samples under 53 and 75% RH.  
For the samples stored at 75% RH (Figure 5.12) the process of recrystallisation did not 
progress in one-step from the amorphous to the most stable crystalline form (Form I), 
being observed an intermediate state between these two forms, as explained next. At these 
conditions, the process of recrystallisation undergoes from the amorphous material to a 
mixture between paroxetine HCl Form II and Form I, which took place in the first 3 days 
of storage and after that, only Form I was detected. The evidences that Form II is present 
are related to the following peaks characteristics of that form: the single sharp peak at high 
wavenumber 3630 cm
-1
 and the peak at 665 cm
-1
. Gradually, the peak at a high 
wavenumber disappeared
 
and a peak at 3334 cm
-1
 started to appear until the 
recrystallisation to Form I was completed. The same happened with two peaks at lower 
wavenumber, disappearance of the peak at 665 cm
-1
 and appearance of the peak at  
675 cm
-1
, characteristic of Form I. In addition, the appearance of the peak around  
1550 cm
-1
 after the 1
st
 day and its disappearance on the 7
th
 day of storage, assigned to the 
O-H bending vibration from the weakly bound water, indicates that the process of 
recrystallisation happened via the formation of the non-stoichiometric hydrate Form II. 
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Figure 5.12: ATR-FTIR spectra of amorphous paroxetine HCl at different time points  
upon storage at 75% RH/25 
o
C: prior storage, 1, 3 and 7 days (upwards). 
 
However, the recrystallisation behaviour mentioned for the samples at 75% RH was not 
observed with the samples stored at 53% RH, which recrystallised directly into Form I, as 
shown in Figure 5.13. 
This could have been because the water vapour pressure at the 53% RH conditions allowed 
the sample to slowly recrystallise into the most stable form, avoiding intermediate 
metastable states. Another explanation could be the large sampling time interval (14 days – 
completely amorphous, 30 days – already Form I), with the phenomenon referred for the 
samples at 75% RH happening during that period. 
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Figure 5.13: ATR-FTIR spectra of amorphous paroxetine HCl at different time points  
upon storage at 53% RH/25 
o
C: prior storage, 7, 14, and 30 days (upwards). 
 
5.3.4.7 XRPD Analysis 
 
The XRPD experiments were in a fair agreement with those obtained with the ATR-FTIR 
measurements, considering some delays in detection/differentiation between the two 
techniques, particularly for the samples at 75% RH. Figure 5.14 shows the XRPD 
diffractograms of paroxetine HCl Form I and II as received. These two forms are easily 
distinguished within the range between 15
o
 and 25
o
.  
As mentioned earlier, samples stored at 0, 22 and 33% RH remained amorphous 
throughout the 60 days of experiments. The samples at 53% RH showed recrystallisation 
peaks matching the pattern of paroxetine HCl Form I after 30 days (data not shown). 
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Figure 5.14: X-ray diffractograms of paroxetine HCl Form I and II, as received. 
 
The samples under 75% RH (Figure 5.15) showed after 7 days a pattern, which revealed a 
mixture of Forms I and II. After 60 days, the XRPD diffractogram was to the pattern of  
Form I, especially considering the range between 20-25
o
. The poor quality of the spectra 
was related to the hardness of the sample and the difficulty in obtaining a complete flat 
surface, ideal for X-ray measurements.  
 
 
Figure 5.15: XRPD diffraction data collect at different time points (in day)  
for the quench cooled paroxetine HCl sample stored under 75% RH. 
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5.4 Conclusions 
 
The use of thermal methods has demonstrated to be a powerful approach to predict the 
physical stability of amorphous compounds. In this chapter, a range of thermodynamic and 
kinetic parameters were used to characterise amorphous paroxetine HCl prepared via 
quench cooling. Overall, parameters determined by using DSC such as configurational heat 
capacity, fragility index and strength parameter classified amorphous paroxetine HCl as a 
fragile glass former. Moreover, the close value of TK to Tg, and the non-equivalence to T0, 
indicated that glassy paroxetine HCl is greatly influenced by the effect of configuration 
entropy. This finding was also supported by the fact that at a storage temperature of 25 
o
C, 
the Tf was only 3.2 
o
C below Tg indicating that under these storage conditions the glass still 
has a considerable degree of configurational entropy, which can be linked to a significant 
molecular mobility and therefore instability. 
Although all the above parameters constitute a source of valuable information when 
dealing with amorphous materials they must be considered carefully as they do not account 
the influence of humidity, which has a crucial influence on the stability of this kind of 
compounds. In the present work, storage under different humidity environments proved not 
only to influence the rate, but also, the pathway of recrystallisation. The non-isothermal 
recrystallisation studies observed in DSC showed that the samples stored at 53% RH 
started to recrystallise at a lower temperature and over a narrow temperature range. 
Moreover, according to the ATR-FTIR results, these samples were found to recrystallise 
directly to the stable Form I, whereas the samples under 75% RH recrystallised via a 
metastable Form II.  
The instability of the glassy paroxetine HCl was also noticed upon prolonged exposure to 
water during the solubility measurements. The measured solubility of amorphous 
paroxetine HCl was lower than the starting crystalline Form II, which was ascribed to the 
recrystallisation to the most stable Form I. This behaviour was not observed during the 
dissolution tests. Although it is important to bear in mind that in vivo the recrystallisation 
to the stable hydrate can occur. 
 
  
 
 
 
 
 
 
 
6 MISCIBILITY PREDICTION AND THE INFLUENCE OF 
PREPARATION METHODS ON THE PROCESSING  
OF PSEUDOPOLYMORPHS OF PAROXETINE HCL 
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Abstract 
This chapter presents a theoretical and practical perspective of processing two 
pseudopolymorphs (Form I and II) of the same drug (paroxetine HCl) using different 
preparation techniques, with particular attention being paid to the performance and stability 
of each system. A non-solvent process, hot melt extrusion (HME), and a solvent method, 
spray drying (SD), were used to convert the two crystalline hydrates into an amorphous 
solid dispersion, using polyvinylpyrrolidone vinyl-acetate (PVPVA) as a carrier. Standard 
differential scanning calorimetry (DSC) and modulated temperature DSC (MTDSC) were 
used to characterise physical mixtures (PMs), fresh and aged solid dispersions, in 
combination with thermogravimetric analysis (TGA), dynamic vapour sorption (DVS),  
X-ray powder diffraction (XRPD) and attenuated total reflection-Fourier transform 
infrared (ATR-FTIR) techniques. Theoretical predictions of drug-polymer miscibility were 
carried out using melting point depression (MPD) approach. MPD method suggested that 
Form I of paroxetine HCl favours a miscible system with PVPVA while Form II is inclined 
to generate an immiscible system with the same polymer as no depression on the onset 
melting point of this form was observed in the presence of the polymer. However, the 
corresponding experimental data showed a single Tg in DSC and a halo pattern in XRPD 
for both samples prepared from SD and HME, indicating the formation of a molecular 
dispersion. Although fully amorphous dispersions were prepared by both SD and HME 
methods, the Form I and Form II systems showed different dissolution and long term 
stability profiles. More specifically, in the case of Form I, HME formulations showed a 
lower release rate in the beginning of the test when compared to the SD, PMs and pure 
crystalline drug. In the case of Form II systems, HME showed the same release profile as 
the pure crystalline form, but also lower than SD and PMs. The lower release observed for 
the HME over the SD samples might be related to the differences in the diffusion of the 
dissolution media into the microparticles (63-106 μm). Regarding stability under storage, 
all the samples kept at 75% RH/25 
o
C recrystallised into the sable Form I, confirmed by 
FTIR, though they exhibit different crystallisation rates, with spray dried samples showing 
a higher tendency to recrystallise. The recrystallisation profile of the HME samples was 
different for the Form I and Form II systems, with the former presenting a slower rate. 
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6.1 Introduction  
 
Pharmaceutical formulations of a drug product should be physically and chemically stable, 
manufacturable, and the drug entity made bioavailable. Although, active pharmaceutical 
ingredients (APIs), and also excipients, exhibit polymorphism or pseudopolymorphism, the 
thermodynamically most stable form is, in general, selected for development. However, 
there are several situations in which the development of a metastable form is desirable, 
namely to achieve rapid absorption and efficacy, or acceptable systemic exposure for a 
low-solubility drug. The term polymorphism, describes the ability of a compound to 
crystallise in more than one form (Haleblian and McCrone, 1969). On the other hand, 
pseudopolymorphism is used to avoid confusion with ‘true polymorphs’ and describes 
crystalline compounds that have a heterogeneous unit cell with solvent molecules within it, 
such as the case of hydrates, when the solvent is water (Brittain, 2009).  
Recently, particular attention has being paid to the transformation of crystalline APIs into 
amorphous phase by the manufacture of solid dispersions by different methods. In solid 
dispersion technologies, the drug is incorporated into a hydrophilic carrier, theoretically at 
molecular level, leading to a loss of crystal lattice energy, thereby increasing dissolution 
rate of the drug. Several parameters are of great importance when designing an amorphous 
solid dispersion formulation such as, the method of preparation used, the physicochemical 
properties of the selected polymer and, with less focus in the available literature, the 
intellectual properties of the starting material, namely water content and crystalline form.  
In this study, two pseudopolymorphs (Forms I and II) of the same drug, paroxetine HCl, 
were chosen as model drug, which allowed to evaluate the influence of the initial 
crystalline state on the prepared system. Paroxetine HCl Form I is a stable hemihydrate 
whereas Form II is a non-stoichiometric hydrate and considered metastable to Form I. The 
polymer selected was polyvinylpyrrolidone vinyl-acetate 6:4 (PVPVA) due to its vast use 
in pharmaceutical research, especially in the preparation of solid dispersions, and relatively 
low hygroscopic behaviour compared to the homopolymer polyvinylpyrrolidone based 
polymers. 
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Within a preliminary investigation into the preparation of solid dispersion systems, 
important theoretical parameters can be used to evaluate the miscibility between each form 
and PVPVA, which can provide a better understanding in terms of the ability of the 
polymer to stabilise the API. Therefore, a number of thermodynamic approaches that are 
available in the literature and commonly used in the pharmaceutical field were applied in 
this study as briefly described below.  
The simpler and straight indication of the miscibility between two or more components is 
the detection of a single glass transition step in DSC, usually designated as the mixed 
phase glass transition temperature (Tgmix) (Gordon and Taylor, 1952). The well-known 
Gordon-Taylor (GT) equation is one means of predicting the Tg of amorphous solid 
dispersions based on the weight fractions, Tg values and coefficients of thermal expansion 
of their components, as presented below by Equation 6.1 for a ternary system  
(API-polymer-water), 
       
                           
                 
 
Equation 6.1 
where, w is the weight fraction, Tg is the glass transition temperature (K) and K is a 
constant. The subscripts 1, 2 and 3 represent polymer, drug and water, respectively. For 
polymer blends of three components, the subscript 3 refers to the component of lowest Tg  
(Truong et al., 2002). The constants K1 2 and K1 3 can be estimated by using: 
(a) Couchman-Karasz Equation (Couchman and Karasz, 1978), 
     
    
    
                
    
    
    
Equation 6.2 
where, ΔCp is the heat capacity change between the supercooled-liquid and the glassy state. 
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(b) Simha-Boyer Rule (Simha and Boyer, 1962), 
      
     
     
                    
     
     
 
Equation 6.3 
where, ρ is the density of each component.  
In theory, if a system is miscible it will exhibit a single Tgmix, which is intermediate to the 
Tg values of the individual components with a relationship to the mixture composition. It 
should be noted that the GT approach only works for ideal systems, i.e., systems with an 
ideal volume additivity and negligible tendency to interact (Schneider and Di Marzio, 
1992). As a result, when an additive lowers the Tg of a substance it has a plasticising effect, 
such as the case of water, whereas if it raises the Tg it has an antiplasticising effect 
(Hancock and Zografi, 1994). In this study, the Tgmix was calculated using  
Gordon-Taylor/Couchman-Karasz Equation. 
Another parameter used in the theoretical framework to correlate miscibility and 
thermodynamic stability of API-polymer systems, is the well-known Flory-Huggins 
interaction parameter, χ (Huggins, 1942; Flory, 1942). Flory-Huggins (FH) theory is based 
on the free enthalpy of mixing which has entropy and enthalpy components. χ is 
independent of composition, but it varies with concentration and temperature allowing a 
possible correlation between theoretical and experimental results (Kontogeorgis, 2007). 
Commonly, the FH interaction parameter can be obtained by using two methods: solubility 
parameter approach and melting point depression method (MPD). However, in this study 
the APIs are in their salt form, thus the solubility parameter cannot be calculated as it does 
not apply to compounds having specific strong intermolecular interactions, such as ionic in 
the case of salts (Zhao et al., 2011).  
The interaction parameter has been extensively determined from melting point approach 
for both polymer-polymer blends (Jo and Kwon, 1991) and for polymer-solvent systems 
(Meaurio et al., 2005). With particular importance on the pharmaceutical area, few years 
ago Marsac and his collaborators developed an approach to estimate the interaction 
parameters between APIs and polymeric systems (Marsac et al., 2006), as shown by the 
relation in Equation 6.4, 
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    )  
  
     
 [         (  
 
 
)                   
 ] 
Equation 6.4 
where, Tm
mix 
is the melting temperature of the drug in the presence of the polymer, Tm
pure
 
and ΔHfus are the melting temperature and the enthalpy of fusion of the pure drug, 
respectively; R is the gas constant, ϕdrug and ϕpolymer are the volume fractions of the drug 
and the polymer, respectively, and m is the ratio of the volume of the polymer to that of the 
lattice side (defined for this purpose here as the volume of the drug).  
If a drug is miscible with a polymer, the chemical potential of the drug in the mixture must 
be lower when compared to the chemical potential of drug alone. Considering this fact and 
the enthalpy nature of the mixing being exothermic, endothermic or athermal, different 
reduction magnitudes in the melting point of the drug can be observed. Exothermic 
processes should produce a large depression on the melting point of the drug and 
progressive less significant for athermal and endothermic mixing processes. On the 
contrary, if the drug and the polymer are immiscible, no melting point depression is 
expected (Marsac et al., 2009). This approach is of great importance in this study as each 
pseudopolymorph of the model drug, showed a different melting response in the presence 
of the polymer.  
As previously described, the Flory-Huggins lattice theory brought an important support to 
the understanding of the thermodynamics of polymer-solvent mixtures, which accounts for 
the entropy (ΔSmix) and enthalpy (ΔHmix) of mixing between large (polymers) and small 
molecules (APIs in the case of solid dispersions) (Baird and Taylor, 2012; Marsac et al., 
2006). One way to better expose this relationship is by considering the free energy of 
mixing, ΔGmix, at absolute temperature (T), as expressed by Equation 6.5,  
                     
Equation 6.5 
Adding the Flory-Huggins interaction parameter, χ, which is related to the enthalpy of 
mixing, the free energy of mixing, can be described by the Equation 6.6 below, 
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Equation 6.6 
where, ndrug and npolymer is the number of moles of drug and polymer, respectively. The first 
two terms on the right hand side of the equation represent the entropy of mixing, while the 
third term stands for the enthalpy of mixing. The entropy contribution always favours 
mixing whereby the enthalpy contribution, which depends on the type and intensity of the 
interactions between the components, can either facilitate or prevent mixing.  
After the brief exposition of some of the theoretical parameters that are commonly used to 
study miscibility and investigate the formation of a single phase amorphous systems, 
another point of concern is the processing conditions. Indeed, it is widely accepted that the 
properties of amorphous materials are highly dependent on their thermal history and hence, 
on the preparation method (Zhang et al., 2009; Janssens et al., 2010; Karmwar et al., 2011, 
2012). Therefore, in this study two different preparative techniques, spray drying (SD) and 
hot melt extrusion (HME) were used. SD is a solvent method that involves the rapid 
transformation of an API-carrier solution/suspension to solid API-carrier particles due to 
the fast evaporation of the solvent. As referred in Chapter 2, the SD process consists of 
four basic stages: atomisation of the solution containing the API and carrier, mixing with 
the drying gas, evaporation of the liquid and finally the separation of the dried particles 
from the gas (Ré, 2006). HME consists in the dispersion of the API in a polymeric or lipid 
carrier matrix using the effect of heat. Several advantages are attributed to this technique. 
Firstly, it is solvent free method and therefore with great economical and safety benefits, 
secondly the new design of the extruders allow a good mixing and homogenising of the 
formulation and finally it is industrially favourable for scaling-up (Miller et al., 2007).  
Later in this work, it is investigated whether the samples prepared by these two methods 
exhibit different structural and thermodynamic characteristics and whether these 
differences can be correlated to their dissolution behaviour and physical stability. 
Moreover, the influence of the pseudopolymorphic form on the prepared system was also 
evaluated, as referred to, earlier in this chapter.  
Thermal analysis, such as differential scanning calorimetry (DSC) and modulated 
temperature DSC (MTDSC), were used to predict drug-polymer miscibility and fully 
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characterise the prepared solid dispersion systems as well as to investigate their physical 
stability under storage. Thermogravimetric analysis (TGA) and dynamic vapour sorption 
(DVS) were used to measure water content and water uptake, respectively. Structural 
techniques were carried out using X-ray powder diffraction (XRPD) and infrared analysis 
(FTIR). 
 
6.2 Materials and Methods  
 
6.2.1 Materials 
Crystalline paroxetine HCl Form I is a stoichiometric hydrate with 0.5 mol of water per 
mol of drug (molecular weight (MW) = 374.83 g/mol, density (ρ) = 1.35 g/cm3) and it was 
purchased from Afine (China). Paroxetine HCl Form II is a non-stoichiometric hydrate 
with 0.8 mol of water per mol of drug (MW = 365.83 g/mol, ρ = 1.36 g/cm3) and it was 
obtained from Huahai Pharmaceuticals (China). Polyvinylpyrrolidone vinyl-acetate 6:4 
(PVPVA, MW ≈ 47 000 g/mol, ρ = 1.17 g/cm3) was kindly donated by BASF (Germany). 
Methanol (analytical grade) was obtained from Sigma Aldrich (UK). Storage environments 
with different relative humidities (RHs) were prepared using salt solutions of sodium 
chloride (75% RH, Fischer Scientific, UK) and magnesium nitrate hexahydrate (53% RH, 
Fluka, Germany). Phosphorus pentoxide (P2O5) was used as desiccant (Alfar Aesar, UK).  
 
6.2.2 Methods 
6.2.2.1 Preparation of the Physical Mixtures  
Physical mixtures (PMs) between each API and PVPVA were prepared by gentle mixing 
using a mortar and pestle. 
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6.2.2.2 Calculation of Fragility Parameters 
The glass forming ability of paroxetine HCl Form I and II was evaluated using the heating 
rate dependence of the Tg (Qi et al., 2008). APIs were heat-cool-heat in DSC at different 
heating rates, 2, 5, 10, 20 and 50 
o
C/min and Tg was measured on the 2
nd
 heating curve. 
Parameters such as fragility index (m) and strength parameter (D) are generally used to 
classify amorphous materials as strong or fragile and can be calculated using the following 
expressions: 
   
    
         
 
Equation 6.7 
where, ΔETg is the activation energy for structural relaxation at temperatures around Tg and 
R is the gas constant (Wang et al., 2002; Crowley and Zografi, 2001).  
  
          
 
      
 
Equation 6.8 
where, mmin is the minimum possible fragility value and has been calculated to be 16 (Mao 
et al., 2006; Graeser et al., 2009b).  
Finally, the zero mobility temperature, T0, (Shamblin et al., 1999), defined as the 
temperature where extrapolated thermodynamic properties of a supercooled liquid are 
equal to those of the crystal, can be expressed by the Equation 6.9, 
       (  
    
 
) 
Equation 6.9 
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6.2.2.3 Melting Point Depression (MPD) 
The APIs and the polymer were passed through a combination of sieves and the fraction 
between 63-106 μm was used in all melting point depression experiments. PVPVA was 
dried over P2O5 for 48 h prior usage. PMs with a drug ratio of 70, 75, 80, 85, 90 and  
100% w/w were prepared at least in triplicate.  
The melting temperature of paroxetine HCl Form I and II in the presence and in the 
absence of PVPVA was measured using DSC at a scan rate of 2 
o
C/min. Experiments at 
slower heating rates of 1 and 0.1 
o
C/min were also performed for the PMs of Form II with 
PVPVA.  
 
6.2.2.4 Preparation of Solid Dispersions 
Spray drying 
Spray dried solid dispersions of paroxetine HCl Form I and II with PVPVA were prepared 
in a 50% (w/w) drug-polymer ratio. The API and the polymer were dissolved in 200 mL 
mixture of methanol-water (50:50 v/v). The solutions were spray dried using a mini spray 
dryer B-290 (Büchi) with an aspirator flow of 100%, solution pump rate of 5.0 mL/min 
and an inlet temperature of 85 
o
C and an outlet temperature of about 50 
o
C. 
Hot Melt Extrusion 
Hot melt extruded solid dispersions were prepared using a co-rotating twin screw extruder 
Thermo Scientific HAAKE MiniLab II (Thermo Scientific). Each system was prepared 
using a total weight of 5 g, in the same drug loading as mentioned above, at a speed of  
100 rpm with a residence time inside the extruder of 10 min. The extrusion temperature 
was 130 and 150 
o
C for the Form II:PVPVA and Form I:PVPVA system, respectively. 
 
6.2.2.5 Thermal Analysis  
Differential scanning calorimetry (DSC, Q1000 TA Instruments) analysis was done at 
different heating rates of 2, 5, 10, 20 and 50 
o
C/min to calculate the heating rate 
dependence of the Tg of Form I. Values for Form II were calculated in Chapter 5. A 
heating rate (HR) of 10 
o
C/min was used for the stability studies, from -10 to 160 
o
C.  
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Form I was analysed in hermetic pans while Form II was analysed in pinhole pans; all the 
stability studies were performed using hermetically sealed pans. 
Modulated temperature DSC (MTDSC, Q1000 TA Instruments) analysis was performed 
with a HR of 2 
o
C/min (modulation of ± 0.318 
o
C every 60 seconds) in pinhole pans for the 
characterisation of the freshly prepared solid dispersions.  
Thermogravimetric analysis (TGA, Hi-Res 2950 TA Instruments) was used to measure the 
water content of the raw materials and solid dispersion formulations. Samples were kept 
isothermal at 110 
o
C for 30 min. The determination of the degradation temperatures (Tdeg) 
of the raw materials was conducted at 10 
o
C/min from room temperature to 300 
o
C. 
Aluminium open pans were used in both measurements. 
 
6.2.2.6 X-Ray Powder Diffraction (XRPD) 
XRPD (Thermo-ARL Xtra, Thermo Scientific) spectra were collected from 5.0
o
 to 40.0
o
 at 
2θ. Extrudates were scanned in powder form after gentle grinding with a mortar and pestle. 
 
6.2.2.7 Attenuated Total Reflection-Fourier Transform Infrared (ATR-FTIR)  
The infrared spectra of the samples were collected using a Bruker IFS 66/S (Bruker Optics 
Ltd.), spectrophotometer, with 64 scans being acquired for each sample from 4000 cm
-1 
to 
550 cm
-1
 with a resolution of 2 cm
-1
. Extrudates were pre-milled by mortar and pestle 
before the tests. 
 
6.2.2.8 Dynamic Vapour Sorption (DVS) 
DVS (Q5000 SA, TA Instruments) was used to study the water uptake behaviour of all 
solid dispersions formulations immediately after preparation and without any pre-treatment 
of the samples. Isothermal (25 
o
C) and isohumic (98% RH) conditions were used for a 
period of 16 h. 
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6.2.2.9 Dissolution Studies 
The drug content of each formulation was assayed spectrophotometrically (Lambda XLS 
UV/VIS, Perkin-Elmer) at 293 nm. Samples were dissolved in methanol and suitable 
diluted with the same solvent.  
Dissolution studies were performed in 900 mL of 0.1 M HCl at 37.0 ± 0.5 
o
C, with a 
rotation speed of 50 rpm using the BP paddle method. Sixty milligrams (60 mg) of each 
sample within 63-106 μm particle size, were used. At predetermined intervals, 10 mL of 
solution was withdrawn and filtered through a 0.45 μm filter. Subsequently, the filtrate was 
analysed spectrophotometrically at 293 nm. All the dissolution experiments were done 
under sink conditions (see Chapter 5). 
To compare the dissolution performances between the SD and HME systems a similarity 
factor (f2) was used. This is an independent model that measures the similarity in 
percentage between two dissolution profiles (FDA, 1997). The similarity factor (f2) is a 
logarithmic reciprocal square root transformation of the square error, which can be 
expressed by Equation 6.10,   
         {[  (
 
 
)  ∑        
 
 
   
]
    
    } 
Equation 6.10 
where n is the number of time points, Rt is the percentage of drug release of a reference 
batch at the time t and Tt is the percentage of drug release of the comparison batch at time t. 
When f2 is greater than 50 (i.e. 50-100), this indicates the sameness or equivalence of the 
both compared profiles. Conversely, when f2 is less than 50 then it is taken as which both 
the profiles are different. In this study, the similarity factor was used to assess differences 
in the dissolution profiles of SD and HME samples acquired over the first 20 min, since the 
dissimilarities were more evident in the beginning of the test.    
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6.2.2.10 Physical Stability 
The stability of the formulations was assessed over time under the effect of humidity. The 
samples were stored in desiccators under 53% RH and 75% RH at 25 
o
C for 4 months. The 
humidity environments were obtained by using saturated salt solutions of magnesium 
nitrate (53% RH) and sodium chloride (75% RH). Sampling at different time points and 
respective characterisation was done for each system using DSC, TGA, FTIR and XRPD 
techniques. 
 
6.3 Results and Discussion 
 
6.3.1 Characterisation of Paroxetine HCl as a Glass Former 
 
Figure 6.1 presents the scanning rate dependence of the Tg, where ln (q) (q is heating or 
cooling rate) is plotted against the temperature. From the slope of the curve, the glass 
formed from Form II showed higher activation energy of structural relaxation at Tg, ΔETg, 
compared to the Form I. This fact is associated with a fragile glass nature and it is an 
indication that the two forms of paroxetine HCl differ in their theoretical stability/ability as 
glass formers (Angell, 1991). Table 6.1 presents the measured Tg (obtained from a heat-
cool-heat cycle of the crystalline materials) and the calculated parameters for fragility 
index, m, strength parameter, D, and the temperature at which the stability is maximum, T0. 
Considering the theoretical descriptions in Chapter 5, Form I is classified as a strong glass 
former (m < 75, D > 10 and higher value of T0) and Form II as a fragile glass. These results 
can suggest greater stability of amorphous materials prepared from Form I when compared 
to those obtained from Form II; this was critically assessed through this study. 
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Figure 6.1: Heating rate dependence of the Tg for paroxetine Forms I and II  
(measurements were performed at least in triplicate). 
 
Table 6.1: Kinetic parameters obtained from the heating rate dependence of the Tg  
for the two pseudopolymorphic forms of paroxetine HCl. 
 
API/Parameter Tg ± s.d. (
o
C) m D T0 (
o
C) 
Form I 31.9 ± 1.8 46.1 19.6 75.3 
Form II 71.1 ± 0.6 107.3 6.5 19.7 
 
6.3.2 Estimation of Drug-Polymer Miscibility 
 
The miscibility properties between drug-polymer systems have been claimed to be an 
important aspect to account when dealing with solid dispersion formulations. The term 
miscibility is used to refer to the formation of a single phase amorphous system through 
liquid-liquid mixing. As previously described, the Flory-Huggins (FH) lattice theory 
provides a useful tool for describing drug-polymer systems since this theory takes into 
account the large size discrepancy between the two components. Based on this, it is 
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possible to estimate the FH interaction parameter, χ, and the Gibbs free energy of mixing 
(ΔGmix). 
The FH interaction parameter was calculated using melting point depression approach 
(MPD) with the relationship shown by Equation 6.4. Physical mixtures between each API 
and PVPVA were prepared in drug rich compositions (70-90% w/w drug loading) and the 
onset melting temperature was measured.  
Figure 6.2 presents the changes in the melting point of each API, at different drug loadings 
in the presence of PVPVA when compared to the melting temperature of the pure drug, 
ΔTm.  
 
 
 
Figure 6.2: Changes in the onset melting point of paroxetine HCl Form I and Form II  
in the presence of PVPVA, as a function of drug loading. 
 
Form I showed a depression of the onset melting temperature in presence of PVPVA, 
which indicates a degree of mixing at the melting temperature. The onset of the melting 
point of paroxetine HCl Form I decreased with the increase of polymer fraction, as 
expected. For low drug content (70 and 75% w/w) the accurate determination of the onset 
melting temperature can be difficult due to the broadening of the fusion peak. In contrast, 
the melting point of Form II remained totally unchanged in the presence of the polymer. 
0
1
2
3
4
5
6
7
8
9
10
65 70 75 80 85 90 95 100
Δ
T
m
(o
n
se
t)
Drug loading (%)
Form I
Form II
 
Chapter VI 
 
216 
 
The first attempt to explain this observation was the small temperature interval between the 
Tg of PVPVA (≈ 105 
o
C) and the melting point of Form II (117 
o
C). As a result, a proper 
drug-polymer mixing might not be achieved when a heating rate of 2 
o
C/min was used, 
since it is well-known that melting point depression is heating-rate dependent (Nishi and 
Wang, 1975; Marsac et al., 2006). Therefore, slower heating rates of 1 and 0.1 
o
C/min 
were used in order to induce a complete molecular mixing. The results are presented in 
Figure 6.3 and confirmed that even at slower heating rates (0.1 
o
C/min) the onset melting 
temperature of Form II remained unchanged. These findings allowed to conclude that 
according to melting point depression experiments, the system Form II:PVPVA is 
immiscible at temperatures close to the melting. 
 
 
Figure 6.3: Influence of the heating rate on the onset melting point of paroxetine Form II  
when physically mixed with PVPVA in a 50:50 w/w ratio. 
 
This is an interesting point to further investigate by using molecular modelling dynamics, 
since the difference between the two pseudopolymorphic forms is the arrangement and 
hydrogen bonding between the water molecules and the crystalline structure. This 
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approach has already revealed to be a powerful technique for predicting the miscibility of 
indomethacin in different carriers (Gupta et al., 2011). 
Figure 6.4 shows the relationship between the melting point temperatures of each API as a 
function of the volume fraction of PVPVA; the FH interaction parameter can be obtained 
from the slope of the linear-fitted curves. The system paroxetine HCl Form I:PVPVA 
presents a good correlation (R
2
 = 0.998) and a negative value of χ (-3.57) indicating a 
tendency for interaction between the drug and the polymer. On the other hand, paroxetine 
HCl Form II:PVPVA system shows surprisingly also a negative value of χ (-1.52) despite 
the fact that no melting depression was observed when this form was heated with PVPVA 
(Figure 6.2 and Figure 6.3) suggesting at first an immiscible system. This will need to be 
confronted with the subsequent experimental results.  
 
 
 
Figure 6.4: Melting point depression results for the paroxetine HCl, Forms I and II, with PVPVA. 
Slope of each curve included for subsequent calculation of the  
Flory-Huggins interaction parameter (χ). 
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Figure 6.5 shows the changes in the Gibbs free energy for the two systems here being 
studied. It is possible to observe that both systems have a ΔGmix lower than zero, though 
lower for the Form I:PVPVA composition, as it would be predicted from the more negative 
value of the χ when compared to the Form II:PVPVA.   
According to Equation 6.6, a favourable (exothermic) mixing between drug-polymer is 
obtained when the interaction parameter has a negative value and therefore ΔGmix < 0. As 
entropy always favours mixing, combined with enthalpy having an unfavourable 
contribution, ΔGmix can still have a negative value even for athermal events (χ = 0). 
Beyond positive values of χ, mixing is endothermic and ΔGmix > 0 at various compositions 
(Paudel et al., 2010).  
 
 
 
Figure 6.5: Gibbs free energy of mixing (ΔGmix) versus polymer volume fraction (ϕPVPVA)  
for Form II:PVPVA and Form I:PVPVA. 
 
6.3.3 Thermal Characterisation of the Raw Materials  
 
The first aspect to take into account and requiring a careful evaluation when dealing with 
solid dispersion systems is related to the physical properties of the raw materials. 
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Therefore, properties such as melting, glass transition and degradation temperatures of 
each API and PVPVA were determined in the first instance and are presented in Table 6.2.  
The melting temperature of the two forms of paroxetine HCl differs of about 20 
o
C and 
therefore different extrusion temperatures were used to enable a better mixing via  
liquid-state phase between drug and polymer prior extrusion. The degradation temperature 
(Tdeg), was calculated by using TGA as the extrapolated onset temperature that denotes the 
temperature at which the weight loss begins. Tdeg was found to be higher than 250 
o
C for 
all the materials, which allowed an extrusion temperature of 10 
o
C higher than the melting 
point of each API. In terms of the water content, drugs are hydrates under normal ambient 
conditions hence contain a relatively high level of water while PVPVA, due to its slightly 
hygroscopic behaviour, also showed a relatively high water content. As further presented 
in this work, the presence of water in these solid dispersions systems has a strong effect on 
their physical properties.  
 
Table 6.2: Thermal properties of the raw materials. 
 
Material 
Tm onset ± s.d. 
(
o
C) 
Tg ± s.d.  
(
o
C) 
Tdeg ± s.d .  
(
o
C) 
Water content 
± s.d. (%) 
Paroxetine HCl 
Form I 
142.0 ± 0.2 31.9 ± 1.8
*
 264.6 ± 4.0 2.59 ± 0.04 
Paroxetine HCl 
Form II 
117.5 ± 0.4 71.1 ± 0.6
*
 269.7 ± 3.9 4.45 ± 0.26 
PVPVA n.a. 105.6 ± 1.4 283.3 ± 1.0 3.51 ± 1.20 
 
     *
Tg value obtained from heat-cool-heat cycle inside the DSC at 2 
o
C/min. 
    n.a. – not applicable 
 
The values of Tg (-135.0 
o
C) and ΔCp (1.94 J/g 
o
C) for water, needed for the calculation of 
Tgmix using Gordon-Taylor/Couchman-Karasz Equation (Equation 6.1 and Equation 6.2), 
were taken from literature (Hallbrucker et al., 1989). 
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6.3.4 Characterisation of the Freshly Prepared Solid Dispersion Systems 
 
6.3.4.1 Thermal Characterisation 
 
After preparation, all solid dispersion systems were immediately characterised. An 
important aspect to recall and correlate to the experimental results obtained is related to the 
previous studies on the miscibility between each API and PVPVA. From the MPD 
approach, Form I showed to be miscible with the polymer at a temperature near to the 
melting point of the drug. On the other hand, Form II showed to be completely immiscible 
with PVPVA, even at heating rate of 0.1 
o
C/min, although the calculations of the FH 
interaction parameter gave a negative result suggesting, somehow, a certain miscibility 
extent for this system. Therefore, it is important to link those predictions with the actual 
results and infer on the validity of the MPD approach in these systems. 
Figure 6.6 shows the results for the Form II:PVPVA systems prepared by HME and SD. 
As it is possible to observe, both techniques were able to produce fully amorphous systems 
without any evidence of phase separation (two individual glass transitions), 
recrystallisation or melting of the drug. However, a marked difference was detected in their 
glass transition temperatures with the spray dried sample having a higher Tg value when 
compared with the melt extruded sample. In addition, an evident broad water loss signal 
(corresponding to a weight loss of 4.29 ± 0.32% w/w in TGA), between 20-60 
o
C was 
noticed in the total heat flow of the spray dried formulation, contrarily to the HME system, 
even though pinhole pans were used for both samples.  
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Figure 6.6: MTDSC analysis of 50% HME and SD of Form II:PVPVA in pinhole pans.  
Note that the extrudates were analysed without any preliminary treatment (non-milled). 
 
In fact, the most obvious indication of the miscibility between two components is the 
presence of a single glass transition temperature, already described as Tgmix. In this 
particular case, it is essential to take into account the contribution of water and include it in 
the calculations of the theoretical Tgmix. Therefore, Tgmix for a ternary system of  
Form II/PVPVA/water, based on Equation 6.1, was calculated to be about 55 
o
C, which is 
in agreement with the value obtained for the non-milled HME sample (61.0 
o
C). However, 
the Tg measured for the spray dried Form II:PVPVA system had a much higher value  
(95.9 
o
C). These results could, in the first instance, indicate miscibility issues between the 
drug and the polymer, as previously suggested by melting point depression approach for 
this particular system and only evident in the case of the HME sample, due to the absence 
of any miscibility promoter, such as a solvent. However, a simpler explanation is obtained 
if the effect of trapped water inside the HME samples is considered. 
Considering that the HME sample was analysed as it was obtained after extrusion, compact 
extrudates in a cylindrical shape, which largely reduces the ability for the water to 
evaporate when compared with the microparticles obtained from SD, differences in their 
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thermal response when heated in DSC are predicted. Clearly, the Tg obtained for the  
spray dried sample corresponds to the ‘dry’ Tg whereas for the HME system, the Tg was 
depressed by the presence of trapped water. To further study the influence of the water in 
the thermal behaviour of the HME samples, the extrudates were milled (particle size 
between 63-106 μm) and analysed in the same conditions. This has allowed the water to 
freely evaporate during the heating cycle in DSC in a comparable manner to what 
happened with the SD sample. As expected and shown in Figure 6.7, the behaviour of the 
milled extrudates, in terms of both Tg value (93.3 
o
C) and water loss profile, are now 
identical to the spray dried sample. 
 
 
 
Figure 6.7: MTDSC traces of 50% HME Form II:PVPVA after milling  
and control of the particle size (63-106 μm) in pinhole pans. 
 
Figure 6.8 below shows the thermograms obtained for the solid dispersions of  
50% Form I:PVPVA prepared via HME and SD. Molecular level mixing is recognised by 
the presence of one single mixed phase Tg without any other thermal event being detected. 
The thermal behaviour of this system was closely similar to the one observed for the  
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Form II:PVPVA system. More specifically, the water plasticisation effect on the non-
milled HME samples was observed when compared to the milled HME (data not shown) or 
SD samples. However, the measured Tg for the non-milled HME sample (74.6 
o
C) showed 
a positive deviation from the predicted Tgmix (42.6 
o
C).  
 
 
 
Figure 6.8: MTDSC analysis of the solid dispersions of 50% Form I:PVPVA prepared by HME  
(non-milled) and SD. Analyses were done in pinhole pans. 
 
Deviations of experimental Tg values for solid dispersions from those predicted by the GT 
are often explained by considering the nature of the interactions between the two 
components (Lu and Zografi, 1998). This fact can be supported by the melting depression 
observed for Form I when physically mixed with PVPVA, indicating some degree of 
interaction.  
All the Tg values were measured in the reversing heat flow signal and are presented in  
Table 6.3 for clarity. TGA measurements of the water content in non-milled and milled 
extrudates are also presented. The milled samples showed a higher water content value 
(nearly double) compared to the non-milled ones, as it would be expected since the water 
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can be released easier. This fact also supports the results observed in DSC. For the spray 
dried products, the water content was considerably higher for the Form II system in 
comparison with the Form I formulation, which will have influence in the FTIR results, as 
it will be shown later. 
 
Table 6.3: Measurements of Tg, ΔCp and moisture content obtained by MTDSC and TGA, respectively, 
for the milled and non-milled HME and SD samples. 
 
System 
Non-milled Milled 
DSC TGA DSC TGA 
Tg ± s.d. (
o
C) 
ΔCp ± s.d. 
(J/g 
o
C) 
Water loss  
± s.d. (%) 
Tg ± s.d. (
o
C) 
ΔCp ± s.d. 
(J/g 
o
C) 
Water loss 
± s.d. (%) 
50% HME  
Form I:PVPVA 
74.6 ± 1.4 0.18 ± 0.03 1.52 ± 0.40 95.9 ± 0.3 0.36 ± 0.05 2.50 ± 0.16 
50% HME  
Form II:PVPVA 
61.0 ± 4.9 0.25 ± 0.03 1.47 ± 0.19 93.3 ± 0.6 0.38 ± 0.04 2.57 ± 0.27 
50% SD  
Form I:PVPVA 
97.2 ± 0.2 0.34 ± 0.06 2.62 ± 0.20 n.a. n.a. n.a. 
50% SD  
Form II:PVPVA 
95.9 ± 0.8 0.34 ± 0.02 4.29 ± 0.32 n.a. n.a. n.a. 
 
n.a. – not applicable 
 
6.3.4.2 Structural Characterisation of the Solid Dispersion Systems  
 
The DSC findings outlined above were supported by XRPD studies which revealed that all 
the formulations prepared via HME and SD were amorphous with a characteristic halo 
pattern (data not shown).  
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ATR-FTIR was used to study intermolecular interactions between APIs and PVPVA. The 
spectra of crystalline drug substances, polymer and drug-polymer PMs were compared 
with the spectra of the hot melt extrudates and spray dried products, as shown in Figure 6.9 
and Figure 6.10, respectively. 
Paroxetine HCl Forms I and II are easily distinguished by a double or two single bands at 
high wavenumber, respectively. These bands are assigned to the stretching vibration of the  
O-H groups in different environments (Chapter 3). 
The spectrum of PVPVA has two main bands corresponding to stretching of the carbonyl 
groups that are proton acceptors and are usually affected by hydrogen bonding: 1673 cm
-1
 
(from the amide group) and at 1732 cm
-1
 (from the ester group). The N-H groups from the 
APIs, are proton donating groups and also participate in intermolecular interactions, 
although in this case its stretching vibration overlap in complex area of the spectra with the 
aromatic ring vibrations and hence are not considered here as a means of evaluating any 
drug-polymer interaction.  
 
 
  
 
 
 
 
 
 
 
 
 
 
Figure 6.9: ATR-FTIR spectra of PVPVA, pure crystalline paroxetine HCl Form II and Form I 
(upwards) and respective PMs (theoretical and experimental). 
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In theory, a 50:50 w/w PM between each API and PVPVA would be expected to result in a 
combination of the FTIR spectrum of the individual components. However, by comparing 
the predicted spectra with the one obtained experimentally an evident difference in the 
main region of PVPVA was observed. The two main bands previously referred  
(1673 and 1732 cm
-1
) became broader and significantly reduced in intensity, which was 
identical in both Form I and Form II systems. A reasonable explanation for this feature is 
probably related to the high water content of the individual raw materials. In fact, the 
interaction between water and hydrophilic polymers, such as PVP and PVPVA, was 
described to influence not only the position of the C=O but also its shape (Weuts et al., 
2004).   
In the case of the FTIR spectra for the freshly prepared solid dispersions (Figure 6.10) it is 
clear that the O-H stretching vibrations associated with the isolated APIs (located at a high 
wavenumber) disappeared and meanwhile a broad band at around 3400 cm
-1 
was identified 
in all the solid dispersions. This is an indication of the formation of an amorphous phase 
between the drug and polymer, which was also supported by the broadening of the peaks in 
the whole spectra. Additionally, the position of the C=O stretch vibration corresponding to 
the ester function of the polymer is practically unchanged, whereas the band corresponding 
to the C=O stretch of the amide function showed a shift towards lower wavenumbers. This 
is due to the different basic nature of the two groups, being the C=O of the pyrrolidone 
group a stronger proton acceptor as compared to the C=O of the vinyl-acetate (Shamblin et 
al., 1998).  
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Figure 6.10: FTIR spectra of the freshly HME and SD solid dispersions of paroxetine HCl  
Form I and Form II with PVPVA. 
 
In general for a group participating in a hydrogen bond, a shift to lower wavenumbers 
indicates a stronger bond while a shift to higher wavenumbers indicates the formation of a 
bond that is weaker than the original bond present in the pure phase (Trasi and Taylor, 
2012). In this study, the downshift of the C=O peak from the amide group cannot be 
directly correlated to any significant hydrogen bonded interaction. Firstly, as it was already 
mentioned, the N-H band from either Forms I and II that could act as a proton donor is 
difficult to identify on the individual spectra and therefore changes cannot be tracked 
within the solid dispersed systems. Secondly, it is important to consider the influence of 
water. Matching the water content measured by TGA for each fresh solid dispersion 
formulation, presented in Table 6.3, the system 50% SD Form II:PVPVA showing the 
higher shift (from 1673 for pure PVPVA to 1659 cm
-1
) has also higher moisture content 
(4.29 ± 0.32% w/w). In contrast, both HME systems (considering the water content 
measured in milled extrudates) and the spray dried Form I:PVPVA, have nearly half 
moisture content (≈ 2.6%) when compared to the spray dried Form II, which matches the 
smaller shifts observed in FTIR. 
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6.3.4.3 Moisture Uptake Studies  
 
In the previous section, the effect of trapped water inside the extrudates was discussed and 
showed to have a great influence on the measured Tg when compared to the spray dried 
samples. Indeed, the presence of water lowers the Tg of amorphous systems and therefore 
increases the molecular mobility, which can also alter the chemical and physical stability 
of amorphous solid dispersions.   
The moisture uptake capabilities of all systems were tested using DVS isohumic and 
isothermal tests (the DVS sample chamber was kept at a constant humidity and 
temperature during the tested period) at 98% RH/25 
o
C for a period of 16 h, when a 
constant weight for all the systems was achieved. This provides a rapid insight on the 
hygroscopic behaviour and water uptake rates of each system since an extremely high 
water vapour was used, which gives some insights prior the stability tests being performed. 
The results are presented in Figure 6.11 and as expected, the spray dried products absorbed 
water at higher rate when compared to the HME ones, which were tested in its rod-shape, 
as milling could increase molecular mobility and give misleading results when submitted 
to high RH environments. After nearly 3 h of testing both SD samples and HME  
Form II:PVPVA showed a similar increase in weight nearly 40% w/w whereas  
HME Form I:PVPVA showed a slightly lower absorption of nearly 32% w/w. However, in 
the end of the experiments (after 16 h) all systems showed a similar water uptake  
(≈ 45% w/w).  
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Figure 6.11: DVS results of the freshly prepared HME and SD systems  
kept under 98% RH/25 
o
C for a period of 16 h. 
 
Another important information that can be exploit from DVS experiments is related to the 
crystallisation of amorphous materials when exposed to changes in humidity. Amorphous 
samples are described to absorb large amounts of water and as they crystallise the water is 
expelled and a weight loss is observed (Grisedale et al.). In this study none of the products 
showed a decrease in weight during the experimental time in DVS suggesting a great 
stability of these systems, which will be further studied during the storage stability.   
 
6.3.4.4 Dissolution Studies 
 
The drug content was determined spectrophotometrically, as described in the Methods 
section, and was within the range 98.4–101.6% for all the systems prepared. 
It is well-known that the dissolution behaviour of pharmaceutical drugs is a complex 
process and depends on several factors such as particle size, surface area, degree of 
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crystallinity and solvation state of the drug. Also, some examples can be scattered from the 
literature showing the influence of the preparative techniques on the dissolution process of 
amorphous solids (Patterson et al., 2007; Dong et al., 2008; Mura et al., 1999c; Mura et al., 
1999a; Karmwar et al., 2012).  
In this section the dissolution profiles of each solid dispersion system prepared via HME 
and SD were investigated and compared with the pure crystalline drugs and binary 
mixtures with PVPVA. Sink conditions were used and the particle size was controlled for 
all the experiments (63-106 μm).  
 
 
 
Figure 6.12: Dissolution profiles of pure paroxetine HCl Form I, binary mixture with PVPVA and 
respective solid dispersions prepared by SD and HME. 
 
Form I has a dissolution rate similar to the PMs and SD samples, as shown in  
Figure 6.12. This is not completely surprising since paroxetine HCl is described to be a 
slightly water soluble drug (Kasim et al., 2004). However, a lower dissolution rate was 
observed for the HME product. These differences in the release rates were quantitatively 
compared by using the magnitude of similarity factor f2, as described in the Methods 
section. The SD and HME systems of Form I have a similarity factor f2 of 29.10 suggesting 
0
10
20
30
40
50
60
70
80
90
100
110
0 10 20 30 40 50 60 70 80 90
D
ru
g
 r
el
ea
se
 (
%
)
Time (min)
Form I
50% PM Form I:PVPVA
50% HME Form I:PVPVA
50% SD Form I:PVPVA
 
Chapter VI 
 
231 
 
that the release profile of Form I from the SD and HME formulations were different  
(f2 < 50). Although, SD and HME solid dispersions were prepared as fully amorphous 
forms, which was confirmed by DSC and XRPD, other parameters seemed to influence the 
dissolution of these solid dispersions systems. 
A similar visual behaviour of the solid dispersions during dissolution testing was observed, 
with all the samples dispersing well in the media without any evidence of material floating 
or forming a solid plug at the bottom of the dissolution vessel. However, the diffusion 
coefficient of the dissolution medium into the micrometer spray dried and hot melt 
extrudated particles is expected to be different with a slower rate for the latter one. This 
fact could explain the initial slower release of the HME system in comparison with the PM 
and SD samples. Additionally, the slower wetting properties of the compact HME particles 
could contribute for these observations. 
 
 
 
Figure 6.13: Dissolution profiles of pure paroxetine HCl Form II, binary mixture with PVPVA and 
respective solid dispersions prepared by SD and HME. 
 
The SD and PMs with Form II had a similar dissolution profiles to the ones observed for 
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HME sample. This might be due to the higher water content of Form II. Also the f2 factor 
had a value equals to 38.09, as an indication of the different release profiles between SD 
and HME systems of Form II perhaps for similar reasons as exposed above. 
 
6.3.5 Physical Stability of Solid Dispersions over Storage  
 
In this section, the physical stability of all solid dispersion systems here being studied was 
evaluated. In addition, the existence of a possible relationship between the two different 
preparation techniques, SD and HME, used in this work and its influence on the stability of 
amorphous solid dispersions was also assessed. Stability studies were carried out under 
two different RH levels (53 and 75% RH) at room temperature (≈ 25 oC), as it is  
well-known that humidity plays an important role in the stability of amorphous 
formulations. It has been extensively reported that the presence of moisture contributes not 
only to increase molecular mobility, which can lead to crystallisation, but at the same time 
promotes the tendency for phase separation to happen. 
Due to the high water vapour pressure at 75% RH and high hygroscopic behaviour of 
amorphous formulations, all the extrudates and spray dried products stored under this 
environment, formed coalesced masses making certain physical analysis problematic, in 
particular XRPD measurements.  
 
6.3.5.1 DSC Studies 
 
DSC studies were performed considering two important aspects: firstly, dehydration of  
Form I happening during heating and therefore hermetic pans were used during stability 
testing; secondly, to avoid recrystallisation or dissolution of the API into the polymer 
during heating, a fast heating rate of 10 
o
C/min was chosen.  
Figure 6.14 presents the typical DSC traces for all the systems after 30 days of storage 
under 75% RH/25 
o
C. From the plot, all the formulations showed a single thermal event 
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that corresponds to the melting of Form I, after confirmation by using ATR-FTIR. An 
important point to account is related to the initial miscibility studies, which showed that 
Form I was miscible with PVPVA and Form II completely immiscible. However, the 
analyses of the freshly prepared solid dispersions showed that both pseudopolymorphs 
formed a single amorphous phase with the polymer and this might be reflected in their 
physical stability. For the aged samples, the onset melting event detected for all the 
samples ranged from 95-100 
o
C, which is clearly lower than the melting observed when 
Form I was just physically mixed with PVPVA (≈ 130 oC) in the same drug loading  
(50:50 w/w). This could be an indication that processing contributes to further increase the 
miscibility between the drug and the polymer, which is detected by a higher melting point 
depression. Nevertheless, it is also important to bear in mind that the API is a slightly 
water soluble drug stored at high humidity and analysed in hermetic pans, thus the 
combination of these factors could accelerate the dissolution of the drug in the polymer 
even with a heating rate of 10 
o
C/min. 
 
 
 
Figure 6.14: DSC curves for HME and SD systems after 30 days storage under 75% RH/25 
o
C and 
analysed in hermetic pans at 10 
o
C/min. 
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All the samples stored at 53% RH/25 
o
C remained fully amorphous during the whole 
experimental time (four months), with a single Tg ranging from 29-32 
o
C being observed. 
The percentage of crystallised drug in each formulation was estimated by using the ratio 
between the enthalpy of fusion of the pure API (ΔHm (0)) and enthalpy of fusion measured 
in the DSC for the aged systems (ΔHm (t) ) multiplied by the drug loading (50% w/w for all 
the formulations in this case) (Shah et al., 2006), as shown in Equation 6.11, 
                      (
      
      
)      
Equation 6.11 
Figure 6.15 shows the recrystallisation profiles of all formulations calculated from DSC 
data using Equation 6.11 during four months of storage under 75% RH/25 
o
C. Significant 
differences were observed in the stability behaviour of the different systems, especially 
regarding the initial time point when recrystallisation was firstly detected by DSC, but also 
the overall profile of recrystallisation. Both spray dried products of Form I and II showed a 
high recrystallisation tendency, reaching its maximum amount of crystals detected after  
30 days, which remained nearly constant during the remain experimental period. The 
sample HME Form II:PVPVA showed a continuous increase in its crystal content over 
time, achieving its maximum after 90-120 days.     
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Figure 6.15: Recrystallisation profiles of the HME and SD systems stored at 75% RH/25 
o
C. 
 
The HME Form I:PVPVA sample showed the lower tendency for recrystallisation. Firstly, 
the presence of crystals started to be noticed in DSC after 30 days of storage, whereas all 
the other solid dispersion systems started to recrystallise after two weeks; secondly this 
system had a lower crystal content at each sampling point when compared to the others 
solid dispersions, though presenting a similar percentage of crystals by the end of the 
study. This fact could be correlated with the glass forming ability of the pure APIs showed 
in the beginning of this study. The glass material obtained from Form I was classified as a 
strong glass and therefore lower tendency to recrystallise compared to the obtained glass 
prepared from Form II that was identified as fragile glass. The fact that all the spray dried 
samples had a similar profile, it could be related to the higher surface area exposed to the 
environmental, promoting the recrystallisation to be more uniform and difficult to isolate 
any difference in the behaviours of Forms I and II. 
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6.3.5.2 TGA 
 
The water content of each system during the experimental time was measured by using 
TGA. The results obtained for the samples stored under 75% RH/25 
o
C are presented in 
Figure 6.16. All the systems showed to have a very similar water behaviour uptake when 
stored at these conditions, being observed a slight decrease over time, probably as an 
indication of API recrystallisation and therefore less hygroscopicity when compared with 
the amorphous state.  
 
 
 
Figure 6.16: Water content of each solid dispersion system overtime stored at 75% RH/25 
o
C. 
 
All the samples stored under 53% RH/25 
o
C showed a slight increase in their moisture 
content, varying from 6-8% for the HME samples and from 4-7% for the spray dried 
samples. However, these differences did not significantly influence the measured Tg of 
these systems when run in DSC. 
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b) 
c) 
a) 
6.3.5.3 ATR-FTIR 
 
Using FTIR analysis, all the solid dispersion systems stored at a high RH were found to 
recrystallise to Form I. Due to the complexity of the FTIR spectra of this type of systems, 
the second derivative was found helpful to reveal characteristic unresolved peaks, essential 
to distinguish between Forms I and II. Figure 6.17 below shows the changes highlighted 
with arrows in the spectra of HME Form II:PVPVA system over time. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.17: ATR-FTIR spectra of HME Form II:PVPVA (a), pure Form I and its 2
nd
 derivative (b) 
and second derivative of the same system (c). Please note that each spectrum was collected at each 
sampling point (0, 7, 14, 30, 60, 90 and 120 days) downwards. 
 
Spray dried samples and HME Form II:PVPVA started to show differences in their FTIR 
patterns after 60 days, while HME Form I:PVPVA only after 90 days. These observations 
do not completely agree with the DSC results, but confirmed the differences in their 
recrystallisation rates. 
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6.3.5.4 XRPD  
 
All the samples stored under 53% RH/25 
o
C confirmed to be X-ray amorphous during the 
whole experimental time (data not shown). For the samples stored at 75% RH/25 
o
C, their 
physical state made XRPD analysis difficult, as the requirements of forming a flat lightly 
compressed sample surface was hard to obtain. This could also explain the delay in 
observing any peaks from the recrystallised API earlier. Figure 6.18 presents the 
diffractograms for the Forms I and II systems prepared by SD and HME after four months 
of storage under 75% RH/25 
o
C. All the X-ray traces show a poor ratio signal to noise 
without well-defined and sharp diffraction peaks. In addition, the presence of a halo pattern 
on the background of each plot indicates the presence of a reasonable amorphous content. 
 
 
 
Figure 6.18: XRPD traces of SD and HME samples of Form I and Form II with PVPVA (50:50 w/w)  
aged at 75% RH/25 
o
C for four months. 
 
The HME samples, in particular the Form I:PVPVA system, seemed to have a lower 
crystalline content compared to the rest of the formulations, though matching with the DSC 
results all the systems had a similar crystal content by the end of the study. Therefore, 
these observations might just be due to the sample preparation, since no difference in their 
physical aspect was observed between the samples stored under these conditions. By 
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comparing the peak lists collected for each system with the corresponding peak lists for 
Form I and II, all the samples recrystallised into Form I, which was also suggested by 
FTIR analysis and it is not surprising since Form I is the most stable form. 
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6.4 Conclusions 
 
Currently, the development of solid dispersions in the industry remains largely a trial and 
error procedure, with the final performance and physical stability the key features to be 
achieved.  
Several theoretical predictions have been developed over the past few years to aid the 
successful preparation of such systems. In this study, MPD was selected to predict the 
miscibility and interaction between two pseudopolymorphs, Form I and Form II, of 
paroxetine HCl and PVPVA. Accordingly to these predictions only paroxetine HCl Form I 
was miscible with the polymer. The MPD approaches for Form II, did not give any 
conclusive results. However experimentally, both forms were able to be molecularly 
dispersed within the polymer matrix, thus forming one-phase system. These results 
supported the limitations of the melting point depression applications and reliability on 
predicting the drug-polymer miscibility.  
The work presented here also demonstrated that the use of different preparation techniques, 
HME and SD, resulted in products with different physical properties. SD produced porous 
particulate samples while HME yielded to denser (as a result of high intensity of mixing 
and pressure during extrusion) products with lower porosity. These differences can 
therefore influence not only the dissolution profile of the prepared system but also its 
physical stability under storage. Moreover, special awareness must be taken when 
characterising hot melt extruded systems due to the effect of trapped water that can lead to 
misinterpretations, namely with respect to the measured Tg. This can be particularly 
important when comparing with dispersions obtained in a powder form, such as spray dried 
systems. In this case, a gentle milling of the extrudates is recommended in order to 
establish more reasonable comparisons. 
In terms of the dissolution performance, the HME systems showed, in both cases of Forms 
I and II, lower dissolution rate when compared to SD samples. This behaviour was 
ascribed to the compact state of the HME microparticules and therefore slower diffusion 
rate in the dissolution media. However, considering pure Form I and Form II individually, 
the dissolution profile of Form I was similar to the PMs and SD samples whereas pure 
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Form II, in contrast, had a dissolution rate similar to the HME sample. This fact might be 
related to the higher water content of Form II compared to Form I.  
Finally, in terms of the physical stability of the formulated systems HME systems showed, 
overall, higher stability than the SD samples. More specifically, HME Form I:PVPVA was 
found to be the most stable system with the lowest recrystallisation rate. This could be 
attributed with the higher glass forming ability of Form I compared to Form II.
  
 
 
 
 
 
 
 
7 OLANZAPINE SOLID DISPERSIONS PREPARED VIA HME: 
IMPACT OF THE DRUG PHYSICAL STATE AND DIFFERENT 
POLYMERS ON THE DISSOLUTION ENHANCEMENT AND 
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Abstract 
 
In this chapter, particular attention was paid to the physicochemical properties of different 
polymeric carriers and their influence on the manufacturing process and capability of 
inhibiting crystal growth over storage. In addition, the relationship between the physical 
structure of the prepared systems and the dissolution behaviour was also assessed 
critically, with a view to examine whether full amorphicity is necessary to achieve a 
favourable dissolution profile. Solid dispersions of olanzapine (OLZ) were prepared via 
hot melt extrusion (HME) in three polymers (PVP, PVPVA and Soluplus
®
 (SLP)). The 
influence of the drug loading and extrusion temperature on the processability by HME was 
also investigated. Drug-polymer miscibility was estimated using melting point depression 
(MPD) and Hansen solubility parameters (δ). Solid dispersions were characterised using 
differential scanning calorimetry (DSC), thermogravimetric analysis (TGA), Fourier 
transform infrared (FTIR), X-ray powder diffraction (XRPD) and scanning electron 
microscopy (SEM).  
All the polymers were found to be miscible with OLZ (interaction parameter, χ < 0 and  
Δδ < 7 MPa1/2), in a decreasing order of PVP > PVPVA > SLP. At a lower extrusion 
temperature (160
 o
C), PVP generated fully amorphous dispersions with OLZ, while the 
formulations with PVPVA and SLP contained 14-16% crystalline OLZ. Increasing the 
extrusion temperature to 180 
o
C allowed the preparation of fully amorphous systems with 
PVPVA and SLP. Despite these differences, the dissolution rates of these preparations 
were comparable, with PVP showing a lower release rate despite being fully amorphous. 
These findings suggested that, at least in the particular case of OLZ, the absence of 
crystalline material may not be critical to the dissolution performance. Regarding the 
storage stability under 75% RH/40 
o
C, the extrudates prepared with SLP and extruded at 
180 
o
C were found to have the greatest stability. Properties such as low hygroscopicity and 
high viscosity (high molecular weight) of SLP might have a strong effect in decreasing 
molecular mobility and thus impairing crystallisation. These two properties seemed to 
control the stability of amorphous OLZ, rather than the stabilisation via hydrogen bonding 
between OLZ and the different polymers. 
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7.1 Introduction 
 
The oral bioavailability enhancement of poorly soluble active pharmaceutical ingredients 
(APIs) continues to represent a significant issue in drug development. One strategy to 
overcome this obstacle is the development of amorphous solid dispersion systems using 
hydrophilic polymers. The term ‘solid dispersion’ was described by Chiou and Riegelman 
as “the dispersion of one or more active ingredients in an inert carrier matrix at  
solid-state prepared by melting (fusion), solvent or melting-solvent method” (Chiou and 
Riegelman, 1971). This definition is still applicable despite the field having developed 
considerably to include a wider range of manufacturing techniques (e.g. hot melt extrusion 
(HME)) and new concepts in structural characteristics, particularly involving the 
recognition of complexities of molecular dispersion of drugs in polymers. 
The mechanisms underpinning the dissolution increase of these formulations are still not 
yet clearly understood. Currently, there is a belief that the fundamental critical factor is the 
molecular dispersion of the drug in the polymer, thereby representing the ultimate in 
particle size reduction and lattice energy negation. A number of papers have addressed 
these and associated issues such as wetting and reduction in agglomeration (Janssens and 
Van den Mooter, 2009; Vasconcelos et al., 2007). In addition, earlier work in the pre-HME 
solid dispersion field suggested that the drug dissolution may be controlled by the 
behaviour of the carrier (so-called ‘carrier controlled dissolution’), by implication 
suggesting that the physical state of the drug may not be important in such systems 
(Corrigan, 1985; Craig, 2002). The specific issue of whether full amorphisation (in terms 
of either molecular dispersion or amorphous phase generation) is actually necessary to 
achieve fast and complete dissolution has been addressed by previous authors. For 
example, Verheyen et al. observed that the dissolution rate of diazepam and temazepam 
could be enhanced when prepared into solid dispersions with polyethylene glycol (PEG) 
6000, although both drugs remained in a highly crystalline state (Verheyen et al., 2002). 
The reason for this behaviour was attributed to the existence of a micro-environment 
created by the polymer at the surface of the drug particles leading to a better wetting and 
solubilisation properties.  
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Another point of concern when dealing with amorphous solid dispersions is their physical 
stability over storage. It is generally accepted that the recrystallisation of these systems is 
dependent on the molecular mobility and the degree of supersaturation of the solute in the 
matrix (Weuts et al., 2005). As the molecular mobility increases, the risk of crystallisation 
also increases. In general, the addition of polymers exerts a protective effect, which can be 
a result of two main factors: an antiplasticising effect of the polymer or interactions 
between the drug and the polymer, or a combination of both. An antiplasticising effect of 
the polymer may contribute significantly by increasing the temperature at which the 
molecular mobility become significant (Van den Mooter et al., 2000). However, several 
studies have shown that crystallisation occurs well below the Tg and hydrogen bonding 
between the drug and the polymer is not always a prerequisite in the stabilisation of 
amorphous compounds (Van den Mooter et al., 2000; Zhu et al., 2010). Based on the 
preceding discussion, it is clear that the physiochemical properties of polymers and their 
role during dissolution and as inhibitors of crystallisation from the amorphous state are not 
yet fully understood.  
In this study, olanzapine (OLZ) was selected as the model drug and formulated with three 
hydrophilic polymers, polyvinylpyrrolidone K30 (PVP), polyvinylpyrrolidone vinyl-
acetate 6:4 (PVPVA) and polyvinyl-caprolactam polyvinyl-acetate polyethylene glycol 
graft copolymer (Soluplus
®
, SLP) via hot melt extrusion (HME). HME is a widely used 
technology in which API and carrier are converted into a product of uniform shape and 
density by the effect of heat and mechanical stress (Crowley et al., 2007; Repka et al., 
2007). HME represents a continuous solvent-free manufacturing method and is relatively 
easy to scale-up, hence presenting a commercially viable approach to dosage form 
development. 
OLZ is an atypical antipsychotic agent used to treat both negative and positive symptoms 
of schizophrenia, acute mania with bipolar disorder, agitation, and psychotic symptoms in 
dementia (Burns, 2001). According to Biopharmaceutical Classification System (BCS), 
OLZ is classified as a Class II drug (low solubility, high permeability) with water 
solubility around 43 mg/L (Thakuria and Nangia, 2011). OLZ has been suggested to 
crystallise in more than 50 different crystalline forms, including anhydrates, hydrates and 
solvates (Reutzel-Edens et al., 2003a; Bhardwaj et al., 2013). In this study, anhydrous OLZ 
Form I, the most stable form and currently used in pharmaceutical formulations, was 
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chosen as the model form. Regarding the polymers used in this work, numerous studies 
have been conducted on the solubility enhancement of water insoluble compounds, in 
particular using PVP and its derivatives as carriers (Moneghini et al., 1998; Hülsmann et 
al., 2000; Tantishaiyakul et al., 1996, 1999). High solubilisation effect and the ability of 
establishing hydrogen bonding with APIs are well recognised properties of PVP based 
polymers (Konno and Taylor, 2006; Trasi and Taylor, 2012). PVP K30 has a higher glass 
transition temperature (Tg) and a relatively low degradation temperature (Tdeg) when 
compared with PVPVA 6:4 what can represent an issue during processing via HME. 
Moreover, PVP is classified as an extremely hygroscopic substance, which is attributed to 
the electronegative groups (C=O) in the pyrrolidone structure being able to establish 
hydrogen bonding with water (Callahan et al., 1982). The co-polymer PVPVA 6:4 has a 
40% replacement with lipophilic vinyl-acetate functional groups and therefore it is less 
hygroscopic than the homopolymer system ( u hler, 2005). SLP on the other hand is a 
synthetic polymer that combines both hydrophilic and hydrophobic components in its 
structure which facilitates increased solubilisation of drugs and thus the preparation of 
fully amorphous solid dispersions. Moreover, its low Tg (≈ 70 
o
C) compared to the PVP 
based polymers permits easier processing of thermolabile APIs, while its low 
hygroscopicity can have an important stabilising effect during storage. Lately, polymer 
blends have also gained considerable attention as they can offer several physicochemical 
attributes to the dosage form as opposed to the use of a single polymer (Six et al., 2004; 
Sakurai et al., 2012; Bley et al., 2010; Yang et al., 2013). 
In this study, the effect of different polymers on the manufacturing process and 
stabilisation over storage was critically assessed. Moreover, attention was paid to the 
physical state of the prepared extrudates and its influence during the dissolution 
performance. At first, the optimal extrusion temperatures for the OLZ-polymer systems 
based on the properties of each material (i.e. Tg, Tm and Tdeg) was evaluated. In addition, 
the thermodynamic solubility/miscibility and interaction of OLZ in each polymer were 
assessed using melting point depression (Marsac et al., 2009; Marsac et al., 2006) and 
solubility parameter approaches (Kontogeorgis, 2007; Hansen, 2007; Krevelen and 
Nijenhuis, 2009). The physicochemical properties and the morphology of the fresh and 
aged extrudates were evaluated using differential scanning calorimetry (DSC), Fourier 
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transform infrared (FTIR), X-ray powder diffraction (XRPD) and scanning electron 
microscopy (SEM). Dissolution experiments and stability studies were as well carried out. 
 
7.2 Materials and Methods 
 
7.2.1 Materials 
Olanzapine (OLZ, molecular weight (MW) = 312.43 g/mol, density (ρ) = 1.30 g/cm3) was 
purchased from Myjoy Ltd. (India), PVP K30 (MW ≈ 41 550 g/mol, ρ = 1.16 g/cm3), 
PVPVA 6:4 (MW = 57 500 g/mol, ρ = 1.17 g/cm3) and Soluplus® (SLP, MW = 118 000 
g/mol, ρ = 1.20 g/cm3) were kindly donated by BASF Chemicals (Germany). Methanol 
(analytical grade) was obtained from Sigma Aldrich (UK). Phosphate buffer, pH = 6.8 
(BP), used for the dissolution studies was prepared with potassium dihydrogen 
orthophosphate (Fischer Scientific, UK) and sodium phosphate dibasic (Sigma Aldrich, 
UK). Storage environment with 75% RH was prepared using a salt solution of sodium 
chloride (Fischer Scientific, UK). 
 
7.2.2 Methods 
7.2.2.1 Preparation of Hot Melt Extrudates 
Hot melt extrudates were prepared using a co-rotating twin screw extruder Thermo 
Scientific HAAKE MiniLab II (Thermo Scientific). Extrudates of OLZ with PVPVA and 
SLP were prepared with ratios of 20:80 and 50:50 (w/w) and extruded at 160 and 180 
o
C; 
OLZ:PVP extrudates were only successfully prepared at 50:50 (w/w) and extruded at  
160 
o
C. Each system was prepared using a total weight of 5 g at a speed of 100 rpm and 
mixed inside the barrel for 10 min.  
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7.2.2.2 Drug-Polymer Miscibility Prediction  
(a) Melting Point Depression (MPD) 
OLZ and polymers were passed through a combination of sieves and a fraction between  
63-106 μm was used in all melting point depression experiments. Polymers were dried 
over P2O5 for 48 h prior to usage. Physical mixtures (PMs) with a drug ratio of 70, 75, 80, 
85, 90 and 100% w/w were prepared at least in triplicate. The melting temperature of OLZ 
both in the absence and presence of polymers was measured using DSC at a scanning rate 
of 10 
o
C/min in standard crimped pans.  
(b) Hansen Solubility Parameter 
The Hansen solubility parameters, δ, of the drug and the polymers were calculated from 
their chemical structures using the van Krevelen and Hoftyzer method according to the  
Equation 7.1 and Equation 7.2 (Krevelen and Nijenhuis, 2009). The total solubility 
parameter (δt) was determined from the interactions between dispersion forces (δd), polar 
interactions (δp) and hydrogen bonding (δh) of the functional groups in the parent molecule 
divide by the molar volume, V. The units of the solubility parameters are MPa
1/2
. 
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Equation 7.2 
where, Fdi, Fpi and Ehi are the group contributions for different components (dispersion 
forces, polar interactions and hydrogen bonding, respectively) of structural groups which 
are reported in the literature at 25 
o
C (Krevelen and Nijenhuis, 2009). 
The drug-polymer interaction parameter, χ, using the solubility parameters difference 
between the drug and the polymer, can be estimated as follow (Krevelen and Nijenhuis, 
2009), 
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Equation 7.3 
where, V0 is the volume of the lattice site, R is the gas constant and T is the absolute 
temperature. 
 
7.2.2.3 Crystallinity Quantification 
The amount of crystalline OLZ present in the fresh extrudates was estimated by 
constructing a calibration curve using the enthalpy of melting of OLZ in the presence of 
the polymer versus the ratio of the drug in the mixture. This was performed in order to 
account for changes in the melting behaviour and enthalpy caused by the presence of the 
polymer. Physical mixtures (PMs) were prepared by mixing OLZ and each polymer with a 
mortar and pestle in ratios of 10:90, 20:80, 30:70, 50:50, 70:30 and 90:10 w/w and 
analysed in DSC. All the PMs were used with a 63−106 μm particle size range. 
Measurements were made at least in triplicate. 
 
7.2.2.4 Thermal Analysis 
Standard differential scanning calorimetry (DSC, Q2000 TA Instruments) analysis was 
performed at a heating rate of 10 
o
C/min. Modulated temperature DSC (MTDSC, Q2000 
TA Instruments) analysis was conducted using a heating rate of 2 
o
C/min,  
amplitude ± 0.318 
o
C and a period of 60 seconds. Scans were carried out within the 
temperature range 0 °C to 220 °C and standard crimped pans were used in all experiments.  
Thermogravimetric analysis (TGA, Q5000 TA Instruments) was used to measure the 
degradation temperature (Tdeg) of the raw materials and the water content of the fresh 
extrudates. Studies were conducted at 10 
o
C/min from room temperature to 300 
o
C. 
Aluminium open pans were used. 
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7.2.2.5 Attenuated Total Reflection-Fourier Transform Infrared (ATR-FTIR)  
FTIR (IFS 66/S, Bruker Optics Ltd.) equipped with a Golden Gate attenuated total 
reflection (ATR) accessory was used. Sixty-four scans, from 4000 cm
-1
 to 550 cm
-1
, were 
acquired for each sample with a resolution of 2 cm
-1
. Extrudates were scanned in powder 
form after gentle grinding with a mortar and pestle.  
 
7.2.2.6 Dynamic Vapour Sorption (DVS)  
DVS (Q5000 SA, TA Instruments) was used to study the water uptake behaviour of all 
solid dispersions systems immediately after preparation and without any pre-treatment of 
the samples. Isothermal (25 
o
C) and isohumic (98% RH) conditions were used for a period 
of 16 h. 
 
7.2.2.7 X-Ray Powder Diffraction (XRPD) 
XRPD (Thermo-ARL Xtra, Thermo Scientific) spectra were collected from scans within 
the range 5.0
o
 to 40.0
o
 at 2θ. Extrudates were pre-milled by mortar and pestle before the 
tests. 
 
7.2.2.8 Scanning Electron Microscopy (SEM) 
SEM (JSM 4900 LV, JOEL) was used to acquire microphotographs on the surface and 
cross-section of the freshly prepared extrudates. To improve conductivity prior 
examination, samples were coated with gold using a Polaron SC7640 sputter gold coater  
(Quorum Technologies). 
 
7.2.2.9 Dissolution Studies 
The drug content of each system was determined by UV detection (Lambda XLS UV/VIS, 
Perkin Elmer) at 253 nm. Samples were dissolved in methanol and diluted with the same 
solvent as appropriate.  
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Dissolution studies were carried out on a Copley CIS 8000 dissolution bath  
(Copley Scientific). The BP paddle method with a rotation speed of 50 rpm was employed 
and 900 mL of phosphate buffer pH = 6.8 (BP) at the temperature of 37.0 ± 0.5 
o
C was 
used. Samples (pure OLZ, PMs and HME) equivalent to 12 mg of OLZ (based on the drug 
loading of each formulation) were used with a 63-106 μm sieve fraction. At predetermined 
intervals, 10 mL of solution was withdrawn and filtered through a 0.45 μm filter. 
Subsequently, the filtrate was analysed spectrophotometrically at 253 nm. All the 
dissolution experiments were performed under sink conditions. 
To compare the dissolution performances between the different systems, a similarity factor 
(f2) was used (see Chapter 6 for the theoretical background). 
 
7.2.2.10 Physical Stability 
The stability of the extrudates was assessed using accelerated conditions according to ICH 
Topic Q 1 A (R2) Stability Testing of new Drug Substances and Products (EMA, 2003).  
The samples were stored in desiccators at 75% ± 5% RH/40 ± 2 °C for three months. The 
humidity environment was obtained by using saturated salt solution of sodium chloride 
(75% RH). Sampling at different time points and respective characterisation was done for 
each system using DSC, XRPD and SEM. 
 
7.3 Results and Discussion 
 
7.3.1 Estimation of Drug-Polymer Miscibility  
 
The thermodynamic miscibility between OLZ and each polymer was investigated by using 
two different approaches (described earlier in the Methods section): melting point 
depression (MPD) and Hansen solubility parameter. The former method describes the 
drug-polymer miscibility based on the Flory-Huggins theory (Flory, 1942), which 
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delineates entropy and enthalpy components at a given temperature (Qian et al., 2010). 
Considering the lattice-based models, the entropy of mixing is predicted to be relatively 
constant (and favourable to mixing), being the balance between adhesive and cohesive 
interactions that determines miscibility (see Chapter 6). As a result, the mixing can be 
exothermic (Flory-Huggins interaction parameter, χ < 0), endothermic (χ > 0) or athermal 
(χ = 0), which leads to different reduction magnitudes in the melting point of the drug 
(Marsac et al., 2009; Marsac et al., 2006).  
The MPD results obtained for OLZ and each polymer system are shown in Figure 7.1. In 
this case, all the interaction parameters, χ, were found to be negative indicating that all the 
three polymers were miscible with OLZ and can be presented as follow: -3.34 (R
2
 = 0.984) 
for OLZ:PVP, -3.26 (R
2
 = 0.998) for OLZ:PVPVA and finally -2.54 (R
2
 = 0.995) for the 
OLZ:SLP system. Based on this results, the degree of miscibility and interaction between 
OLZ and each polymer was suggested to follow the decreasing rank order  
PVP > PVPVA > SLP. 
 
 
 
Figure 7.1: Melting point depression results obtained for each olanzapine (OLZ):polymer system 
(PVP, PVPVA and Soluplus
®
 (SLP)). Slope of each curve included for subsequent calculation of the  
Flory-Huggins interaction parameter (χ). 
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Figure 7.2 shows the changes in the Gibbs free energy (see Chapter 6 for the background 
theory) for the three systems. For small values of the interaction parameter, the free energy 
of mixing is negative and shows a concave dependence on composition indicating 
miscibility. As expected and according to Equation 6.6 in Chapter 6, the ΔGmix is negative 
for all the OLZ:polymer systems, though presenting lower values for the OLZ:PVP and 
OLZ:PVPVA systems when compared to the OLZ:SLP and therefore indicating greater 
miscibility for these systems. 
 
 
 
Figure 7.2: Free energy-composition phase diagrams of olanzapine (OLZ) and each polymer system 
(PVP, PVPVA and Soluplus
®
 (SLP)). 
 
The second approach in analysing OLZ:polymer system miscibility was by using Hansen 
solubility parameters (δ), which were calculated based on van Krevelen and Hoftyzer 
group contribution (Equation 7.2). Figure 7.3 shows the chemical structure of OLZ. As an 
example, the calculations of the Hansen solubility parameter carried out for OLZ are given 
in Table 7.1. The van Krevelen and Hoftyzer group contribution method used to calculate 
the total interaction forces for OLZ and each polymer was based on literature values 
(Krevelen and Nijenhuis, 2009).  
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Figure 7.3: Chemical structure of olanzapine. 
 
Table 7.1: Solubility parameter component group contribution using van Krevelen-Hoftyzer method. 
 
Structural 
Groups 
Fdi  
((MJ/m
3
)
1/2 
mol
-1
) 
Fpi
2
  
((MJ/m
3
)
1/2 
mol
-2
) 
Ehi  
(J/mol) 
V  
(cm
3
/mol) 
(2) –CH3 840 0 0 67 
(4) –CH2 1 080 0 0 64.4 
(1) =CH 200 0 0 13.5 
(4) =C 280 0 0 -22 
(1) –Phenyl 1 270 12 100 0 52.4 
(1) –S– 440 0 0 12 
(1) –NH– 160 44 100 3 100 4.5 
(2) –N 40 2 560 000 10 000 -18 
(1) –N= 20 640 000 15 000 5.0 
(3) – Ring (> 5 
atoms) 
570 0 0 48 
∑ 4 900 5 816 200 18 100 226.8 
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The δ for each component, difference between drug and each polymer (Δδ), and interaction 
parameter (χ) are provided in Table 7.2. It is reported that compounds with similar values 
of solubility parameter, nominally Δδ < 7.0 MPa1/2, are more likely to be miscible, whereas 
if Δδ > 10.0 MPa1/2 the compounds are most probably immiscible (Greenhalgh et al., 
1999). From the presented results, OLZ had a solubility parameter (25.68 MPa
1/2
) closer to 
PVP (26.28 MPa
1/2
), while PVPVA and SLP had a slightly lower solubility parameter 
values, 24.37 and 23.07 MPa
1/2
, respectively. In the present case, the difference between 
the solubility parameter of OLZ and each polymer was lower than 7.0 MPa
1/2 
indicating 
good miscibility for all systems. 
 
Table 7.2: Calculated solubility parameters and interaction parameters using  
Hansen group contribution theory for OLZ and each polymer. 
 
Compound δ (MPa)
1/2
 Δδ (MPa)
1/2
 χ 
OLZ 25.68 n.a. n.a. 
PVP 26.28 0.60 0.03 
PVPVA 24.37 1.31 0.16 
SLP 23.07 2.61 0.62 
 
                              n.a. – not applicable 
 
The value of χ, calculated based on Equation 7.3, refers to the square of the difference in 
solubility parameters that were calculated from the values of group contributions at 25 
o
C. 
A closer value of χ to zero suggests greater interaction between the drug and the polymer 
(Krevelen and Nijenhuis, 2009). According to the results in Table 7.2 miscibility between 
OLZ and each polymer is likely to follow the same order as observed with MPD 
experiments (PVP > PVPVA > SLP).  
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These two methods used here to predict drug-polymer miscibility have concomitant 
strengths and limitations, as has been discussed extensively in the literature. In brief, the 
MPD approach is temperature and composition dependent whereas the calculation of 
solubility parameters allows the estimation of the degree of miscibility based on the 
chemical structure of the drug and polymer at room temperature (Forster et al., 2001b; 
Hancock et al., 1997). Moreover, MPD methods may not be performed properly if the drug 
degrades at the melting temperature, while the group contribution method for the 
calculation of Hansen solubility is not applicable for drug-polymer systems presenting 
strong intermolecular interactions (Zhao et al., 2011). In this work, the two approaches 
used to predict the miscibility between OLZ and each polymer were in good agreement, 
with PVP being identified by both as the polymer presenting the greatest degree of 
miscibility with OLZ, followed by PVPVA and finally SLP. The agreement between the 
two approaches lends weight to the applicability of the theoretical approaches used, 
although clearly experimental measurements, as performed below, are ultimately the most 
reliable means of testing miscibility. 
 
7.3.2 Properties of the Raw Materials 
 
In general, for HME processing the temperature should be higher than the glass transition 
temperature (Tg) of the carrier in order to decrease its viscosity and promote an adequate 
mixing with the drug and an ideal flow through the extruder. The optimal extrusion 
temperature has to be carefully determined based on the melting temperature (Tm) of the 
drug, the Tg of the amorphous carrier and the thermoplastic properties of the carrier  
(Srinarong et al., 2011). Therefore, it is imperative that the thermal properties of drug 
substances and excipients are well understood prior to extrusion. 
Table 7.3 shows the main thermal properties of OLZ and each polymer. PVP has the 
highest Tg and the lowest degradation temperature (Tdeg, measured by using TGA as the 
onset temperature) when compared to PVPVA and SLP. According to the presented 
results, neither OLZ nor the polymers appeared to degrade at the extrusion temperatures 
used in this study (160 
o
C for all the three systems and 180 
o
C for PVPVA and SLP as PVP 
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degraded at this temperature). Particular attention was paid to PVP due to the smaller 
temperature interval between its Tg, Tdeg and the processing temperature. However, holding 
PVP isothermally in the TGA at 160 
o
C for 30 min resulted in a 0.81 ± 0.10% loss of mass, 
suggesting that 160 
o
C might be a suitable temperature for the extrusion of the OLZ:PVP 
formulation.   
 
Table 7.3: Experimental thermal properties of OLZ and polymers. 
 
Material Tm onset ± s.d. (
o
C) Tg ± s.d. (
o
C) Tdeg ± s.d. (
o
C) 
Water content 
± s.d. (%) 
OLZ 193.6 ± 0.3 71.4 ± 0.4
*
 265.3 ± 4.0 0.36 ± 0.06 
PVP n.a 161.6 ± 0.2 179.8 ± 1.6 5.53 ± 0.94 
PVPVA n.a. 105.6 ± 1.4 282.3 ± 1.0 3.48 ± 1.15 
SLP n.a. 72.9 ± 0.3 309.1 ± 1.3 2.36 ± 0.14 
 
n.a. – not applicable 
*Tg value obtained from heat-cool-heat cycle inside the DSC at 2 
o
C/min in crimped pans 
 
7.3.3 Physical Characterisation of HME Systems 
 
Attempts to extrude PVP with a low drug loading of 20% were unsuccessful. It is well 
known that the use of PVP in HME formulations is limited due to its high Tg (≈ 160 
o
C) 
and low Tdeg which is below 180 °C. Therefore, the incorporation of small molecules of 
API allow the polymer segments to have greater mobility due to plasticisation effects and 
hence be extruded at lower temperatures (Lakshman et al., 2008). Studies with ibuprofen 
and ethyl cellulose showed that higher drug loadings of ibuprofen not only eased the 
extrusion behaviour of ethyl cellulose by decreasing its Tg but also improved the physical 
properties of the prepared films (De Brabander et al., 2003; De Brabander et al., 2002). In 
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the present work, the low drug loading of 20% w/w did not elicit a suitable plasticisation 
effect for PVP and thus did not allow extrusion. However, when the drug loading was 
increased to 50% w/w, the extrusion process was difficult, but possible. As a result, the 
extrudates were prepared in block-like shape with a rough appearance instead of thin 
spaghetti-like strands as usually obtained in a smooth extrusion process. Despite the 
difficulties associated with the extrusion process, this formulation (50% OLZ:PVP) 
appeared to be completely amorphous with a single Tg value and no evidence of 
recrystallisation or melting of OLZ was seen when analysed in DSC, as shown in  
Figure 7.4. 
 
 
 
Figure 7.4: DSC curves of 50% drug-loaded systems with Soluplus
®
 (SLP), PVPVA and PVP  
(downwards) extruded at 160 
o
C and run at 10 
o
C/min in standard crimped pans. 
 
The data in Figure 7.4 shows an initial water loss peak reflecting the approximately 1-2% 
water content of these systems, as measured by TGA, followed by a glass transition and, in 
some cases, melting of the crystalline drug. Extrudates of PVPVA and SLP with 20% drug 
loading were easily extruded even at 160 
o
C since the Tg of these polymers is much lower  
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(Tg (PVPVA) ≈ 105 
o
C; Tg (SLP) ≈ 70 
o
C). Therefore their liquid-like state at that temperature 
allowed an appropriate mixing with OLZ and a consistent flow of the material through the 
barrel. However, in contrast to the 50% OLZ:PVP system, the 50% drug-loaded PVPVA 
and SLP systems extruded at 160 
o
C were not fully but only partially amorphous, which 
was confirmed by the melting of OLZ at ≈ 170 oC.  
The quantification of crystalline OLZ in those extrudates was calculated using calibration 
curves of the melting enthalpy of OLZ when physically mixed with PVPVA or SLP in 
different ratios, as shown in Figure 7.5. The percentage of drug crystallinity was calculated 
to be 14.5 ± 1.6% and 16.5 ± 0.1% for the OLZ:PVPVA and OLZ:SLP systems, 
respectively. These findings are nevertheless evidence of the high solubilisation effect of 
PVP previously predicted by the MPD and Hansen methods when compared to the other 
polymers. 
 
 
 
 
 
 
 
 
 
Figure 7.5: Calibration curves of the enthalpy of melting of olanzapine (OLZ) in the presence of  
PVPVA (left) or SLP (right) versus the ratio of crystalline OLZ in the physical mixtures. 
Measurements were carried out at 10 
o
C/min in crimped pans.  
 
In terms of the PVPVA and SLP systems with a 50% drug loading, when the temperature 
was increased to 180 
o
C, fully amorphous solid dispersion systems were prepared without 
any evidence of crystalline OLZ observed in DSC. Figure 7.6 shows the measured Tg for 
all the formulated systems. The difference in the processing conditions (extrusion 
temperature) and consequently the existence of crystalline OLZ in the final extrudates did 
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not have a great influence on the measured Tg of the PVPVA and SLP systems. As 
expected, 50% OLZ:PVP showed the highest Tg (≈ 108 
o
C), followed by the formulations 
with PVPVA (≈ 90 oC) and finally SLP (≈ 74 oC).  
 
 
 
Figure 7.6: Measured Tg values for all the freshly prepared formulations using DSC (total heat flow) at  
10 
o
C/min in crimped pans. Blue and red bars represent systems extruded at  
160 
o
C and 180 
o
C, respectively. 
 
FTIR spectroscopy was employed to study the interactions in solid dispersions between 
OLZ and the three polymers. The FTIR spectra of all PMs were only the summation of the 
OLZ and each polymer isolated spectrum, giving no evidence of any interaction between 
the drug and polymers in PMs (data not shown). OLZ has a single hydrogen bond donor 
(N-H) and all the polymers have in common at least one proton acceptor (C=O) able to 
participate in hydrogen bonding. In the case of PVPVA and SLP, a second group (C=O) 
from the vinyl-acetate component is present, however it is stereo chemically hindered and 
it does not participate in hydrogen bonding. Typically, the formation of hydrogen bonds 
within a given system may be readily identified through either, a downshift in the 
absorption band, band broadening, and/or peak intensification (Konno and Taylor, 2006).  
As shown in Table 7.4 a greater level of interaction between OLZ:PVP and OLZ:PVPVA 
systems was observed with downshifts higher than 4 cm
-1
. In contrast, no interaction 
between OLZ and SLP seemed to take place as no shifts to lower wavenumber were 
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detected. The N-H stretching vibration of OLZ was not detected in all the three systems as 
an indication of the conversion to an amorphous phase.   
 
Table 7.4: Shifts on the carbonyl groups for each polymer and respective HME system (cm-1). 
 
Polymers and HME systems 
 
 
 
PVP  1667 
50% OLZ:PVP (160 
o
C)  1655 
PVPVA 1731 1673 
20% OLZ:PVPVA (160 
o
C) 1731 1664 
20% OLZ:PVPVA (180 
o
C) 1732 1666 
50% OLZ:PVPVA (160 
o
C) 1733 1664 
50% OLZ:PVPVA (180 
o
C) 1733 1663 
SLP 1731 1632 
20% OLZ:SLP (160 
o
C) 1732 1632 
20% OLZ:SLP (180 
o
C) 1732 1632 
50% OLZ:SLP (160 
o
C) 1734 1633 
50% OLZ:SLP (180 
o
C) 1734 1634 
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The DSC findings outlined above were supported by the XRPD studies which showed a 
considerable presence of crystalline OLZ (Figure 7.7a) for the 50% drug-loaded PVPVA 
and SLP extruded at 160 
o
C (Figure 7.7b).  
 
 
 
 
Figure 7.7: XRPD spectra of (a) pure OLZ and (b) 50% drug-loaded formulations from top to bottom: 
SLP, PVPVA and PVP extruded at 160 
o
C and SLP and PVPVA extruded at 180 
o
C. 
 
Although the XRPD peaks in those systems were relatively broad and with significant 
background noise associated it is still possible to confirm that the diffraction peaks did 
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correspond to OLZ Form I. It was noted that the diffraction peaks were broader than for 
the pure drug, possibly indicating a reduction in crystal size. In contrast, no distinct 
intensity peaks were observed in the diffractograms of the PVP 50% and in all 20% 
extruded systems, confirming the formation of fully amorphous solid dispersions. 
In terms of their optical appearance, all the systems had a characteristic reddish coloration, 
as shown in Figure 7.8 for the 50% drug-loaded extrudates. The first assumption to explain 
this feature would be degradation of OLZ, since the colour tonality is similar in all 
formulations and thus degradation of the carrier could be excluded. However, when OLZ 
melts, the yellow bright crystals turn into a red liquid. Additionally, TGA showed that the 
degradation of OLZ has an onset point at around 265 
o
C. Moreover, the drug content was 
determined spectrophotometrically in methanol and ranged between 95.6-104.0% in all 
systems excluding the possibility of drug degradation. This transformation in colour needs 
further investigation, as a chemical reaction not yet reported might be taking place. A 
similar behaviour was observed with crystalline piroxicam that transforms from colourless 
to a yellow bright colour when melted, dissolved in water or transformed to an amorphous 
state. The reason for this observation was found to be associated with the ionic character of 
the charged piroxicam molecules formed by intermolecular proton transfer (Sheth et al., 
2005). 
 
 
Figure 7.8: Photographs of 50% drug-loaded extrudates. 
 
It was also noticed that the extrudates prepared with PVPVA and SLP at 160 
o
C are not 
transparent contrarily to those extruded at 180 
o
C, as a result of the incomplete melting of 
OLZ:PVP OLZ:SLP OLZ:PVPVA 
160 
o
C 180 
o
C 160 
o
C 180 
o
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OLZ. Also the OLZ:PVP extrudates did not have the typical rod-shape appearance due to 
its difficult extrusion. All the 20% drug-loaded extrudates had a transparent appearance 
and a lighter colour as less amount of OLZ was present. 
Overall, following the physical characterisation of the different solid dispersion systems 
prepared with OLZ, they can be mainly divided into two major groups:  
(a) Fully amorphous solid dispersions: 50% OLZ:PVP extruded at 160 °C, 50% OLZ 
with PVPVA and SLP extruded at 180 
o
C and all the 20% drug-loaded 
formulations prepared with PVPVA and SLP;  
(b) Partially amorphous solid dispersions: 50% OLZ with PVPVA and SLP extruded 
at 160 
o
C. 
It was noted that the greater miscibility of OLZ with PVP, suggested by the MPD and 
solubility parameter calculations, was supported by these findings. The question then arises 
as to whether the variability in the degree of crystallinity will have an influence on the 
associated drug release behaviour.  
 
7.3.4 Dissolution Studies 
 
The drug content of all formulations was at 95.6–104.0% of the theoretical values.  
Figure 7.9 and Figure 7.10 show the dissolution curves of pure OLZ and freshly prepared 
HME systems at 50% and 20% drug loading, respectively. A significant enhancement in 
the dissolution rate was observed for all solid dispersion systems prepared by HME 
compared to the pure crystalline OLZ. More specifically, in the case of the 50% drug-
loaded extrudates, the T50 values were circa 3 min for the dispersions with PVPVA and 
SLP (either extruded at 160 or 180 
o
C) compared to 10 min for the OLZ:PVP and finally  
30 min for the drug alone. The systems containing 20% OLZ extruded with PVPVA and 
SLP showed an even faster dissolution rate with T50 values between 1 and 2 min at both 
processing temperatures. It was interesting to observe in Figure 7.9 that with a constant 
drug loading (50%) and processing temperature (160 °C), the decreasing order of drug 
release rate from different polymer based systems was PVPVA (partially amorphous) > 
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SLP (partially amorphous) > PVP (fully amorphous). This was an indication that drug 
release may not always be faster from a fully amorphous state than a partially amorphous 
structure with crystal domains.  
In addition, PVPVA and SLP systems extruded at the two different temperatures produced 
very similar dissolution profiles. More specifically, the similarity factor, f2, for the  
50% OLZ:PVPVA systems was calculated to be 65.6, whereas for the case of OLZ:SLP f2 
had a borderline value of 50.5. Nevertheless, in both cases f2 was greater than 50 indicating 
that the release profile of the drug from the partially (extrusion at 160 
o
C) and fully 
(extrusion at 180 
o
C) amorphous solid dispersions was comparable in this specific case.  
 
 
 
Figure 7.9: Dissolution profiles of pure OLZ and HME systems with PVP, PVPVA and Soluplus
®
 
(SLP) with 50% drug loading extruded at 160 and 180 
o
C (FAS – fully amorphous systems and  
PAS – partially amorphous systems). The legend on the right hand side follows the same order as the 
curves in the plot (downwards). 
 
The dissolution curves of the 20% drug-loaded systems extruded at the different 
temperatures were found to be superimposable for each polymer system (Figure 7.10). 
Furthermore, the release profile was controlled by the type of polymer with the 
formulations prepared with SLP showing a slower release rate when compared to PVPVA. 
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However, at this drug loading fully amorphous solid solutions were obtained with both 
processing temperatures and therefore these results are not surprising.  
 
 
 
Figure 7.10: Dissolution profiles of 20% drug-loaded HME extrudates with PVPVA and SLP extruded 
at 160 and 180 
o
C (all systems were characterised as fully amorphous systems). The legend on the right 
hand side follows the same order as the curves in the plot (downwards). 
 
From the above results, clearly, the nature of the polymer is an important determinant of 
dissolution as well as the degree of crystallinity. However what is particularly interesting is 
that the two 50% dispersions in PVPVA and SLP at 160 
o
C and 180 
o
C also showed no 
differences, despite these being the same polymers but with differing degrees of drug 
crystallinity. Earlier work in the solid dispersion literature
 
(Corrigan, 1985; Craig, 2002)
 
has suggested that dissolution rate of some or many binary systems may be determined by 
the dissolution of the carrier polymer and not the drug at all. More specifically it has been 
suggested that the polymer may form a concentrated layer adjacent to the solid surface into 
which the drug may dissolve rapidly, hence it is the dissolution of the polymer-rich layer 
that determines drug release and not the actual dissolution of the drug itself. The results 
presented here are consistent with this approach, suggesting that it is the polymer and not 
the drug that determines the dissolution profile. Therefore, it may in fact be the 
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characteristics of the polymer that are changing and the drug structure may, in some cases 
at least, be incidental and irrelevant to performance. 
In contrast, the release rate of the drug from the physical mixtures as shown in Figure 7.11 
is slightly reduced for the PVP and PVPVA systems in comparison to the drug alone and 
this effect is much more obvious for the PM of OLZ:SLP resulting in only less than 60% 
drug release at the last sampling point of 120 min with visible particles remaining in the 
medium. The reason for this feature it is not yet clearly understood, but apparently the 
incomplete dissolution of the polymer at this pH influenced somehow the dissolution 
behaviour of the drug. This was more evident when the polymer ratio increased in the 20% 
OLZ formulations with a drug release of about ≈ 36% in the end of the test (data not 
shown). 
 
 
 
Figure 7.11: Dissolution profiles of OLZ and PM with PVP, PVPVA and SLP in  
1:1 drug-polymer ratio. 
 
These particles were collected from the dissolution vessel and examined under SEM, as 
shown in Figure 7.12. Considering that SLP showed in FTIR no degree of interaction with 
OLZ when compared to the other polymers, the assumption that the formation of strong 
hydrogen bonds between OLZ and SLP was the reason for the incomplete dissolution 
profile may not be correct. One explanation could be entrapment of the drug on the porous 
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structure of SLP leading to kind of ‘insoluble complex’ and therefore incomplete release of 
the drug. 
Figure 7.12 shows also microphotographs of pure OLZ with an irregular shape; PVP and 
PVPVA as round microspheres due to the fact that these two polymers are industrially 
prepared via spray drying and finally SLP appearing as irregular particulates. The 
cylindrical shape of PVP and PVPVA is probably favourable for the dissolution of OLZ 
from the PMs in comparison to SLP.  
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Figure 7.12: SEM microphotographs of pure OLZ, PMs of OLZ with each polymer and finally the 
particles collected from the dissolution vessel of 50% PM OLZ:SLP after 120 min of testing. 
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7.3.5 Polymer Effect on the Inhibition of OLZ Crystallisation in HME Solid 
Dispersions 
 
In this study, the physical stability of all prepared solid dispersion systems was 
investigated under storage at accelerated conditions, testing at the same time the influence 
of high humidity (75% RH) and temperature (40 
o
C) on the recrystallisation of OLZ.  
The stability of OLZ-polymer systems as a function of time was found to depend greatly 
on the polymer physicochemical properties. Overall, OLZ:SLP system extruded at 180 
o
C 
showed the greatest stability of all solid dispersion systems studied with only the first signs 
of drug recrystallisation observed in DSC and under SEM after the three months of 
storage, although no crystals were detected in XRPD.  
During the stability studies, the 50% drug-loading systems with PVPVA and SLP extruded 
at 160 
o
C, even though not fully amorphous after its preparation, did not show an increase 
in their crystal content during storage. This was confirmed by the enthalpy of melting of 
OLZ Form I that remained nearly constant during the entire period of study and by the 
OLZ crystallinity in XRPD. The sample 50% OLZ:PVP was prepared fully amorphous at 
the same extrusion temperature, and it was proved amorphous until two months of storage, 
when the first evidence of recrystallised OLZ started to be noticed. The 50% OLZ:PVPVA 
prepared at 180 
o
C showed a similar stability profile to the 50% OLZ:SLP extruded at the 
same temperature, although some evidence of crystalline OLZ was possible to be detected 
in XRPD after the three months of storage, contrarily to the SLP system. Figure 7.13 
shows the XRPD data for all the 50% systems after being stored for three months under  
75% RH/40 
o
C. All the 20% drug-loaded extrudates with PVPVA and SLP remained 
amorphous during the whole study according to the DSC analysis, however due to the high 
percentage of polymer they formed a coalescence masses which complicates XRPD and 
SEM analysis. 
Generally, greater stability of solid dispersion systems is often linked to the high Tg of the 
polymer. In the present case however, the polymer Tg does not appear to be the key factor 
influencing and predicting the recrystallisation tendency of OLZ. In fact, in this study SLP 
has the lowest Tg compared to PVP and PVPVA but showed the greatest stability. Also the 
formation of specific interactions, such as hydrogen bonding, between the drug and the 
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polymer have been extensively correlated with greater stability of solid dispersions and 
better inhibitors on the crystal growth of APIs (Matsumoto and Zografi, 1999; Khougaz 
and Clas, 2000; Kestur and Taylor, 2010). Although, some controversies were found 
related to this matter and further investigations should aim at quantifying the degree of 
these bonds between drug and polymer to improve predictions on physical stability of melt 
extrudates (Forster et al., 2001a). As shown earlier, the extrudates prepared with SLP did 
not give any evidence of hydrogen bonding using FTIR spectroscopy as compared to the 
extrudates prepared with the other polymers. As a result, the existence of intermolecular 
interactions might not be a relevant factor in the stabilisation mechanism between OLZ and 
each polymer system although this should not be completely discarded.  
 
 
 
Figure 7.13: XRPD data collected for the 50% formulations (both extrusion temperatures) after three 
months of storage at 75% RH/40 
o
C. For simplicity, the legend on the plot follows the same order  
as the presented curves. 
 
Following the preceding discussions, two other factors need to be considered, the 
molecular weight (MW) and the hygroscopic nature of the polymer. The MW of a polymer 
is expected to influence viscosity and therefore reduce crystal growth. In addition, 
hygroscopicity is always linked to instability, as it increases molecular mobility and 
therefore tendency for nucleation to happen. In order to evaluate the hygroscopic tendency 
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of each fully amorphous system, DVS studies were conducted. The results obtained 
showed that after 16 h at 98% RH/25 
o
C, PVP solid dispersion had a water uptake of 
around 58%, followed by PVPVA system with 44% and finally SLP samples with only an 
increase in weight of 20%. Therefore, it seems likely that the stabilisation of OLZ solid 
dispersions during storage is highly dependent on the high MW and lower hygroscopic 
nature of SLP, when compared with the other polymers. 
Absorption of high amounts of water can lead to the formation of drug-rich and  
polymer-rich amorphous phase as a result of moisture-induced drug-polymer immiscibility 
(Rumondor et al., 2009; Konno and Taylor, 2008; Van Eerdenbrugh and Taylor, 2010). In 
this study, the use of standard DSC with a heating rate of 10 
o
C/min in order to avoid 
dissolution of OLZ in the polymer matrix upon heating, did not allow the identification of 
any phase separation in the PVP and PVPVA systems, which can be considered in further 
studies.  
Figure 7.14 depicts the scanning electron micrographs of the surface and internal  
(cross-section surface) appearance of the 50% drug-loaded extrudates, fresh and after three 
months of storage. The fresh extrudates prepared with PVPVA and SLP at 160 
o
C showed 
a distribution of OLZ crystals, either on the surface and cross-section, confirming the 
incomplete melting of the drug during extrusion. In contrast, the formulations extruded at  
180 
o
C showed a complete smooth surface without any evidence of crystalline OLZ. For 
the system prepared with PVP, although no crystals were identified, the surface of these 
extrudates was not completely smooth as a consequence of the difficult extrusion process 
of this system. For all the 20% drug-loaded extrudates no signal of crystallinity was 
observed (data not shown). After three months of storage, the PVP systems showed 
evidence of recrystallised OLZ either on the surface and cross-section of the extrudates. 
Similar observations to the fresh samples were obtained for the PVPVA and SLP systems 
extruded at 160 
o
C. The samples extruded at 180 
o
C showed clearly recrystallisation of 
OLZ on the surface of the extrudates, but no sign on the internal cross-section. 
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Figure 7.14: SEM microphotographs of 1:1 fresh solid dispersion systems (surface and cross-section) and after storage at 75% RH/40 
o
C for three months  
(cross-section and surface). The extrusion temperature for the PVPVA and SLP systems is also stated.
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7.4 Conclusions 
Overall, the predicted miscibility and interaction between OLZ and each polymer 
calculated based on MPD and Hansen solubility parameters agreed with the experimental 
results in that at the same extrusion temperature (160 
o
C) and drug loading (50%), PVP 
was found to have the greatest miscibility with OLZ leading to the molecular dispersion of 
OLZ. In contrast, the extrudates prepared with PVPVA and SLP, under the same 
conditions, crystalline OLZ was detected via DSC, XRPD and SEM observations. At a 
higher extrusion temperature, both systems with PVPVA and SLP were characterised as 
one-phase systems with a single Tg value observed in DSC. This therefore demonstrates the 
complex interplay between miscibility and processing but also demonstrates that there is a 
role for solubility parameter and MPD predictions in anticipating experimental findings.  
In terms of the dissolution performance, the general assumption that a higher dissolution 
rate is obtained when the drug is completely converted to an amorphous form is not 
consistent with the findings presented in this chapter. In this specific case, it was noted that 
at 50% loading and 160 
o
C processing, PVP showed the slowest release despite being the 
only fully amorphous system. It was interesting to note that no clear relationship was found 
between dissolution and drug crystallinity or indeed with processing temperature, with the 
release rates being much more dependent on the choice of polymer. Therefore, in this case 
at least, it may be the behaviour of the polymer that determines dissolution performance 
rather than the physical state of the drug. 
The chemistry of the polymer was also found to determine the stability of the OLZ solid 
dispersion systems. The extrudates prepared with SLP were found to have the greatest 
stability, despite the lower Tg of this polymer and the inexistence of any specific 
interactions detectable by FTIR between OLZ and SLP. Properties such as the high MW 
and low hygroscopicity of this polymer might be responsible for the greatest stability 
observed.  
Another interesting finding is related to the SEM observations of the aged HME samples. 
The 50% drug loaded formulations showed that the recrystallised crystals of OLZ differed 
on their shape and arrangement on the surface of the extrudates. This observation is system 
dependent as expected due to the different polymer chemistry. Local thermal analysis 
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(LTA) might be a helpful technique to be used in further studies, enabling, if present, the 
identification of different polymorphic forms of OLZ. This might be significantly 
important in the case of SLP which showed a limited crystal growth after three months of 
storage. 
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Learn from yesterday, live for today, hope for tomorrow.  
The important thing is not to stop questioning.  
Curiosity has its own reason for existing. 
 
Albert Einstein 
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8.1 Summary and Concluding Remarks 
 
Polymorphism and pseudopolymorphism are nowadays recognised as an important 
phenomenon during the early research screening and throughout development. This has 
been a result of successful scientific improvements, strong regulatory and economic 
demand. Although methods for polymorph control and characterisation are still imperfect, 
more sophisticated and sensitive characterisation techniques are now available to control 
this important and challenging problem. The work presented in this thesis has reiterated the 
importance of having integrated characterisation strategies, as a way to achieve an in-depth 
understanding of the structure-property relationship in organic solids. This scientific 
approach was applied throughout this thesis for the solid state characterisation of 
olanzapine and paroxetine HCl, and the respective prepared systems.  
Paroxetine HCl has been in the market for more than two decades and it has been 
extensively used for the treatment of depression, general anxiety and social phobia. Despite 
its widespread use, the physicochemical properties of the two crystalline forms of this 
drug, Form I and Form II, have not been fully investigated. Paroxetine HCl Form II was 
assigned in previous works to be an unstable anhydrate form with a very hygroscopic 
behaviour and paroxetine HCl Form I is a stoichiometric hemihydrate and the most stable 
form (Buxton et al., 1988; Barnes et al., 1988).  
In Chapter 3, a broad range of physical characterisation techniques were used in order to 
obtain a detailed view of the effect and interaction of water with the structure of Form II. 
High water content (≈ 3.83%, 0.80 mol of water/mol of paroxetine HCl) and an unusual 
thermal behaviour, presented the first doubt on the designation of Form II as an anhydrous 
form. It was then crucial to clarify the relationship between water and Form II. VH-XRPD 
was the key technique in this study since it provided enough evidence of hydrate formation 
as only changes in lattice spacings were observed accompanying the uptake of water. This 
fact indicated that Form II exists as a non-stoichiometric hydrate and its designation as an 
anhydrous form is no longer valid.  
Overall, this work has highlighted the importance of distinguishing between water 
adsorption, as a consequence of a hygroscopic nature, and hydrate formation. Also 
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important to emphasise that Form II was a non-stoichiometric hydrate with characteristics 
and behaviour similar to channel hydrates, although these channels were not found in the 
structure at a molecular level. Furthermore, these results reiterate the importance of using a 
combination of several techniques and taking advantage of the available computational 
tools in the characterisation of pharmaceutical materials, particular with non-stoichiometric 
hydrates as they often produce a further level of complexity.  
Continuing within the solid state characterisation of paroxetine HCl, the conditions that led 
to the dehydration of Form I were investigated and a new anhydrous form, structurally 
different than the dehydrated Form II, was identified as a consequence of this process 
(Chapter 4). The dehydration process of Form I was far more complex than initially 
expected and the dehydrated product was found to be very unstable and quickly rehydrated 
to the initial hydrate Form I. With these challenges, structural investigation of the 
dehydrated Form I was performed using VT-XRPD which allowed the dehydration process 
to be carried out in situ. These results showed that the patterns obtained at high 
temperatures were different than those of the dehydrated Form II, indicating that the two 
forms were structurally different. In addition, the pattern of the dehydrated Form I was 
highly similar to the hydrate Form I, with the unit cell parameters remaining the same, just 
smaller in volume as a consequence of dehydration.  
From the work presented in this chapter, a new anhydrous form of paroxetine HCl has been 
identified. This new form is, however, extremely unstable and difficult to handle under 
normal environment conditions. The structure solution of the new anhydrate from powder 
diffraction data was not possible. In addition, the use of single crystal X-ray technique was 
unsuccessful as the crystal broke during heating. Nevertheless, important insights and 
understanding on the dehydration of pharmaceutical compounds can be further applied in 
the particular case of stoichiometric hydrates with a peculiar behaviour of dehydration.  
After the fundamental characterisation studies, paroxetine HCl Form II was converted into 
an amorphous state via a melt quench method. From a pharmaceutical perspective, 
amorphous materials can improve solubility and therefore bioavailability of APIs. 
However, any potential benefits of amorphous systems are counterbalanced by their 
metastable nature and intrinsic tendency to recrystallise when submitted to stress 
conditions. In this work thermodynamic and kinetic parameters were investigated and 
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applied to the characterisation of the prepared amorphous form. Although theoretical 
approaches have been extensively used on the prediction of amorphous compounds as 
glass formers, limited work has been carried out in order to correlate those approaches with 
the experimental physical stability. Parameters such as Kauzmann temperature (TK), 
fragility (m) and relaxation time (τ) classified the amorphous paroxetine HCl prepared 
from Form II as a fragile glass. The predicted fragility of this form was in agreement with 
the experimental results obtained during physical stability studies and also after prolonged 
exposure to water during the solubility experiments. In addition, the storage conditions, 
more specifically the water vapour pressure, was found to influence the pathway of 
recrystallisation from the amorphous state. This might be of practical importance during 
the stability studies of APIs converted into an amorphous state.   
Later in this thesis (Chapters 6 and 7), attention was paid to the parameters involved in the 
formulation of drug products into solid dispersions. As referred, single amorphous phase 
compounds are usually tempered by a number of potential drawbacks, mainly physical and 
chemical instability. The preparation of amorphous solid dispersions represents, nowadays, 
the ultimate strategy to stabilise those systems. Numerous parameters must be accounted 
when intending to prepare amorphous solid dispersions.  
A thorough investigation on the preparation, performance and stability of solid dispersion 
systems prepared with paroxetine HCl Form I and II was carried out. PVPVA was selected 
as the carrier and the influence of preparation techniques (spray drying (SD) and hot melt 
extrusion (HME)) was also evaluated. Melting point depression approach was used to 
predict the miscibility between each pseudopolymorphic form of paroxetine HCl and 
PVPVA. Interestingly, Form I was found to be miscible with PVPVA whereas Form II did 
not show any depression on the onset melting in the presence of the polymer. Regardless 
the theoretical predictions, the experimental results showed that both forms were able to be 
molecularly dispersed within the polymer carrier, with a single Tg value observed in DSC 
and a halo pattern in XRPD. This was an interesting finding and shed some light on the 
validity of the use of melting point depression method in the prediction of miscibility and 
interaction in drug-polymer blends. The influence of the preparation method was observed 
on the thermal behaviour of the fresh samples and on the propensity for recrystallisation 
during the stability studies. Differences concerning the dissolution performance and 
stability of the SD and HME systems were also encountered. Higher dissolution rates were 
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observed for the spray dried samples, either containing Form I or Form II, relative to the 
HME samples. However, the situation was reversed in terms of stability.  
The work on the formulation into solid dispersions was endeavoured to further study the 
impact of different polymers on the processing, dissolution behaviour and physical stability 
of a BCS Class II drug (olanzapine, OLZ) using HME. Chapter 7 addressed the different 
parameters that should be taken into consideration when preparing solid dispersions in 
particular using HME. Miscibility between the drug (OLZ) and each polymer system 
(PVP, PVPVA and Soluplus
®
 (SLP)), drug loading, extrusion temperatures and the 
chemical structure of the polymer were found to be of great importance in determining the 
solid state of the prepared systems (fully or partially amorphous systems). Interestingly in 
the particular case of OLZ, the physical solid state of the final products did not have any 
significant influence on their dissolution performance. These findings suggested that it was 
the nature of the polymer rather than the physical state of the drug in the dispersed system 
that determined the dissolution profiles. Despite the plethora of reports suggesting that 
high dissolution rates can be achieved when the drug is dispersed in the polymer carrier at 
a molecular lever, further investigation in this field with more care is required. 
Furthermore, the physicochemical properties of the selected polymers also play an 
important role in the stabilisation of these kinds of systems. In particular, parameters such 
as high Tg and the ability to establish hydrogen bonding with the drug are not always 
strictly necessary, at least in this case, to achieve great stabilisation. Indeed, the systems 
prepared with SLP were found to be more stable than those prepared with PVP or PVPVA, 
despite its lower Tg and its inability of establishing hydrogen bonding with OLZ. 
Therefore, more attention should be paid to properties such as molecular weight and lower 
hygroscopic nature when developing solid dispersion systems. 
Overall this work provided important insights into formulating poorly soluble APIs into 
solid dispersions. The mechanisms behind the dissolution enhancement are complex and 
formulation dependent. The selection of a suitable polymer in order to maximise the 
potential advantages associated to solid dispersions should be done carefully. In addition, 
the formulation of solid dispersions containing the API in a highly crystalline state might 
be a promising strategy, at least in certain cases, to improve both dissolution and stability 
of solid dispersions. 
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8.2 Recommendations for Future Work 
 
Whilst carrying out this Project, a number of possible areas were identified and can be 
further investigated. However, due to the limited time available or because they were 
outside the scope of this research, they were not considered in this thesis. 
The first two chapters of this thesis focused on the solid state characterisation of two 
pseudopolymorphic forms of paroxetine HCl. The knowledge acquired here could benefit 
the characterisation and/or identification of non-stoichiometric hydrates as 
misinterpretations are likely to happen with this particular class of compounds.  
In terms of the dehydration studies carried out with paroxetine HCl Form I, although the 
new anhydrate form was found to be highly unstable, the determination of its crystal 
structure could perhaps give important insights in correlating the determined crystalline 
arrangement with its extremely high hygroscopic behaviour and thereby instability. Since 
the use of single crystal X-ray could not be used due to the breakdown of the crystal of 
Form I during the heating up process, the use of synchrotron radiation (high resolution 
XRPD) might be a feasible possibility.  
Concerning the formulation studies carried out in this thesis, a few aspects could be further 
investigated. Starting with the solid dispersions systems prepared with paroxetine HCl. The 
understanding, at a molecular level, of the interactions between PVPVA and paroxetine 
HCl, could help to improve molecular modeling dynamics techniques that allow to predict, 
in a more reliable manner, drug-polymer miscibility.  
Finally, with the studies carried out in the last chapter, two possible areas can be taken 
further. The first one would include the use nano-thermal analysis (nano-TA) to analyse in 
more detail the spatial distribution of crystalline/amorphous material on the surface of the 
extrudates. In addition, this technique would provide important information in 
distinguishing between the different crystalline forms of OLZ, in case more than one form 
was present, since this was not possible by using bulk characterisation techniques (e.g. 
DSC). Secondly, the development of solid dispersion systems containing more than one 
carrier (concept of polymer blend), in particular combining Soluplus
®
 (low hygroscopicity) 
with PVP based system polymers (higher solubilisation properties) could be a way to 
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improve both dissolution and stability. In addition, the generation of crystalline nano-
suspensions of OLZ within that polymer matrix might be a fruitful strategy to formulate 
this drug.         
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9.1 Appendix A – Chapter 3 
Table A1 lists the unit cell dimensions of paroxetine HCl Form II as a function of relative 
humidity (RH). Representative Pawley-fits are shown in Figure A1. 
 
Table A1: Unit cell dimensions of paroxetine HCl Form II determined from XRPD measurements at 
various relative humidity levels. Rwp indicates the quality of the Pawley-fit. 
 
  
Relative 
humidity 
(%) 
a (Å
3
) b (Å) c (Å) β (°) Volume (Å3) Rwp 
Sorption 
10 11.374(2) 5.9380(11) 13.828(2) 100.876(13) 917.1(3) 3.70 
30 11.416(3) 5.9757(13) 13.880(3) 100.499(15) 931.0(4) 3.84 
40 11.419(3) 5.9839(13) 13.895(3) 100.485(14) 933.6(4) 3.79 
50 11.424(3) 5.9869(13) 13.902(3) 100.472(14) 935.0(4) 3.80 
60 11.425(4) 5.9889(13) 13.907(3) 100.462(14) 935.7(4) 3.78 
70 11.430(4) 5.9914(13) 13.916(2) 100.471(13) 937.1(4) 3.72 
80 11.431(3) 5.9945(13) 13.921(2) 100.473(13) 938.0(4) 3.76 
90 11.435(3) 5.9974(12) 13.925(2) 100.479(12) 939.0(4) 3.65 
Desorption 
25 11.418(3) 5.9712(11) 13.880(2) 100.585(12) 930.2(3) 3.68 
15 11.403(3) 5.9576(11) 13.866(2) 100.721(12) 925.5(3) 3.75 
5 11.354(2) 5.9295(10) 13.811(2) 100.987(11) 912.8(3) 3.53 
1 11.325(2) 5.9140(9) 13.788(2) 101.207(12) 905.8(3) 3.65 
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Figure A1: Experimental XRPD pattern (blue), fitted curve (red) and difference (grey) obtained in the 
Pawley fit for data measured at 1% RH (top), 50% RH (middle) and 90% RH (bottom). 
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9.2 Appendix B – Chapter 4 
Analysis of Diffraction Patterns  
 
Pawley refinement (Coelho, 2007) was performed at each temperature either using the unit 
cell parameters of the hemihydrate Form I or the new parameters obtained for the 
anhydrous form. The results of the fitting are presented below in Figure B1. The unit cell 
parameters obtained are presented in Table B1.  
 
a) Heating 25 oC/1 h – Unit cell parameters of the hydrate Form I  
 
b) Heating 50 oC/1 h – Unit cell parameters of the hydrate Form I 
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c) Heating 75 oC/1 h – Unit cell parameters of the hydrate Form I 
 
d) Heating 100 oC/5 h – Unit cell parameters of the hydrate Form I 
 
e) Cooling 100 oC/1 h – Unit cell parameters of the new anhydrous form 
 
f) Cooling 75 oC/1 h – Unit cell parameters of the new anhydrous form 
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g) Cooling 50 oC/1 h – Unit cell parameters of the new anhydrous form 
 
h) Cooling 25 oC/1 h – Unit cell parameters of the new anhydrous form 
 
i) Cooling 25 oC/6 h – Unit cell parameters of the new anhydrous form 
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j) Cooling 25 oC/6 h – Unit cell parameters of the hydrate Form I 
 
Figure B1: Experimental XRPD pattern, fitted curve (red) and difference (grey) obtained  
in the Pawley fit. 
 
Table B1 presents the unit cell parameters obtained at each temperature. The rows in red are less 
reliable due to the poor fit. During heating the unit cell parameters of the hydrate Form I (hyd) were 
used and during cooling the unit cell parameters of the new anhydrous form (anh), except for the last 
measurement at 25 
o
C/6 h, where the parameters of the hydrate cell were used. 
 
 Temperature 
(
o
C) 
 a (Å) b (Å) c (Å) β (o) V (Å3) 
Heating 
25 
o
C/1 h (hyd) 14.615(2) 10.1819(11) 13.0419(17) 107.194(5) 1854.0(4) 
50 
o
C/1 h (hyd) 14.632(2) 10.1864(14) 13.044(2) 107.273(7) 1856.5(5) 
75 
o
C/1 h (hyd) 14.655(5) 10.191(3) 13.039(5) 107.411(13) 1858.2(12) 
100 
o
C/5 h (hyd) 14.75(3) 10.227(18) 13.09(3) 107.44(9) 1884(7) 
Cooling 
100 
o
C/1 h (anh) 14.400(2) 10.5362(15) 12.7706(13) 110.490(5) 1814.9(4) 
75 
o
C/1 h (anh) 14.392(2) 10.5184(14) 12.7572(13) 110.396(5) 1810.1(4) 
50 
o
C/1 h (anh) 14.385(2) 10.473(2) 12.738(2) 110.297(7) 1799.8(6) 
25 
o
C/1 h (anh) 14.291(16) 10.439(12) 12.662(13) 110.37(7) 1771(4) 
25 
o
C/6 h (anh) 14.427(5) 10.464(3) 12.711(5) 110.866(14) 1793.1(11) 
 25 
o
C/6 h (hyd) 14.6253(16) 10.1862(13) 13.0620(16) 107.150(5) 1859.4(4) 
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Dehydration Kinetics  
 
Table B2 and Figure B2 represent an example of the Ea calculation for a single value of 
conversion fraction, (α) by using OFW method with non-isothermal data. The procedure is 
repeated for the all the conversion values. 
 
Table B2: Calculations using OFW method for an individual value of α. 
 
β (K/min) 1 2 3 4 5 
Temperature (K) 344 352 354 357 361 
log (β) 0 0.69 1.10 1.39 1.61 
1000/T (K
-1
) 2.91 2.84 2.82 2.80 2.77 
 
 
 
 
Figure B2: Plot of the OFW method, for a single value of conversion at the different heating rates  
1, 2, 3, 4 and 5 K/min. 
 
Table B3 lists the reaction models considered in this work, to which the isothermal data 
was fitted.  
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Table B3: Reaction models used in solid-state reaction kinetics. 
 
Model Reaction Model Symbol Differential Form f(α) Integral Form g(α) 
Nucleation 
Power law P1   
 
   
 
  
Power law P2   
 
   
 
  
Power law P3   
 
   
 
  
Power law P4 (
 
 
)   
 
   
 
  
Avrami-Eroféev 
(n=1.5) 
A3/2 (
 
 
)      [        ]
 
  [        ]
 
  
Avrami-Eroféev 
(n=2) 
A2       [        ]
 
  [        ]
 
  
Avrami-Eroféev 
(n=3) 
A3       [        ]
 
  [        ]
 
  
Avrami-Eroféev 
(n=4) 
A4       [        ]
 
  [        ]
 
  
Geometrical 
Contraction 
Zero-order 
(Polany-Winger 
Eq.) 
R1 1   
Phase-Boundary 
controlled 
reaction -
contracting area 
R2       
 
  [       
 
 ] 
Phase-Boundary 
controlled 
reaction -
contracting area 
R3       
 
  [       
 
 ] 
Reaction-
order 
First-order 
(Mampel) 
F1                
Three-halves 
order 
F3/2      
 
   [      
 
   ] 
Second-order F2                  
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Third-order F3         
 
 
 [         ] 
Diffusion 
One-dimensional 
diffusion 
D1 (
 
 
)      
Two-dimensional 
diffusion  
(Valensi Eq.) 
D2   [        ]                
Three-
dimensional 
diffusion  
(Jander Eq.) 
D3       
 
   [     
  
   ] [       
   ]  
Three-
dimensional 
diffusion 
(Ginstling-
Brousnshtein Eq.) 
D4 (
 
 
) [     
  
   ]     
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I stand at the seashore, alone, and start to 
think. . . 
There are the rushing 
waves mountains of molecules 
each stupidly minding its own business 
trillions apart 
yet forming white surf in unison. 
 
Ages on ages before 
any eyes could see 
year after year 
thunderously pounding the shore as now. 
For whom, for what? 
On a dead planet 
with no life to entertain. 
 
Never at rest 
tortured by energy 
wasted prodigiously by the sun 
poured into space. 
A mite makes the sea roar. 
 
Deep in the sea 
all molecules repeat 
the pattern of one another 
till complex new ones are formed. 
They make others like themselves 
and a new dance starts. 
 
Growing in size and complexity 
living things 
masses of atoms 
DNA, protein 
dancing a pattern ever more intricate. 
 
Out of the cradle 
onto dry land 
here it is 
standing: 
atoms with consciousness; 
matter with curiosity. 
 
Stands at the sea, 
wonders at wondering:  
I a universe of atoms, 
an atom in the universe. 
 
 
Richard P. Feynman  
  
 
